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40-70% of medical devices and equipment in low- and middle-income countries 
(LMICs) are broken, unused or unfit for purpose: ad-hoc, undiscerning and inefficient 
procurement methods and processes contribute towards this problem. This thesis 
presents the findings of four original studies on medical device and equipment 
procurement within LMICs. Chapter I reports findings of a systematic literature review 
on procurement and prioritization methods; recommendations from reviewed literature 
are synthesised. Chapter II describes fieldwork conducted in The Gambia and Romania 
to explore the processes and dynamics behind medical device procurement in 
contrasting settings. Findings suggest procurement processes are strongly influenced by 
political/cultural power dynamics; health technology assessment evidence is rarely 
considered. Chapter III discusses the feasibility of conducting medical device specific 
economic evaluations for informing procurement planning. A case study on the cost-
effectiveness of alternative treatment interventions for femur-shaft fracture fixation in 
Sub-Saharan Africa is presented. Chapter IV consists of a critical appraisal of the 
medical device specific elements of the One Health Tool for health system planning. 
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MEDICAL DEVICES AND EQUIPMENT IN LOW- AND MIDDLE-INCOME 
COUNTRY HEALTH SYSTEMS 
 
Over 5.8 billion persons living in low- and middle-income countries (LMICs) require 
access to health care services. (1) Successful health care delivery hinges on the 
availability of qualified health care personnel, sustainability of health care financing, 
and safety and availability, appropriateness, accessibility and acceptability of health 
care technologies. (2–4) Policy, debates and research on health technologies historically 
focused on the role of medicines or clinical interventions;(5,6) recently, however, health 
technologies more generally have come under scrutiny, including medical devices and 
equipment. (MDEs) (7)  
 
MDEs are broadly defined as products used in health care provision, whether for 
assistive, diagnostic, treatment or monitoring purposes. Examples include implants, in-
vitro diagnostics, delivery beds, malaria nets, surgical instrumentation as well as more 
complex clinical equipment such as linear accelerators.(7) The World Health 
Organization (WHO) recognizes the importance of MDEs in ensuring universal health 
coverage and urges its member states to carefully select, procure, manage and distribute 
technologies. (8–10) Reports from LMICs, however, suggest that MDEs frequently fall 
into disuse in resource poor settings: 40-70% of products are estimated to be broken or 
remain unused in health facilities. (11,12) 
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In its “Priority Medical Devices” report, the WHO suggests such issues arise due to 
mismatches in MDE demand and supply and undiscerning procurement systems.(3) 
LMIC demand focuses on the procurement of technically simple, low-cost and easy to 
use devices able to function in settings with little to no infrastructure and user training. 
In contrast, MDE manufacturers are primarily active in, and attuned to, the needs of 
high-income settings. High-income country health systems are well resourced, staffed 
by a technologically savvy workforce, and include hygienic and well-serviced health 
care facilities/infrastructure.  
MDE deployment challenges in LMICs may also arise due to a lack of technical experts 
able to advise on the selection of setting-appropriate devices.(13) Regulatory bodies 
able to oversee and advise on tendering are also routinely absent.(14) These challenges 
result in the procurement of products unfit for use in LMICs and directly translate to 
lost health care resources and poor population health outcomes. 
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THESIS AIMS AND CONTENT 
 
This PhD explores the procurement of MDEs within LMICs, specifically the methods 
and tools available to LMIC stakeholders for reaching product selection decisions 
within procurement planning. For the purposes of this thesis, procurement planning is 
defined as a specific element of MDE management, separate from subsequent activities 
including product tendering, distribution, and use and decommissioning. (Figure 1) 
While all these elements are relevant to planning in that they invariably define the 
decision-space in which stakeholders operate, the current work will not address any 
specificities relating to the efficiency or design of different tendering systems, financing 
arrangements or MDE decommissioning procedures. Instead, the methodological and 
normative aspects of procurement planning are explored, with particular focus on 
prioritization of MDE purchases given severe resource constraints. 
Thesis aims 
The studies within this thesis were designed to meet the following aims: 
1. Identify reported methods and tools available to LMIC decision-makers on 
MDE procurement and prioritization to determine relevant issues/factors and 
document common challenges and best practices as described in the global 
literature; (Chapter 1) 
2. Empirically explore MDE procurement processes and dynamics in designated 
LMIC settings to ascertain the motives, constraints and incentives of decision-
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makers in the selection, purchasing and use of specific health products; (Chapter 
2) 
3. Informed by the above and using LMIC appropriate case studies, to explore and 
critically discuss the role of health technology assessment methods, in particular 
MDE specific health economic evaluations, for their relevance in procurement 
planning; (Chapter 3) 
4. Informed by the above findings, to critically appraise and discuss the role of 
health system planning tools - in particular the One Health Tool developed at the 
initiative of the Interagency Working Group on Costing (World Bank, World 
Health Organization among others) - for their usefulness and relevance in MDE 
procurement planning. (Chapter 4) 
 
Chapter 1: Systematic literature review of medical device and equipment procurement 
methods for LMICs 
KD designed and conducted a systematic literature review to identify methods used or 
recommended for MDE procurement or prioritization within LMICs. A systematic 
review protocol outlines the design of the review, its aims and objectives as well as 
methods employed.(15) A second manuscript reports review findings and provides a 
synthesis of recommended procurement methods and practices as described in appraised 
documents; a list of prioritization criteria for MDE selection is also outlined. The 
review highlights that both feasibility and normative criteria are relevant to MDE 
procurement: i.e. issues of servicing and maintenance capacity, user training and 
robustness of product design need to be considered alongside health needs and value for 
money when selecting and purchasing MDEs. Notably, health technology assessment 
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methods are mentioned sparingly throughout the literature, suggesting limited uptake of 
such methods for informing MDE procurement.  
Chapter 2: Medical device procurement in The Gambia, Romania and in the view of 
international experts: findings of a qualitative study  
Informed by early findings of the systematic literature review, KD designed and 
conducted a qualitative study with health care professionals, health facility managers, 
biomedical engineers and regional and national policy and decision-makers in the public 
health systems of The Gambia and Romania. The study also includes interviews with 
international consultants in engineering, health economics and health policy active in 
major international organizations and consultancies.  Interviews explore how and why 
stakeholders select certain MDEs for procurement over others; Bourdieu’s theory of a 
logic of practice is used for data interpretation.(16) Findings suggest that MDE 
procurement processes are uncoordinated and greatly influenced by socio-political 
factors, including considerations of prestige and power. Neither country uses 
transparent health technology assessment based systems for resource allocation.  The 
early findings of this study led to the formulation of a BMedSci student project into 
differences between the public and private health care sector in MDE prioritization and 
management experiences in a province of India – this study was undertaken by Vatsal 





Chapter 3: Long-bone fracture care for low-income settings: an economic evaluation 
of alternative treatment strategies 
Notably, both of the above studies highlight that decision-makers in LMIC contexts 
rarely use health technology assessment and health economic evaluation related 
evidence in procurement planning. KD explores and discusses the feasibility and 
usefulness of MDE-specific evaluations for LMIC procurement via the use of a case 
study. A health economic evaluation exploring the cost-effectiveness of alternative 
treatment strategies for the fixation of femur shaft fractures in the Global Burden of 
Disease Africa D and E regions in Sub-Saharan Africa is presented. The chapter 
includes a critical discussion of methods and issues encountered in conducting the 
study, specifically on the use of the generalized cost-effectiveness analysis methods 
championed by the World Health Organization. (17) The chapter also presents MDE-
evaluation relevant insights on the use of the Bill and Melinda Gates’ Foundation guide 
to health economic evaluation.(18) 
The case study designed by KD was informed by a qualitative BMedSci student project 
focused on the adoption of the SIGN intramedullary nail for long-bone fracture repair 
within Tanzania. This study was conducted by A. Gummaraju and supervised by KD 
and Dr. Semira Manaseki-Holland. (Appendix 2)  
Chapter 4: Tools for medical device procurement planning: A critical appraisal of the 
One Health Tool 
The final chapter presents a critical appraisal of the One Health Tool for health system 
planning. KD undertook this appraisal during an internship at the World Health 
Organization within the Essential Medical Products Department in March-May 2015. 
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KD developed a checklist informed by the findings of the three studies undertaken 
above, including considerations relevant to health technology assessment, MDE 
procurement, use or management, and used this to appraise the MDE related inputs and 
methodological assumptions of the One Health Tool. The relevance and usefulness of 
such tools for MDE related procurement planning in LMICs is further discussed. 
Discussion and concluding remarks 
The studies included in this thesis complement and build upon previous MDE related 
research undertaken by the WHO. The systematic review presented in Chapter 1 
expands upon a literature review included in the WHO's "Priority Medical Devices" 
report and adds original insights and value in two ways.(3) First, the study included here 
systematically searches, identifies and appraises globally relevant literature on MDE 
procurement and offers a comprehensive characterization of this literature, including 
relevant summative insights on best procurement practices. In contrast to the "Priority 
Medical Devices" report, the systematic review therefore also captures insights from the 
WHO's own publications and research in this area. Second, the systematic review 
includes a clear and concise account of relevant MDE prioritization criteria, derived via 
the use of reproducible and validated methods previously specified in a study protocol. 
The qualitative study presented in Chapter 2 additionally adopts a rigorous qualitative 
research design to explore the dynamics of MDE procurement in contrasting low- vs. 
middle-income country settings. While differences in MDE management between 
countries have been noted in previous WHO publications(3), no qualitative exploration 
of the issues contributing to such differences was previously undertaken. Research 
summarized here emphasises the role of social and political dynamics in MDE 
 9 
procurement and suggests improved MDE resource allocation processes and practices 
will require investment into, and empowerment of, professionals with a working 
knowledge of both biomedical engineering and health technology assessment methods.   
Chapters 3 and 4 include an MDE specific critical appraisal of health economic 
evaluation methods and health system planning tools first pioneered by the WHO. 
(19,20) Drawing on insights from research presented in Chapters 1-2, case studies 
"testing" the applicability, relevance and usability of WHO proposed methods and tools 
were designed. Original insights and recommendations on what methods appropriate for 
MDE focussed health economic evaluations and MDE related resource allocation 
planning are presented. 
The thesis concludes with an overall summary of research findings, their place and 
relevance in the global literature, including a discussion on potential limitations and 
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CHAPTER 1: METHODS FOR MEDICAL DEVICE AND 
EQUIPMENT PROCUREMENT AND PRIORITIZATION 
WITHIN LOW- AND MIDDLE-INCOME COUNTRIES: 
FINDINGS OF A SYSTEMATIC LITERATURE REVIEW 
 
The systematic review protocol enclosed in this chapter has been published: 
Diaconu K., Chen Y.-F., Manaseki-Holland S., Cummins C., & Lilford R. (2014). 
Medical device procurement in low- and middle-income settings: protocol for a 










Medical device procurement in low- and
middle-income settings: protocol for a systematic
review
Karin Diaconu1*, Yen-Fu Chen2, Semira Manaseki-Holland1*, Carole Cummins1 and Richard Lilford1,2
Abstract
Background: Medical device procurement processes for low- and middle-income countries (LMICs) are a poorly
understood and researched topic. To support LMIC policy formulation in this area, international public health
organizations and research institutions issue a large body of predominantly grey literature including guidelines,
manuals and recommendations. We propose to undertake a systematic review to identify and explore the medical
device procurement methodologies suggested within this and further literature. Procurement facilitators and
barriers will be identified, and methodologies for medical device prioritization under resource constraints will be
discussed.
Methods/design: Searches of both bibliographic and grey literature will be conducted to identify documents relating
to the procurement of medical devices in LMICs. Data will be extracted according to protocol on a number of
pre-specified issues and variables. First, data relating to the specific settings described within the literature will be noted.
Second, information relating to medical device procurement methodologies will be extracted, including prioritization
of procurement under resource constraints, the use of evidence (e.g. cost-effectiveness evaluations, burden of
disease data) as well as stakeholders participating in procurement processes. Information relating to prioritization
methodologies will be extracted in the form of quotes or keywords, and analysis will include qualitative
meta-summary. Narrative synthesis will be employed to analyse data otherwise extracted. The PRISMA guidelines
for reporting will be followed.
Discussion: The current review will identify recommended medical device procurement methodologies for
LMICs. Prioritization methods for medical device acquisition will be explored. Relevant stakeholders, facilitators
and barriers will be discussed. The review is aimed at both LMIC decision makers and the international research
community and hopes to offer a first holistic conceptualization of this topic.
Keywords: Developing countries, Prioritization, Procurement, Medical devices
Background
Medical devices and equipment are crucial for quality
health service delivery. Reports and research on low- and
middle-income countries cite a lack of basic medical
devices as well as medical equipment falling into disuse
within these settings [1,2]. This severely impairs health care
provision and also translates to lost resources and funds.
The WHO Priority Medical Devices project suggests two
potential causes for this problem [2]. First, medical device
manufacturers target high-income country economies due
to a higher potential profit. Thus, medical device supply
and equipment design are restricted to products and speci-
fications suitable for deployment settings with advanced
infrastructure and technologically knowledgeable human
resources. Second, issues around the judicious procurement
of medical devices arise for low- and middle-income coun-
tries (LMICs) [see Additional file 1: Definitions: Medical
device procurement]. Inappropriate selection of products
impedes equipment uptake and use within deployment
settings. Medical devices should be appropriate for and
* Correspondence: kdd217@bham.ac.uk; s.manasekiholland@bham.ac.uk
1Public Health, Epidemiology and Statistics Unit, Department of Health and
Population Sciences, University of Birmingham, B15 2TT Edgbaston, West
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Full list of author information is available at the end of the article
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Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
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readily available in LMIC settings as well as accessible and
affordable for health care facilities, their staff and national
governments [2-5].
However, little is known about how medical device
procurement does or should take place within LMICs, and
processes may substantially differ from those employed in
high-income countries (HICs). Within the latter settings,
technology acquisitioning processes are guided by princi-
ples of quality care delivery and value for money to ensure
containment of rising health care costs. A diverse range of
stakeholders is involved in deliberation of potential pur-
chases: clinicians, public health commissioners, researchers
and patients. The review of clinical and cost-effectiveness
evidence as well as value-based criteria such as equity form
the basis of such deliberations [6-10]. The WHO Baseline
Country Survey on medical devices illustrates that in
contrast to HICs, LMICs undertake medical device
procurement at national rather than regional or facility level
([11] and Table 1: Author’s calculation: chi-square with 3
degrees of freedom, total sample n =162, p <0.01). The
survey fails, however, to provide more granular detail on
stakeholders involved in these processes as well as principles
pursued—e.g. is cost-effectiveness a desired feature of
potential purchases?
To guide decision makers in the procurement of medical
devices for LMICs, numerous recommendations, guidelines
and tools have been issued by international think tanks and
public health organizations. Substantial heterogeneity can
be observed in relation to these: recommendations may
focus on procurement for specific interventions or service
delivery packages, clinical areas or specialties, as well as
entire health facilities and ancillary services offered [12-14].
The WHO itself recommends medical equipment selection
for procurement take the shape of ‘availability matrices’
[15]. This involves targeting clinical areas and interventions
associated to a country’s highest burden of disease and
identifying medical equipment key for investment in or
provision of said services.
To date, no systematic review and appraisal of the litera-
ture around medical device procurement recommendations,
guidelines and research exists. We propose to undertake
such a systematic review to identify how medical device
procurement and prioritization within LMICs should take
place in the future, based on research which reports on
procurement and prioritization processes as well as
recommendations put forth in publicized guidelines and
similar materials. The current paper serves as a study
protocol for this exercise. We believe that a systematic
review on this topic would prove beneficial to decision
makers and procurement practitioners within LMICs by
helping identify initial core principles for equipment
purchasing. Further, we wish to explore prioritization
methodologies proposed within the literature. Under
resource constraints, prioritization is a crucial part of a
procurement process and directly informs equipment
selection. Medical device-specific prioritization criteria
will be identified, and this may inform the wider debate
on how prioritization processes are shaped and imple-
mented [16-18]. Identified principles and methodologies
will be discussed and interpreted in light of information
relating to settings described, type of medical equipment
proposed for procurement, as well as type of issuing
organization and reason for document development.
The main research question is: What methods inform
or are recommended for LMIC specific medical device
and equipment procurement? In the course of exploring
the above study question, we also expect to consider: the
evidence base used to inform medical device procurement
methods and processes and the factors impacting upon
medical device procurement and the methods proposed
for medical device prioritization.
Methods/design
Search strategy
Early scoping searches on medical device procurement
methods for LMICs revealed a large body of grey literature,
issued by international public health agencies, think tanks
or similar institutions, but very few journal articles or
research studies. It was therefore important to design
search and selection strategies to be as broad and inclusive
as possible, with no time or language restrictions. The
range of documents to be included will, however, be
restricted to freely available digitized material, partly due
to resource constraints, partly because we believe this
Table 1 Procurement of medical devices at national level in relation to country income classification (World Bank 2014)
Country classification Does procurement of medical devices occur at national level?
(Responses from WHO Baseline Country Survey 2010)
Yes No
Low income 25 8
Low-middle income 31 7
Upper-middle income 30 17
High income 17 27
Total 103 59
Author’s calculation: chi-square with 3 degrees of freedom, total sample n =162, p <0.001.
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most closely mirrors the various materials that LMICs
would be able to access. We acknowledge this as a limita-
tion of the study; however, scoping searches indicate that
the majority of documents to be retrieved are part of the
grey literature and digitized and freely available through
the World Health Organization and ancillary institutions.
A full list of sources to be searched is provided in Table 2.
To identify relevant documents from the literature,
search terms grouped around three distinct topics will be
employed: medical devices and equipment, procurement
and LMICs. Guided by a consensus definition of medical
devices [19], the review will focus on any type of medical
device ranging from consumables (e.g. bandages, needles)
to routine medical equipment (e.g. stethoscopes, ECG
machines) and devices (e.g. condoms) as well as medical
furniture (e.g. delivery beds). Search terms will refer to
medical devices and equipment, medical supplies and
medical or biomedical technologies and will include rele-
vant subject headings. Further search terms and subject
headings include synonyms for procurement and terms
around LMICs and income levels.
An OVIDMEDLINE search string is provided in Table 3.
Where possible, keyword combinations similar to the
search string provided will be used in all sources in order
to identify the relevant material. No restrictions around
the specific type of material to be retrieved will be
employed: databases, reports, notices, presentations, con-
ference proceedings, journal articles, manuals and books
will all be reviewed provided that they are freely available
and digitized. Native language speakers will be identified
Table 2 Type of search conducted and sources searched
Search type Search sources




OVID MEDLINE, OVID Embase, Cochrane Library, CRD databases (DARE, NHS EED, HTA),
CEA Registry, LILACS, African Index Medicus, Econlit, HMIC
Keyword searches Website searches TRIP, National Guideline Clearinghouse, International Guideline Library, NHS Evidence and
Clinical Evidence (NICE), Clinical Evidence (BMJ), INAHTA, CADTH, HTAi, Web of Science,
CHE York, CHEPA, Cost Effectiveness Analysis Registry, Office of Health Economics
Organizational
databases/websites
WHO Health Technology e-documentation centre, WHO, UNDP, UNICEF, UNAIDS, WB
Group (IBRD particularly), MSF, AfDB, ADB, EBRD
National donor
agencies
DFID, USAID (including MSH), AUSAID, GIZ, BMZ, JICA, and other relevant agencies that




Contacting experts Contact with experts to identify additionally relevant literature
Table 3 Example of search strategy for MEDLINE (OVID SP) up to week 2 of January 2013
No. Search strategy
1. device.mp. or exp “Equipment and Supplies”/
2. (device* or equipment* or suppl*).mp. [mp = title, abstract, original title, name of substance word, subject heading word, keyword heading
word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
3. exp Technology, Radiologic/ or exp Technology Assessment, Biomedical/ or exp Fiber Optic Technology/ or exp Educational Technology/ or
exp Biomedical Technology/ or technology.mp. or exp “United States Office of Technology Assessment”/ or exp Technology/ or exp Food
Technology/ or exp Technology, High-Cost/ or exp Technology Transfer/ or exp “National Center for Health Care Technology (U.S.)”/ or exp
Wireless Technology/ or exp Technology, Dental/ or exp Green Chemistry Technology/ or exp Technology, Pharmaceutical/ or exp Remote
Sensing Technology/
4. 1 or 2 or 3
5. (procure* or purchas* or acqui* or commission* or buy*or order*).mp. [mp = title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
6. (countr* adj2 (income or poor or poverty or develop* or resource or low* or mid*)).mp. [mp = title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
7. (third adj2 world).mp. [mp = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol
supplementary concept, rare disease supplementary concept, unique identifier]
8. (emerging adj2 (econom* or market*)).mp. [mp = title, abstract, original title, name of substance word, subject heading word, keyword heading
word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
9. developing country.mp. or exp Developing Countries/
10. 6 or 7 or 8 or 9
11. 4 and 5 and 10
Conducted last: 28 January 2013, 15:10 (GMT). Number of records identified: 2,297.
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to assess, select and report on non-English studies, thus,
limiting potential translation bias.
Selection and inclusion
All records identified in the search will then be screened
for potential inclusion into the review (see Figure 1 for a
selection algorithm). At first stage, only titles will be
considered and all documents mentioning medical devices,
either specific devices or equipment/supplies in general or
interventions likely to make use of equipment (e.g. vaccina-
tions, orthopaedic surgery) will be retained. This is to
ensure that documents are indeed focused on the topic of
interest. One researcher will undertake title review; how-
ever, a second independent researcher will check a random
10% sample of documents for each of the sources searched.
Any disagreements will be resolved through discussion or
consultation with a third reviewer.
Abstracts will then be reviewed in light of four pre-
specified selection criteria or questions (Figure 2). These
are directly linked to the outcome questions to be investi-
gated and are formulated so as to retain documents
including recommendations or discussions of medical de-
vice procurement and prioritization processes, or docu-
ments clearly indicating factors which may impact upon
medical device procurement. In addition, we have chosen
to include only documents discussing processes relating
to the procurement of more than one device: this is
because we consider that any prioritization process poten-
tially employed in procurement would fundamentally rely
on the comparative assessment or evaluation of more than
one technology/product. Reviewers will, however, take
into account that documents may restrict their focus to
one device while still including a discussion on the relative
merits of similar devices: e.g. a document on the procure-
ment and pre-qualification of a particular intrauterine
contraceptive device may still be included provided that it
includes a more detailed discussion on similar devices and
their specifications [20]. Documents discussing only regu-
latory issues relating to procurement or medical device
supply have also been excluded as they are considered too
narrow in focus to provide meaningful information on the
outcome question set.
The selection questions to be used are detailed below
and have been piloted by two independent reviewers on a
sample of 20 documents retrieved from OVID MEDLINE
and the WHO E-Health Technology Documentation
Centre. The latter database has been identified in scoping
searches as including a large body of relevant material and
was therefore considered suitable for piloting. The ques-
tions were deemed appropriate for the purposes of this
study and are outlined below along with examples of doc-
uments identified in the piloting process as appropriate/
inappropriate for inclusion. These examples were made
available to reviewers for consultation during the study
selection phase of the review.
A. Is the record a guideline, recommendation or policy
document aimed at health service providers/
commissioners/managers, or does the record
include a clearly stated recommendation for
medical device procurement within low and middle
income settings?
Example of ‘yes’: World Health Organization [21]:
Procuring Single-use Injection Equipment and Safety
Boxes. The executive summary indicates that the
objective of the document is to “accompany
pharmacists, physicians, procurement staff and
programme managers through the process of
All remaining documents eligible for inclusion in review and undergoing data extraction provided full text documents are digitized and freely available
Documents retrieved through search strategy(Retain digitized materials with abstracts available)
Selection Step 1:Title appraisal (One reviewer)Retain: all titles referencing medical devices
Selection Step 2:Title appraisal (Second independent reviewer)Random 10% check of titles per each source searched
Selection Step 3:Abstract appraisal (One reviewer)See Figure 2 for selection algorithm
Selection Step 4:Abstract appraisal (Second independent reviewer)Random 10% check of abstracts per each source searched
Selection Step 5 (Optional: to be used when abstracts prove ambiguous)Full-text appraisal: Use criteria for abstract review
Figure 1 Study selection algorithm. Method for study selection to
be employed by the reviewers.
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procuring single-use injection equipment and safety
boxes of assured quality, on a national or international
market, at reasonable prices”.
Example of ‘no’: Ross et al. [22]. Study protocol:
Ethics, Economics and the Regulation and Adoption
of New Medical Devices: Case Studies in Pelvic
Floor Surgery [22]. Rejected because the methods
section of the abstract indicates this study uses
examples from a Canadian context; no link to
LMICs is stated.
B. Does the record highlight any clearly stated issues or
factors relevant to procurement or device
prioritisation for low- or middle-income settings?
Example of ‘yes’: Anderson, B. O et al. [23].
Optimisation of breast cancer management in low-
resource and middle-resource countries: executive
summary of the Breast Health Global Initiative
consensus, 2010 [23]. Abstract indicates that journal
article includes a discussion on “programme
infrastructure and capacity (including appropriate
equipment and drug acquisitions, and professional
training and accreditation).”
Example of ‘no’: Porto, J. P et al. [24]. Nosocomial
infections in a paediatric intensive care unit of a
developing country: NHSN 45(4), 475–479 [24].
Rejected because abstract does not mention
procurement or device prioritization.
C. Is a class of medical devices or medical equipment
generally the subject of the record? (i.e. is the record
focusing on more than one device?)
Example of ‘yes’: Kalifa et al. [25]. Imaging in
pediatrics. Strategy and economic implications for the
Third World, Annales de Pediatrie 39(2): 67–70
[French] [25]. Abstract mentions medical imaging
equipment and provides two distinct examples:
ultrasonography and roentgenography.
Example of ‘no’: Malkin, R., Anand, V. [26]. A Novel
Phototherapy Device ©. [26]. Rejected because
abstract indicates document focuses on product
development of a single device.
D. Does the record consider issues beyond medical
device regulation/regulatory policy—i.e. is the record
not restricted to medical device regulation?
Example of ‘yes’: Kalifa et al. [25]. Imaging in pediatrics.
Strategy and economic implications for the Third
World, Annales de Pediatrie 39(2): 67–70 [French]
[25]. Abstract indicates that document content is not
restricted to device regulation, instead focusing on two
medical device classes and their use in LMICs.
Example of ‘no’: World Health Organization [27].
Medical Device Regulations: Global Overview and
Guiding Principles [27]. Rejected because document is
restricted to a discussion on global regulatory
frameworks and principles.
Figure 2 Abstract and full-text inclusion and exclusion criteria. Method for abstract selection to be employed by the reviewers.
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Please note that the selection questions are used as
detailed in Figure 2. This means that documents will be
included in the review if answers:
! A, C, D = Yes
! B, C, D = Yes
! A, B, C, D = Yes
The selection criteria will be re-evaluated as necessary
by reviewers, and any amendments to this original study
protocol will be noted in the published systematic review.
We acknowledge that abstracts may prove ambiguous,
and that reviewers may therefore wish to refer to full-text
documents at times. When this is needed, reviewers
should make use of the same four questions specified
above for study selection, and note that, a full-text review
has been carried out. A random 10% sample of abstracts
obtained from each of the sources searched will undergo
screening by a second independent reviewer, and all
disagreements will be resolved through discussion or
consultation with a third reviewer.
Data extraction
All documents which were screened and deemed eligible
will be included in the proposed study. The task of data
extraction will be split across reviewers, who will read full-
text documents to obtain data on a pre-specified list of
variables and questions (see Table 4: Data extraction tem-
plate). Similar to the selection criteria, the data extraction
template has been piloted on a random sample of 17
documents which were deemed eligible for inclusion from
OVID MEDLINE and the WHO E-Health Technology
Documentation Centre.
To address our study aims and outcome questions, data
relating to the following five domains will be extracted:
! Document identifier and characteristics: This covers
information unique to the document (e.g. authors,
year of publication, journal) as well as a categorization
of the document according to purpose of publication
(e.g. guideline, research study).
! Described setting: Information on country descriptions
will be noted where available in order to provide a
context to data extracted and further interpretation.
! Methodological data: This is the most substantial
task and covers information relating to prioritization
and procurement methodologies as well as factors
affecting procurement processes. Where explicit
prioritization methodologies are described, reviewers
will be instructed to extract quotes or keywords
describing these processes in order to allow for close
textual interpretation. Further questions require
reviewers to provide dichotomous ‘yes/no’ answers
relating to the use of evidence in procurement (e.g.
use of cost-effectiveness evidence, health needs
assessments), availability of procurement policies/
frameworks (e.g. health technology management
frameworks), influence of stakeholders (e.g. which
institutions or facilities affect the process of
procurement) as well as influence of processes/
health campaigns (e.g. quality assurance, targeted
programmes or interventions). For any additional
information, reviewers wish to capture, an additional
“notes” section is provided.
! Equipment related data: Any information available
related to the equipment to be procured is captured
here: clinical area equipment is used in, equipment
specification, cost of procurement, and maintenance,
installation or decommissioning information among
others.
! Capacity building: Reviewers are asked to note any
proposed training strategies related to medical device
procurement in LMICs.
Analysis and interpretation
Two methods of data analysis will be employed for this sys-
tematic review, each corresponding to the type of data ex-
tracted. Where reviewers are tasked with extracting quotes
or keywords, relating in particular to prioritization methods
described in the literature, qualitative meta-summary was
deemed the most appropriate method for analysis [28].
Treating extracted quotes and keywords as a primary (i.e.
uninterpreted) description of phenomena that document
authors wish to report, qualitative meta-summary proposes
the grouping of topically similar data and the generation of
further abstractions aimed at describing underlying themes
and processes. This allows for a richer contextual inter-
pretation of data, something particularly valuable when
trying to generate initial theses in relation to how medical
device procurement and prioritization is viewed within
the literature.
For data otherwise extracted, i.e. dichotomous data
extracted on remaining pre-specified variables, narrative
synthesis was deemed appropriate [29]. In the first instance,
this will entail generating descriptive statistics and examining
associations between variables through the use of chi-square
(or Fisher’s exact) tests as appropriate. Associations between
the following variables may be investigated: presence of
health technology management frameworks (and actors
engaged in technology management) and use of commis-
sioning strategies for procurement, health service delivery
levels, evidence in procurement (e.g. health needs assess-
ments) as well as health facility equipment priorities and
assigned maintenance responsibilities for health care facil-
ity staff. Further explorations will focus on the disease
areas or type of equipment cited and specifications
recorded for these in addition to instructions on deploy-
ment in health facilities and human resource training
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Table 4 Data extraction template






1. Study ID + bibliographic information
2. Type of record
● Is the record a guideline/recommendation/policy document or an academic article?
● Is the document part of a greater study/document? (if so, appraise that document as well but link
information relating to evidence)
● Are the authors contactable?
3. Institution of origin and who the institution reports to
● Record institution (if this is an academic article, record university)
● Why did the institution develop the record?
● Under what remit does the institution operate? (e.g. if university was commissioned to develop record,
record how the institution commissioning the research will use the record, if specified)
4. Setting/country of origin and any information regarding the below (note if specified in record)
● Economic and development indicators: HDI level, GDP, GDP/capita, Health expenditure as % GDP, % total
government expenditure or medical device expenditure as % of health budget
● What does the disease burden look like? Is any epidemiological evidence presented?
● How is health care funded?
● What other factors related to country/countries in question are mentioned (e.g. income inequality, access
to health care, national security, infrastructure, health service infrastructure)?
5. Methodological data: Answers to be recorded to the below questions from the record considered.
1) Is prioritization of medical device purchasing/selection explicit?
a) If yes, describe the method presented in the record and further evaluate below questions.
2) Is it clear who/what institutions hold the responsibility for medical device management?
a) If yes, note the institutions and their remit (e.g. national, international).
3) Are budget impact (national, local or by facility level) or national health care/service funding policies
mentioned and if so is any relation to procurement or prioritisation made explicit?
4) Is health technology assessment mentioned?
Health technology assessment example phrases: evidence base; clinical and cost effectiveness data; HTA
appraisal systems; HTA process—i.e. timing, cost, staffing, expertise, national/international remit.
a) If yes, is it clear how the HTA evidence is integrated into the prioritisation and procurement decisions?
Describe the mechanism.
b) Is it clear who is responsible for HTA appraisal and for issuing recommendations? Who has access to the
HTA evidence? How is this disseminated?
5) Are direct care providers mentioned?
Examples of direct care providers: nurses, medics, volunteers etc.
a) If so, is it clear what their influence on purchasing/prioritisation is? (e.g. do they directly commission, do
they prefer certain suppliers)
b) Are any issues regarding staff training and ability to deliver services mentioned? (e.g. staff may not be
trained to use a particular device)
c) Is it clear how staff is involved in the maintenance of medical devices?
6) Are care pathways or clinical guidelines mentioned?
Examples of clinical guidelines: WHO guidelines for diabetes management, etc.
a) Is it clear what clinical guidelines or care pathway information was used in device selection or
prioritisation?
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Table 4 Data extraction template (Continued)
7) Is health needs assessment mentioned?
a) If yes, what are the health priorities of the population in question and how were they derived in the HNA
process?
b) Is it clear how the health needs assessment informed procurement decisions?
8) Are commissioning strategies for health services and equipment mentioned?
For example: Afghanistan’s MSH guide on “Equipment for BPHS for Health Posts” refers to a national
procurement strategy so both documents would need to be evaluated and the national procurement
strategy would form the basis for the guide assessed.
a) If yes, record what types of strategies are mentioned? (e.g. national, international)
b) If yes, what is the relation of said strategy to the current record being assessed? Does one form the basis
of the other, do they operate complementarily and is adherence to one or the other or both mandatory?
c) Follow up on the national or local strategy and undertake a record assessment.
9) Are health service delivery facilities (e.g. hospitals, health centres, mobile units) mentioned?
a) If yes, which facilities are directly mentioned?
b) If yes, is it clear which medical devices are a priority for each facility or facility level?
c) If yes, are ambient conditions of the facility necessary for device performance mentioned? (e.g. running
water, electricity availability)
d) If yes, and if a device list is present, is it clear if device purchasing was restricted to a particular class of
devices: e.g. consumables that do not require electricity, mobile devices that need little maintenance, etc.
10) Does the record mention expert advice on the device procurement/prioritisation?
a) If yes, what kind of expert would be consulted and what documentation do said experts provide to
inform device procurement/prioritisation?
11) Are particular standards regarding devices mentioned? Mentions of standardization regarding devices
could include naming specific brands, product specifications, specific suppliers, specific regulatory
nomenclatures)
12) Are any costs mentioned in the record?
a) If so, record which costs are mentioned.
13) Are execution strategies mentioned in regards to particular health campaigns? (either of national or
international importance)
Examples include: HIV/AIDS campaigns which are commissioned through UNAIDS
a) If yes, who/what institution advises on device procurement and prioritisation?
b) Is it clear what the recommendations regarding device procurement are? Note down recommendations.
14) Are more up to date versions of lists/guidelines/methods of the same record present?
a) If yes, appraise newer record versions as well.
15) Is evidence of evaluation strategies regarding procurement lists, guides, methods present?
a) What evaluation strategies are mentioned?
b) Who undertakes said evaluations?
c) Is it clear what evidence is being used to inform evaluations?
6. Equipment related data: Answers to be recorded to the below questions.




d) Record the equipment categories mentioned.
2) How detailed is the equipment specification? (i.e. are measurements mentioned; is a description
provided;)
3) How many distinct products are mentioned?
4) Is a mix of devices mentioned and is it clear if certain devices are complementary (i.e. they need to be
used in conjunction with one another)?
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levels, as well as installation and maintenance necessities.
The influence of publication year issuing organization and
reason for document development on details associated to
the above variables may also be explored. Documents may
also be grouped according to their type (e.g. research studies,
guidelines) to highlight potential differences in reporting on
procurement or prioritization processes. Capacity building
strategies related to procurement will be discussed. Mind-
maps showcasing associations may be created to provide
visual representations.
Reporting
For reporting purposes, we will follow the PRISMA state-
ment for systematic reviews and refer readers to this proto-
col for further clarifications [30]. We expect that we will not
be able to report on all items in the statement, e.g. relating
to risk of bias within or across studies (items 12, 15, 19, 22)
or to quantitative outcomes, synthesis of results or add-
itional subgroup analyses (items 13, 20, 21). Outcomes will
be discussed as aforementioned through the use of qualita-
tive meta-summary or narrative synthesis. Registration with
PROSPERO is not appropriate in the case of this review, as
it does not concern itself with a clinical intervention.
Discussion
It is unclear how medical device procurement and
prioritization take place within LMICs. Internationally pro-
posed guidelines, recommendations or reports—whether
developed by public health agencies or research institutions
—are routinely issued to counsel LMICs on this topic and
may impact upon their national policy formulation. It is
therefore germane to understand the procurement/
prioritization methodologies proposed within this literature.
The aims of this systematic review are to identify said
methodologies, explore the factors reported as affecting
procurement practices in LMICs and create an initial
framework for how medical device prioritization and
procurement should be designed and conceived in
resource-constrained settings.
We acknowledge several limitations of the proposed en-
deavour. First, we note the difficulty associated with
undertaking a first-line review on a topic associated with
methodologically diverse literature. We expect that docu-
ments reviewed will range from procurement notices and
emergency medical device lists to procurement manuals
or research studies on medical device prioritization. As
little prior evaluative literature on this topic exists and as
heterogeneous priority setting criteria are suggested to
be equally legitimate [31], we are reluctant to quality ap-
praise studies we include in the review or limit inclusion
to only one type of study which may advance a particu-
lar prioritization methodology. This may imply more la-
borious and complex data analysis and may furthermore
undermine the validity of any findings. Reviewing the
literature obtained from such diverse sources, however, is
greatly beneficial for hypothesis generation as it allows for
consideration of multiple viewpoints and identification of
minutiae associated with medical device prioritization and
procurement for LMICs. In particular, it will allow for the
mapping of all the different types of literature and poten-
tial methodological differences on this topic.
Second, we make no concerted effort to identify or
include national policy documents relating to medical
devices in this review. This is because the focus of the re-
view is normative and concerns itself with the identification
of procurement and prioritization methodologies within
Table 4 Data extraction template (Continued)
5) Does the list mention how many items of one product to purchase?
6) Are any national/regional device coverage targets set? (i.e. how many devices/institution/region
7) Is any cost data present and if so, note down what cost data is available.
8) Is any information on installation available and if so, note what recommendations are given.
9) Is any information on maintenance available and if so, note what recommendations are given.
10) Is any information on necessary ambient conditions supplied and if so, note what said conditions are.
(i.e. “needs constant electricity supply”)
11). Is any recommendation regarding device disposal given and if so note what said recommendation is.
7. Capacity building: Answers to be recorded to the below questions.
1) Does the record outline any strategies for training people in medical device purchasing or medical device
management?
a. If yes, record what said strategies are.
8. Notes
Recording of any additional information that seems of relevance.
Example: WHO Priority Medical Devices frequently refers to diagnostic coding systems and disability
classification systems.
Provided as Excel spreadsheet to reviewers. Data extraction template provided to reviewers.
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internationally disseminated recommendations and guide-
lines as well as research studies. We are thus interested
in answering the question of how procurement and
prioritization should take place considering current
research and guideline materials. We acknowledge that
national policies may in fact employ different procurement
or prioritization methodologies, which we may fail to iden-
tify here and thus, encourage further inquiries into both the
policy literature as well as the empirical implementation
literature beyond. Should materials meet inclusion criteria,
they will be selected for review. It is beyond the scope of
this review to undertake an appraisal of all internationally
available policy documents. Indeed, we caution that a sys-
tematic review of policies alone may fail to identify macro-
level issues and themes relating primarily to international
decision making paradigms (e.g. paradigms of international
donor organizations or funding bodies supporting LMIC
procurement). An inquiry into the normative bases of med-
ical device procurement for LMICs is valuable in the initial
exploration, and identification of issues, paradigms and
processes is to be considered by decision makers. Review
findings may provide a starting point to future policy
analyses or research endeavours within this field.
Furthermore, the review may be limited in scope, as it is
not designed to identify and include prioritization
methodologies referring to entire intervention packages
rather than devices or equipment. To make sure that
applicable methodologies are not discounted, reviewers
will consult experts in international health to identify any
such relevant methodologies and discuss the findings of
the current review in light of these.
An accurate understanding of medical device procure-
ment and prioritization methods is of particular importance
in resource-constrained settings with limited financial
capabilities, human resource skills and health infrastruc-
ture. The findings of this systematic review will provide
initial hypotheses as to what factors and stakeholders affect
these processes and may aid in the formulation of a quality
assurance framework able to provide LMIC decision
makers with a rounded conceptualization of the topic.
Additional file
Additional file 1: Definitions: Medical device procurement. Definitions
for medical device/equipment procurement and prioritization within
procurement cycles are provided.
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1. 1. INTRODUCTION 
Successful health service delivery hinges on the safety, availability, accessibility, 
appropriateness and affordability of medical technologies, including medical devices 
and equipment (MDEs). (1,2) Rising costs and the pro-technology bias encountered 
among patients and clinicians challenge health systems globally and prompt countries to 
explore cost-effective health care solutions. (3) 
To ensure efficient resource allocation and optimal technology usage, high-income 
countries (HICs) have invested in the development of health technology assessment 
(HTA) methods and institutions. Organizations such as the National Institute for Health 
and Care Excellence in the United Kingdom, the Canadian Agency for Drugs and 
Technologies in Health and the Medical Services Advisory Committee in Australia have 
been established to guide procurement decisions on the basis of evidence-review and 
cost-effectiveness principles. (4–6) Such agencies are increasingly emerging across low- 
and middle-income countries (LMICs); notable examples include organisations in 
Thailand, Taiwan and Mexico. (7–11) HTA methods are however inconsistently used 
across settings. For example, Griffiths et al suggest substantial differences exist in the 
use of health economic methods across LMICS.(12) Findings of the 2015 WHO Global 
Survey on Health Technology Assessment similarly indicate that MDE specific HTA 
appraisals focus predominantly on technology safety and clinical effectiveness rather 
than value for money.(13) 
Inefficient spending patterns relating to MDEs have been reported across LMICs 
resulting in technology deployment difficulties. Estimates suggest that between 40-70% 
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of MDEs in resource poor settings are broken, unused or unfit for purpose. (1,14) In the 
Priority Medical Devices report, the World Health Organization (WHO) suggests three 
causes for this problem: indiscriminate procurement methods, substantial 
infrastructural/financing challenges and absence of national regulatory authorities. (5)  
 
Little is known about how MDE procurement takes place within resource-constrained 
settings. The WHO Baseline Survey on Medical Devices is a recent attempt to explore 
this. (16) The survey’s findings suggest that LMICs predominantly conduct 
procurement at central ministry level within the public sector. However, the survey does 
not provide further granular information on how LMICs plan or select what devices to 
procure. Identifying best practices and common pitfalls in MDE planning may pre-empt 
challenges in technology deployment, adoption and use and lead to improved 
population health outcomes. Ascertaining pragmatic MDE prioritization criteria and 




This chapter reports on the findings of a systematic literature review meant to explore 
the following research questions: 
• What methods inform or are recommended for MDE procurement in LMICs?  
• What evidence-base is used in, or what factors impact upon, procurement 
methods/processes?  
• What prioritization criteria are used in MDE procurement?
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1. 2. METHODS  
The protocol presented in Section 1. 0. offers a full account of methods used. For ease, 
methods are briefly presented below. 
Searches and study selection 
Both bibliographic databases and grey literature were searched with no language or time 
restrictions imposed. KD and Matthew Bentham (MB) selected documents according to 
pre-specified screening and eligibility criteria. See Tables 1-2 for details on sources 
searched and search strategy employed; Figures 1-2 illustrate the document screening 
and abstract selection criteria.  
Searches retrieved documents referencing MDEs, LMICs and procurement. Two 
independent reviewers (KD and Samantha Burn - SB) screened titles for relevance, 
discarding documents not referencing medical technologies. KD and MB further 
screened abstracts according to pre-specified inclusion/exclusion criteria. (Figure 2) 
Documents with explicit references to MDE procurement processes or procedures 
within LMICs were retained; material focusing on the procurement/evaluation of a 
single device or on LMIC medical technology regulatory issues was excluded. 
Disagreements on the inclusion/exclusion of studies involved consultation of a third 
reviewer (SB) and were resolved by consensus. 
Data collection 
One reviewer (KD or MB) extracted data on a pre-specified list of questions from all 
included documents. (see Protocol) Questions related to: accounts of MDE procurement 
and technology management processes; the relevance of health HTA and health needs 
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assessments in procurement; the input of health care professionals or specialist staff  
(e.g. biomedical engineers, economists) in procurement decisions; device installation, 
maintenance and decommissioning procedures/recommendations; health service 
delivery levels and clinical guideline procurement recommendations; budget impact, 
technology costs and intended national/regional coverage levels. KD ascertained if 
documents included explicit accounts of MDE prioritization processes and extracted 
quotations or descriptions of processes for qualitative analysis. Please see Appendix 7 
for a full list of references and data extracted. 
Analysis 
Two methods of analysis were employed to summarize and interpret the data extracted. 
(Figure 3) Narrative synthesis was used to offer a summative and descriptive overview 
of issues relevant to research questions posed.(17) Qualitative meta-summary was used 
to explore MDE prioritization for those documents outlining explicit prioritization 
methods/processes. KD iteratively applied descriptive codes to the extracted data and 
then grouped similar codes into categories and themes. Emergent patterns and 
relationships between themes were explored to arrive at summative findings. (18)  
Reporting 
PRISMA reporting guidelines were followed as applicable. (19,20)  
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1. 3. FINDINGS 
Bibliometric analysis: 
The search strategy located 11,220 unique records of which 217 were selected for 
inclusion, all published 1984-2013. As several records retrieved were entire books or 
journal issues where more than one chapter or article met the inclusion criteria, data was 
extracted from 250 individual documents. Figure 3 shows a PRISMA flow-chart 
outlining the study selection process. Section 1. 6. includes a full reference list of 
included records and the ancillary electronic files include a full list of data extracted. 
 
Tables 3-4 present characteristics of included documents. The majority are peer-
reviewed journal articles (n=125, 50%) and recommendations or guideline documents 
synthesizing lessons from international procurement experiences/practices. (n=72, 29%) 
The WHO and other UN associated organizations authored 141 (56%) documents. Only 
50 (20%) documents refer to specific countries or regions, the remaining documents 
referencing resource poor settings or LMICs in general. (Table 4) 
 
As procurement methods may differ by technology, data on cited health 
conditions/clinical interventions (Table 5) and MDE descriptions (Table 6) was also 
extracted. Predominantly, documents reference HIV/AIDS and associated comorbidities 
(n=29, 12%) and interventions for reproductive, maternal and child health. (n=23, 9%) 
MDEs referenced include laboratory devices (n=22, 9%), equipment for surgical care 
(n=16, 6%) and reproductive health (n=16, 6%). No consensus classification system for 
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equipment or devices was stated; authors instead categorized equipment according to 
size, cost, clinical area or health service delivery level. (Table 6) 
Narrative synthesis: Procurement structures and methods 
 
1. What methods inform, or are recommended for, MDE procurement in LMICs? 
A distinction must be made between descriptions of MDE procurement structures – i.e. 
how stakeholders interact and reach decisions, from procurement methods – i.e. 
algorithms or approaches used to determine which technologies to purchase. 
 
i) Procurement stakeholders and their interactions 
Appraised documents identify different stakeholder groups interacting to reach 
procurement decisions. Stakeholders range from international donor agencies, LMIC 
governments and ministries of health to individual LMIC health facilities. Stakeholders 
operate at different health system levels and appear to perform different procurement 
tasks (Figure 4).  Across documents, authors indicate that procurement activities 
frequently involve all stakeholder groups outlined; only one document described 
processes where donors solely undertook procurement on behalf of LMICs. (21) 
At macro level, authors of reviewed documents describe international donor agencies 
and LMIC governments engaging in procurement partnerships. LMICs possess the 
human resource and health system capacity to support donor campaigns; in turn, donors 
share financial and technical resources. For example, Management Sciences for Health 
(on behalf of USAID) prompted the government in Afghanistan to use health economic 
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and ethical criteria in defining the basic and hospital care package. (22,23) Donors (e.g. 
USAID) and international agencies (e.g. UNICEF) enjoy a greater share of market 
power than LMICs due to their involvement in multi-country procurement. Donors thus 
provide an advantageous negotiation position for LMICs, helping secure flexible 
payment or bulk-pricing arrangements. (24,25) 
 
Potential disadvantages of donor involvement include sudden discontinuation of 
assistance arrangements and financial aid restrictions. (25) For example, donors may 
restrict financing to countries adhering to strict procurement/tendering regulations; such 
restrictions may preclude LMIC governments from strengthening technology-
manufacturing capacity through the award of national procurement contracts. (24) 
Similarly, funding opportunities may be restricted to donor-preferred causes such as 
HIV/AIDS diagnosis and treatment, and preclude investments into incipient health 
system infrastructure, including for example sanitary provisions (e.g. water and 
sewage), electricity supply and infection prevention and control protocols. (26) 
 
At meso level, LMIC governments, their ministries of health and relevant subunits 
engage in the minutiae of acquisition planning, tendering and equipment 
distribution/oversight activities. Stakeholders set procurement targets - i.e. project what 
equipment to procure via the use of experience or needs based planning methods (see 
next section) - and agree national technology distribution plans. (1,27) 
Not all medical device procurement decisions are made at regional, country or supra-
national level: individual health facilities also engage in direct acquisition. (28,29) 
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Authors of reviewed documents caution that such practices are inconsistent: hospitals 
frequently lack dedicated funding for MDE procurement and may instead rely on 
donations, reuse and recycling practices, to meet technological needs. (28,30,31).  
 
Whichever stakeholders engage in procurement processes, the literature is largely 
unclear on how stakeholder views are aggregated or divergent opinions handled - only 
three documents including descriptions of such accounts were identified. Nobre et al. 
point to the usefulness of multi-criteria decision analysis methods, aimed to aggregate 
and integrate individual stakeholder opinions to reach final technology selection 
decisions. (32) Consensus methods or DELPHI processes (33) and routine committee 
based evaluations of procurement processes (34) are further discussed. 
ii) Procurement methods 
Thorough review of the literature suggests two main MDE procurement methods are 
used, or proposed for use, across LMICs. Stakeholders either rely on experience to 
determine what equipment to procure or engage in needs-assessment exercises to 
determine what equipment is most appropriate for meeting current health service needs. 
When using the former method, past procurement and consumption patterns are 
reviewed and used as a template for reaching current and future decisions. For example, 
this method was used in the development of the first Core Medical Equipment lists 
collated by the WHO. To develop the latter lists, biomedical engineers and clinical 
experts reached a consensus on the type of MDEs that different health care facilities 
should stock based on professional expertise and experience. This method is particularly 
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useful in areas affected by little to no innovative practice, e.g. it may be used to keep an 
existing laboratory functional provided service delivery does not change. (27)  
 
In contrast to experience-based methods, needs-based procurement relies on 
stakeholders explicitly defining health priorities at any given time and agreeing service 
delivery targets based on context specific epidemiological information. For example, the 
WHO Priority Medical Devices Availability Matrix identifies conditions corresponding 
to the highest global (or national) burden of disease and indexes interventions 
corresponding to these conditions. (35) Devices necessary for carrying out each 
intervention are listed and added to a 'wish list'. Such methods thus identify prescient 
health needs and evaluate procurement options in the context of defined 
vertical/horizontal programs, available budgets, present physical infrastructure and 
human resource skill mix/availability. (36–38) Needs-based methods may also rely on 
the development of basic or advanced health care packages- e.g. see the Basic Package 
for Primary Care Services by the Ministry of Health in Afghanistan. (22,23) 
 
In practice, stakeholders are reported to use mixed-method approaches. For example, 
CENETEC in Mexico uses historical procurement trends to recommend what 
equipment to buy in clinical areas with little to no innovative or updated practice, and 
needs-based methods to issue procurement recommendations for national priority health 
care areas such as tele-medicine or cancer care. (39)  
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2. Factors and evidence inputs considered in procurement decisions 
Table 7 summarizes factors and evidence inputs referenced as influencing procurement; 
the citation frequency of each item is suggested as a proxy for the relative importance of 
the factor in decision-making. 
 
Equipment cost, specialist recommendations and technology regulatory approval are the 
primary factors that appear to influence procurement decisions. Authors of reviewed 
documents caution that the true cost of MDEs is underestimated in practice as 
stakeholders neglect to include costs associated with MDE maintenance, servicing and 
user training requirements. (1,39–44) Across the literature, the input of specialists is 
recommended to ensure improved technology procurement: e.g. biomedical engineers 
can advise on maintenance/servicing/user training issues, and health economists on the 
relative cost-effectiveness of technologies. (1,42,45–51) Appraised documents also 
cited international certification (e.g. approval by the FDA, a CE mark in the EU, 
inclusion in a WHO prequalification scheme) as a proxy for technology safety, a desired 
feature in MDEs to be procured. (41,52,53) 
 
Evidence inputs identified across the literature include: health needs assessment (HNA) 
exercises/reports, clinical guidelines and health technology assessment 
exercises/reports. HNA is cited in relation to needs-based procurement methods: i.e. 
routine health-needs appraisals clarify national investment priorities. (35) Authors of 
reviewed documents widely endorse the use of clinical guidelines for technology 
selection; however note these do not historically include clear technology 
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investment/use recommendations.(35) Additional inputs considered are MDE 
availability checklists and tools designed around clinical guidelines. (54–56) 
 
Few documents cite the use of HTA, though where referenced, the relevance of HTA 
for MDE procurement, more specifically for product selection, is strongly emphasised. 
(42,49) Authors of reviewed documents comment on the difficulty of undertaking HTA 
(health economics in particular) within resource constrained settings due to data paucity, 
lack of specialist capacity and funding, and a general lack of knowledge on how such 
evidence may feed into decision making processes. (1,50,51) MICs, however, have 
made substantial progress in the use of HTA for the promotion of transparent and 
evidence-based decision making: e.g. see HITAP in Thailand, CENETEC in Mexico 
and a bill for the promotion of HTA use across Latin America. (34,39,50) 
 
Data on the factors cited as affecting medical device uptake or use in LMICs was also 
extracted. Frequent challenges of relevance to procurement decision-makers include 
careful technology specification and alignment to deployment setting and ambient 




Findings of the meta-synthesis: MDE prioritization criteria 
One hundred and one of the 250 reviewed documents included explicit accounts of 
MDE prioritization methods; these documents were included in the meta-synthesis to 
explore and identify MDE prioritization criteria. Please see Appendix 3 for a full 
account of findings generated and codes and abstracted themes/topics developed during 
the meta-synthesis. 
Five main prioritization criteria corresponding to both normative and feasibility issues 
were identified across reviewed documents. Criteria are listed below in order of 
descending citation frequency. (Appendix 3) MDEs are prioritized for procurement 
when they:  
• Are of LMIC-appropriate technical specification, i.e. MDEs : 
o Align with the skills and coverage levels of available human 
resources: e.g. technologies are easy to use and do not rely on the 
presence of specialist staff; 
o Align with the infrastructure impositions encountered in resource 
poor deployment settings: e.g. technologies include water filters and 
provisions for uninterrupted power supply; 
• Correspond to essential or priority health interventions, i.e. MDEs : 
o Relate to health services already delivered within the current health 
system structure or add to the range of services to be delivered; 
o Relate to an established health priority and are clinically effective; 
• Are financially sustainable for the health system; 
• Are cost-effective; 
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• Are politically and socially acceptable in intended deployment settings. 
Recurrent themes in the literature concern the identification of priority health areas and 
services as well as the identification of technologies suitable to deployment settings. 
(See Table 9 for data extracted on LMIC friendly technical specifications.) For example, 
the WHO, USAID and UNFPA all recommend prioritizing MDEs used in interventions 
addressing prominent disease burdens or supporting existing health service delivery 
efforts. (30,35,57) Purchases are further screened and prioritized according to their 
suitability to LMIC settings: i.e. MDEs for which no trained professionals are present or 
which lack established maintenance or decommissioning services are deprioritized for 
purchase/marked for disinvestment. (31,39,41,58–60) 
Budget constraints, experiences gained in past procurement cycles, political/cultural 
support and equity considerations also influence prioritization decisions. Current and 
future budget impact is balanced against evaluations of past procurement performance: 
e.g. if supply chains are not present to source a particular technology, this is either 
deprioritized or alternative sources for investment identified. (61) The consideration of 
budget impact at product selection and technology purchasing/adoption stages in 
LMICs therefore contrasts with practices in high-income settings.  For example, 
countries such as the UK view budget constraints as secondary to adoption decisions 
and HTA assessors are urged not to reach technology selection decisions based on a 
product's likely budget impact.(62) Non-invasive, culturally acceptable technologies 
with records of accomplishment and safe use are preferred; however, technologies 
endorsed by political groups may further bypass normal prioritization or decision-
making channels and be procured on the basis of strong advocacy. (63) 
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Patterns in extracted texts suggest different types of criteria are considered at different 
decision making-levels.  (Figure 5) This may be due to stakeholders at each health-
system level undertaking/being responsible for different prioritization steps. For 
example, micro-level stakeholders - i.e. health care professionals in individual health 
facilities - are described as prioritizing equipment according to technical specifications 
and design: portable, durable, electric-surge resistant equipment. (64,65) Meso-level 
stakeholder - i.e. regional and specialist authorities engaged in procurement planning in 
the context of interventions/programs- in turn prioritize equipment that is affordable, 




1. 4. DISCUSSION 
 
The current manuscript is the first review to systematically appraise LMIC specific 
medical device procurement literature. The findings of this systematic review suggest 
that MDE procurement within LMICs presents substantial differences to technology 
procurement within HICs. While individual health facilities may have the capacity to 
directly tender in the latter settings, review findings indicate this practice is not 
consistent across LMICs. HICs further use HTA and health economic principles and 
methods to select technologies appropriate for reimbursement and advise on the 
containment of health care costs. (4,5) Only a fifth of documents included here 
reference such methods for MDE procurement. Difficulties in using health technology 
assessment and/or health economics within LMICs are widely noted in the literature; 
political, cultural and specialist support for the use of such methods is lacking and the 
necessary data on local epidemiology, costs and treatment impact for LMICs is also 
scarce. (8) Such methods are, however, recommended for the development of 
transparent and rational procurement practices(67–69) and more or less intense 
implementation pathways can be pursued. For example, Chalkidou et al (7) propose the 
development of a holistic decision-making system where HTA principles are 
incorporated in all stakeholder deliberations and applied to all publicly funded health 
care services. In contrast, Lilford et al. (70) recommend the use of a pragmatic decision-
algorithm to identify contentious investment options for which a full HTA report and 
health economic analysis is to be commissioned. 
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The review further identifies two over-arching methods used or proposed for MDE 
procurement: experience-based methods rely on the perceived success of previous 
procurement exercises; need-based methods instead identify current health needs and 
develop bespoke technology procurement plans to tackle these. It is necessary to 
conceptualize methods as embedded within specific decision-making systems: 
documents included in this review cited a wide-user buyer divide. Stakeholders at meso 
or macro health system levels are responsible for procuring technologies but are not 
direct technology users and cannot call on MDE use experience during product selection 
stages. In contrast, MDE users are likely to be heavily influenced by their own clinical 
or procurement experience and may neglect to objectively consider all potentially 
appropriate technologies that would meet health service needs and be financially 
sustainable. While no consensus emerges on how LMIC based MDE procurement 
should occur, opinions in the literature converge on what evidence inputs and factors 
should be considered in decision-making. Table 10 synthesises recommendations and 
best practice noted in the literature. 
 
The findings of the meta-synthesis echo previous work on normative and feasibility 
criteria considered by decision makers in technology investment and prioritization. 
(68,71–73) In contrast to previous conclusions, however, MDE procurement is chiefly 
driven by feasibility concerns: i.e. as MDEs run the substantial risk of being unused due 
to technology misalignment to deployment settings. Decision makers should therefore 
prioritize products with appropriate technical specifications and established 
maintenance services. Further research into a unified set of criteria able to guide LMIC 
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medical device and equipment procurement is needed. Criteria identified here may serve 
as a first draft of such a document. 
 
The findings of this review should be interpreted with due caution - this was a 
hypothesis generating exercise meant to explore the state of the literature; best practices 
in MDE procurement were synthesised to inform current professionals and researchers 
in this field of global trends. The search and selection algorithms were deliberately 
broad and only digitised materials were consulted. Materials were substantially 
heterogeneous, ranging from procurement bids and reports to guideline documents or 
procurement checklists. Normative and descriptive findings were not always clearly 
distinguished in the included documents and therefore are presented here alongside one 
another. Reviewed documents frequently included reflections on past procurement 
experiences (descriptive accounts) alongside notes on desired or optimal practices 
(normative accounts). A full picture of these accounts is offered: Tables 7-8 include key 
references to both descriptive and normative accounts under "areas of concern"/"best 
practice" respectively; Table 9 summarizes normative recommendations on MDE 
design as derived from descriptive accounts in the literature (references in Appendix 3); 
Table 10 summarizes normative positions echoed in the literature with relevant 
examples referenced. Despite the variability in sources, perspectives and accounts 
included, the systematic review offers a comprehensive account of methods and 
prioritization criteria relevant to MDE procurement efforts. 
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Despite the variability in sources and accounts included, the systematic review offers a 




1. 5. CHAPTER SUMMARY AND KEY FINDINGS 
A systematic review of the literature on LMIC-specific MDE procurement methods is 
presented; 250 individual documents were appraised. Documents were identified 
following a thorough search of both bibliographic and grey literature and application of 
strict inclusion and exclusion criteria. Materials included research articles, procurement 
reports, recommendation documents as well as guidelines or checklists. Across 
documents, a diverse set of recommendations on how MDE procurement should be 
undertaken emerges; recommendations and notes on best practice were synthesised 
using both narrative synthesis and qualitative meta-summary.  
Key Finding 1: The literature suggests two main methods are used (either solely 
or in combination) for product selection; stakeholders are either guided by past 
procurement experience or focus on identifying products to address a high 
priority condition. 
Experience based-methods imply the review and/or evaluation of historical procurement 
trends and updating procurement practices as needed on a case-by-case basis. The 
opinions and personal experiences of stakeholders, of both the procurement process and 
products selected, form the foundation of this method. (E.g. see (27,74)) Needs-based 
methods in contrast rely on stakeholders first identifying a health area of need and then 
products necessary for service provision in this area. (E.g. see (35))  Methods are likely 
to be combined in practice. 
Key finding 2: MDE cost and technical specifications/alignment to ambient 
conditions are the primary factors influencing product selection. Evidence 
 
35 
sources such as health needs assessments are also relevant, however, health 
technology assessment is mentioned in few documents.  
The systematic review also explored what factors, issues or evidence sources were 
noted as relevant to procurement planning. Authors noted that cost is the most 
significant factor affecting MDE selection: high product costs are prohibitive for 
resource constrained settings and decision-makers therefore procure cost-minimizing 
technologies. Authors of reviewed documents emphasise, however, that decision-
makers may neglect to consider the full life-cycle cost products are likely to incur; costs 
for user training, maintenance and servicing are frequently not considered. Where such 
costs have not been accounted for during product selection, devices are likely to remain 
unused during deployment.  
Use of relevant evidence may improve procurement planning; the systematic review 
therefore documented the types of evidence sources decision-makers may turn to when 
selecting MDEs.  Notably, the review suggests health needs assessments play a major 
part in procurement planning. In contrast, health technology assessment (HTA) 
reports/health economic (HE) evaluations are referenced in a minority of cases, 
suggesting the relevance and potential of such methods is not widely realized across 
stakeholders. 
Key Finding 3: The literature suggests MDE procurement is a complex process 
where stakeholders acting at different health system levels undertake different 
actions. 
Authors of reviewed documents emphasize that a multitude of stakeholders are engaged 
in MDE procurement. Macro-level stakeholders for example may set the overall 
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direction or scope for MDE related resource allocation; meso-level agents (e.g. regional 
planners) may instead be responsible for the tendering and distribution of products. 
End-users – that is clinicians and patients – are mainly consulted on issues of clinical 
need and product experience. The involvement of multiple stakeholders and tendering at 
meso-level by planning decision-makers, rather than clinicians, creates a user-buyer 
divide. This divide leaves room for discoordination when stakeholders do not realize 
effective and efficient communication channels between decision-making levels.  
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1. 8. TABLES 
TABLE 1: SOURCES SEARCHED* 
Search type Search sources 
OVID Medline 






OVID Medline, OVID Embase, Cochrane 
Library, CEA Registry, HMIC, Econlit, 
VHL Portal (includes LILACS) 
African Index Medicus, NHS EED, Web 
of Science (including CPCI)** 
Key word 
searches 
Website searches TRIP, National Guideline Clearinghouse, 
Office of health economics International 
Guideline Library, CHEPA, CHE York 
HTAi, CADTH, INAHTA  
Organizational 
databases/websites 
WHO e-health documentation centre and 
WHO website, UNICEF, UNAIDS, 
UNFPA, African development bank, 
Asian Development Bank, EBRD, World 
Bank, MSF, UNDP 
National/regional 
donor or research 
agencies 
DFID, MSH, AUSAID, GIZ, BMZ, JICA, 
SWISSAID, CIDA (Canada), DANIDA, 
AFD, ACORD, SIDA, IAC 
Grey literature ZETOC 
*Pascal was mentioned in the protocol but was not accessible; ‘Solutions for public 
health’, BMJ Clinical Evidence and EBRD were searched but found not relevant – 
searches were discontinued. 




TABLE 2: SEARCH STRATEGY 
1. device.mp. or exp "Equipment and Supplies"/ 
2. (device* or equipment* or suppl*).mp. [mp=title, abstract, original title, name 
of substance word, subject heading word, keyword heading word, protocol 
supplementary concept, rare disease supplementary concept, unique identifier] 
3. exp Technology, Radiologic/ or exp Technology Assessment, Biomedical/ or 
exp Fiber Optic Technology/ or exp Educational Technology/ or exp 
Biomedical Technology/ or technology.mp. or exp "United States Office of 
Technology Assessment"/ or exp Technology/ or exp Food Technology/ or exp 
Technology, High-Cost/ or exp Technology Transfer/ or exp "National Center 
for Health Care Technology (U.S.)"/ or exp Wireless Technology/ or exp 
Technology, Dental/ or exp Green Chemistry Technology/ or exp Technology, 
Pharmaceutical/ or exp Remote Sensing Technology/ 
4. 1 or 2 or 3 
5. (procure* or purchas* or acqui* or commission* or buy*or order*).mp. 
[mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
6. (countr* adj2 (income or poor or poverty or develop* or resource or low* or 
mid*)).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
7. (third adj2 world).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 
concept, rare disease supplementary concept, unique identifier] 
8. (emerging adj2 (econom* or market*)).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept, rare disease supplementary concept, unique identifier] 
9. developing country.mp. or exp Developing Countries/ 
10. 6 or 7 or 8 or 9 
11. 4 and 5 and 10 
Conducted last: 28 January 2013, 15:10 (GMT) 











































(% of total) 
Article 47 8 25 16 2  25 2 125 
(50.00%) 
Bulletin   3   1   4     
(1.60%) 
Checklist       3  3     
(1.20%) 




      1  1     
(0.04%) 
Evaluation  1       1     
(0.04%) 




        1     
(0.04%) 
Manual       14  14   
(5.60%) 
 
Policy  2       2     (0.08%) 
Procurement 
notice 











































(% of total) 
Recommendat
ion 
4 1 5 3  5 19 1 38   
(15.20%) 
Report      1 6  7     
(2.70%) 
Resolution       1  1     
(0.04%) 
Spread sheet / 
database 
      2  2     
(0.08%) 






















*Definitions: Research institutions or academic groups = Universities, specialist research bodies or collaborations; LMIC national health authorities = national 
governments, government units or departments; International consultants, NGOs or public health monitoring organizations = Organizations such as Management 
Sciences for Health, the Centre for Disease Control among others; Hospitals or health care delivery facilities = organizations with clinical health service delivery remit; 
Medical device manufacturers = commercial entities and device suppliers; Government sponsored donor organizations and the World Bank = USAID, DFiD, GIZ, 
CIDA and the WB; WHO and UN Associate = WHO, PAHO and UNDP, UNFPA, UNAIDS; Not identified = document authors solely, no identified issuing 
organization. 
Article = peer-reviewed material published in academic journal or magazine; Bulletin = notification; Presentation = conference presentation or talk/speech; 
Consultative document = draft document circulated for comment; Evaluation = audit document; Guideline = document identifying guiding principles and procedures; 
Information booklet = document providing basic information on interventions/devices; Policy = LMIC issued document relating to device management; Procurement 
notice = tendering or bidding documents, initial advertisements of tender; Recommendations = Research or review documents providing clearly stated summary 
recommendations; Report = document with pre-specified topic, may include research evidence, discussion of current and best practice; Resolution = document with 




TABLE 4: PARTICULAR COUNTRIES AND REGIONS REFERENCED IN DOCUMENTS 

















Cameroon (1) Peru (1) USA (1) *** Eastern 
Europe (2) 
 Congo (1) Guyana (1) Brazil (3)  Africa (1) 
  Mali (1) Mongolia (1) China (2)   
  Chad (1) Pakistan (1) Thailand (1)   
Eritrea (1) Philippines (1) Mexico (1)   
Ethiopia (2) Vietnam, (1)    
Gambia (1) Zambia (1)    
Afghanistan 
(2) 
Lesotho (1)    
Bangladesh 
(2) 
    
Kenya (1)     
Malawi (1)     
Morocco (1)     
Nepal (3)     
Tanzania (3)     
Uganda (1)     
Zimbabwe (1)     
*Citations are made in 50 documents (one document may refer to more than one 
country). Remaining documents reference LMICs generally. 
** Chile was classified as an upper middle income country up to 2014. 
*** The USA is used as a comparator in one study.
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TABLE 5: SPECIFIC HEALTH CONDITIONS, DISEASE AREAS AND 
SERVICES/INTERVENTIONS CITED ACROSS THE INCLUDED LITERATURE (FREQUENCIES 
OF CITATION)* 
Health conditions and disease areas cited 
and frequency of citations 
Service areas/interventions cited and 
frequency of citations 




Interventions for reproductive, 




Surgery and trauma care 13 
High burden diseases: diarrhoea, 
malaria, HIV, respiratory issues 
7 Emergency medicine and disaster 
response 
4 
Malaria 5 Injection practices 2 
Cardiological conditions 3 Imaging 2 
Respiratory conditions, asthma and 
COPD 
3 Blood safety 1 
Tropical diseases  2 Forensic science 1 
Gastroenterological conditions 2 Primary care 1 
Tuberculosis 2   
Bacteriological diseases and 
interventions 
1   
Measles 1   
H1N1, H5N1 1   
Narcotic use 1   
Renal disease 1   
Non-communicable diseases 1   
Fractures and orthopaedic conditions 1   
Cardiovascular disease 1   
*Total n= 124, remaining documents do not include references to specific health 
conditions. (One document may reference more than one condition/clinical area.) 
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TABLE 6: EQUIPMENT CATEGORIES FOR PROCUREMENT AS NOTED IN THE REVIEWED LITERATURE (N=131) 
Classification of equipment (frequency of 
citation) 
Equipment or device cited (frequency of citation) Selected key references* 
Cost and size High cost (>$25,000) (1)  
Large medical equipment (1) 
 
 SR20: Nah, 2007 
SR78: Miao, 2007 
Risk associated 
with use 
High risk: implants (1) 
 
 SR 35: Keller, 2010 
Area of use Surgical care and trauma 




Reproductive, maternal and 
child health (16) 
 
 







Respiratory  (4) 
 
Cardiology (4)  
 
Ophthalmic (1) 
Anaesthetic (5) Instrumentation and other devices 
(7) Oxygen supply and monitoring: concentrators 
and pulse oximeter (3) Intensive care (1) 
Instrumentation and resuscitation equipment (7) 
 
Condoms and contraceptives (6) Birth kits and 
instrumentation (8) Obstetric instrumentation and 
devices (2) 
 
Radiotherapy: megavoltage, linear accelerator (5) 
 
Laboratory and RDT (16) Imaging and laboratory 
(6), CT and ultrasound (4), X-ray (1) 
 
Gastroenterological equipment (1) 
 
Ventilators, nebulizer, equipment for diagnosis of 




SR40: Arevalo, 2007 
SR57: McCunn, 2010 
SR6.: Bewes, 1984 
SR167: WHO, 2007 
 
SR42: Chandani, 2001 
SR82: Nessa, 1992 
SR138: WHO, 1991 
 
SR162: Borras, 1993 
 
SR149: WHO, 2003 
SR158: Palmer, 2011 
 
SR84: Nicholls, 1984 
 
SR197: IUaTBLD, 2008 
 
SR15: Ribeiro, 2010 
 




Classification of equipment (frequency of 
citation) 




Cold chain, blood supply and 










Biotechnologies (1) Refrigeration, injections, 
transfusion devices and storage (3) 
Cold chain (2) Vaccines (1)  Infection control (2) 
 
 
HIV diagnosis and treatment (6) 
Malaria diagnosis and treatment (2) Tuberculosis (3)  
 
 
SR71: Ruyter, 1984 
 
SR19: Thorsteinsdottir, 2007 
SR148: Lloyd, 1999 
SR58: Ansa, 2002 
SR256: Woodle, 2000 
 
SR28: Walkowiak, 2008 
SR90: Onwuwejke 2000 





Secondary or tertiary (9)  
 
Primary level health care equipment(1) 
 




SR141: Kaur, 2001 
 
SR4: Unknown, 2005 
General 
descriptors 
Miscellaneous (11) Consumables/disposables, instruments, minor 
diagnostics and treatment/monitoring (8) 
Waste management (1) 
Injections (4) 
SR18: Hussein, 2004 
 
SR154: Pruss, 1999 
SR117: Ekwueme, 2002 




TABLE 7: EVIDENCE INPUTS AND FACTORS CONSIDERED IN MEDICAL DEVICE PROCUREMENT PLANNING 
Factors/evidence 
input  
Definition Area of concern Selected key 
references* 




Costs considered in the 
procurement planning 
process 




disposal, user training 








Include all afferent 
expenses associated with 
medical device deployment 












clinical or procurement 
specialist input into 
decision making 
Lack of availability 
within LMICs and 
potential lack of 
technology specific 








Create national training 
programs/specialized 
procurement units to advise 












FDA, EU- CE mark 
International 
registration may result 
in product price 
increases and prove 






High-risk equipment should 
be internationally certified 







health priorities and/or 
technological needs 
May not provide 
full/trustworthy 
information and be 
disregarded in national 





















Definition Area of concern Selected key 
references* 
















Incorporate medical device 
procurement necessities and 










Methods of economic, 




Data paucity on health 
impacts, medical 
device coverage, 
equipment life span, 








Within resource constraint, 
adopt transparent and 
evidence-based processes to 











TABLE 8: CHALLENGES AFFECTING SUCCESSFUL MEDICAL DEVICE UPTAKE AND USE 
Factor (frequency of citation) Definition Area of concern Best practice 
Alignment to deployment 
setting (n=175) 
Device alignment to healthcare 
delivery level and conditions 
encountered in deployment 
setting 
No clear indication which 
devices correspond to which 




Ambient conditions in 
deployment setting (n=95) 
Ambient conditions in 
deployment settings affecting 
successful medical device 
uptake/use 
Reflective of lacking 
infrastructure, medical devices 
do not reach full life-expectancy 
Develop technological needs 
assessment: note present 
conditions; consult LMIC 
friendly specification list 
Skill mix in deployment setting 
(n=134) 
Skill mix in deployment settings 
affecting successful medical 
device uptake/use 
Lack of safe medical device use 
and preventive maintenance 
training; medical devices do not 
reach full life-expectancy 
Provision of training manuals 
and supplier training for any 
purchase 
Device specifications (n=135) Device specifications to accord 
to the conditions in which it is to 
be used: e.g. durability, 
humidity/temperature resistance 
No clear indication of LMIC 
friendly device specifications 
Device specifications should 
conform to LMIC environment 
and settings (see Table 9) 
Installation and maintenance 
provision (n=66) 
Service availability/affordability 
for installation and 
preventive/corrective equipment 
maintenance; including financial 
resources 
Lacking financial and human 
resources to carry out 
maintenance/servicing of 
available devices 
Installation and maintenance 
services should be included as 
part of medical device 
procurement and all ancillary 
costs considered in procurement 
Decommissioning and disposal 
(n=16) 
Provision for safe medical 
device decommissioning and 
disposal; including financial 
resources 
Lacking financial and human 
resources to carry out 
Identify decommissioning or 
disposal mechanisms and 




TABLE 9: MEDICAL DEVICE SPECIFICATIONS AND DESIGN DESIRABLE FOR LMIC 
SETTINGS 
Design domain Specification 
User friendliness Easy to use; rapid; low training needs 
Portability Compact and portable (choose desktop 
variety if theft is an issue) 
Avoidance of bulky and heavy design 
Reliance on external factors Elimination of external power sources 
Include water purification system 
Minimal need for sample preparation 
Minimal need for spare parts 
Design Long shelf-life at ambient temperature 
Rapid 




Choice of durable material 
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TABLE 10: A SYNTHESIS OF RECOMMENDATIONS EXPRESSED IN THE LITERATURE FOR CONSIDERATION BY INTERNATIONAL DONORS, LMIC 
STAKEHOLDERS AND THE INTERNATIONAL RESEARCH COMMUNITY 
Recommendation Explanation 
Close the feedback loop The WHO deplores the mismatch created by low-resource settings procuring high-end technologies. (1)  
 
Authors in the literature recommend LMICs and donor institutions evaluate past procurement efforts and create 
participatory structures for health facility representatives to engage in planning/procurement consultations. This 
increases transparency and pre-empts technology adoption/use issues by informing all stakeholders of health facility 
needs/infrastructure/skill mix. 
Fully cost out potential 
purchases 
Authors in the literature note discrepancies in costing practices, we therefore recommend national costing templates 
are created and disseminated to facilities and procurement agents for MDE purchases.  
Costing templates should be context specific and include:  
a) Expenses related to equipment installation, servicing (inspection, installation, preventive and corrective 
maintenance, decommissioning and disposal); 
 
b) Investments into infrastructural refurbishments of deployment health facilities and user training that would aid in 
keeping MDEs operational.  
 
The WHO Cost-It templates present a good starting point for this at hospital or program level. We remind users to 
include inspection, installation and decommissioning/disposal costs in templates under the ‘other’ headings. (75) 
Make MDE servicing a legal 
requirement 
Authors in the literature recommend LMIC regulatory agents develop minimum, legally binding, standards for 
national/regional MDE servicing.  
 
Procured equipment should be subject to specialist inspection and installation once in deployment settings; service 
provisions/funding allowances for preventive and corrective maintenance, decommissioning and disposal should be 





Include explicit MDE 
availability 
recommendations in clinical 
guidelines. 
We note that historically clinical guidelines do not include specific recommendations on what medical devices should 
be available for specific interventions - authors note this as an issue for biomedical engineers or procurement agents 
engaged in product selection.  
Develop a list of generic 
specifications for LMIC 
friendly equipment. 
Authors in the literature recommend the elaboration and listing of generic medical device and equipment technical 
specifications to aid LMIC procurers. The list of broad product features we have identified in this review is a start in 
this endeavour, but international engineering expertise is needed to create technical specifications or target product 
profiles specific to LMICs. (Table 9) 




1. 9. FIGURES 

























FIGURE 3: PRISMA FLOWCHART 
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CHAPTER 2: MEDICAL DEVICE PROCUREMENT IN THE 
GAMBIA, ROMANIA AND IN THE VIEW OF 
INTERNATIONAL EXPERTS: FINDINGS OF A 
QUALITATIVE STUDY IN TWO CONTRASTING LMICS 
This manuscript will be refined for submission to a peer-reviewed journal as follows: 
K. Diaconu, A. Lindenmeyer, C. Cummins, I. Filip, A. Morar, M. Ndow, B. Cham, R. 
Lilford, S. Manaseki-Holland: The dynamics of medical device procurement under 
resource constraints: Findings of a qualitative study in The Gambia and Romania 
Contributions:  
KD has designed and conducted this study, conducting all primary fieldwork and data 
collection, as well as analysis and manuscript drafting. AL acted as a reflective and 
critical partner during data analysis and interpretation of findings and provided critical 
feedback during manuscript drafting. CC, RL, SMH supervised this work and similarly 
provided critical support and feedback during all study stages, ranging from design, data 
collection to analysis and drafting. IF, AM, MN, BC assisted in fieldwork and data 
collection in Romania and The Gambia, and acted as reflective partners during analysis 






Low- and middle-income countries (LMICs) face substantial challenges in the delivery 
of health services. Difficulties arise due to financial constraints, lack of technical 
capacity and/or trained workforce to manage or deliver services, and the restricted 
availability and accessibility of medicines and medical devices and equipment (MDEs). 
(1,2) MDEs are key health system components used across the spectrum of service 
delivery from disease prevention and diagnosis to treatment and monitoring. (3) 
Examples include in-vitro diagnostics, biotechnologies, implants, consumables, medical 
furniture and complex equipment such as Magnetic Resonance Imaging systems. (4,5) 
Current reports suggest that MDEs are not functional or poorly maintained in LMICs, 
resulting in impaired care provision and adverse health outcomes. (1,6,7) The World 
Health Organization (WHO) ascribes such issues to: undiscerning product selection and 
procurement, the absence of regulatory authorities able to oversee procurement and 
inspect devices, and the lack of funds necessary to procure high-quality products or 
keep devices operational during their life span. (5,8,9) 
Recognizing the relevance of MDEs in achieving universal health coverage, the WHO 
and international organizations such as Management Sciences for Health issued 
guidance on procurement and product selection. (10,11) Chapter 1 presents the findings 
of a systematic literature review of the international bibliographic and grey literature on 
MDE procurement: recommendations for best practice are summarized and discussed. 
Reviewed documents recommend careful consideration of life-cycle costs and technical 
specifications during product selection. Procurement decision-makers should consider 
the overall cost of devices, including user training, maintenance and decommissioning, 
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and select products that can withstand the local conditions of resource poor deployment 
settings, e.g. lack of clean water or interrupted electricity supply. Additional 
recommendations within the reviewed literature (12,13) and elsewhere (14–16)  concern 
the use of health economic or health technology assessment evidence to promote 
transparent decision-making and maximize health utility given scarce resources. The 
principal argument within this literature is that MDE procurement within LMICs could 
be greatly improved if health technology assessment methods were taken up. 
To explore the dynamics and specificities of procurement processes and methods in 
both low and middle-income countries, KD designed and conducted a qualitative study 
involving semi-structured interviews and fieldwork components in The Gambia and 
Romania. To gain insights into processes and decision-making dynamics in LMICs 
more generally, high-level experts in international agencies consulted on MDE 
procurement were also interviewed. The primary aim of the study was to explore the 
context in which procurement decisions were made and the roles played by various 
actors: doctors, nurses, local and national managers, policy makers and international 
agencies. The study explored the barriers and facilitators that decision-makers at various 
health system levels – ranging from individual health care facilities to regional or 
national authorities – encountered during product selection. Additionally, the study 
sought to identify what guidelines, tools or information sources stakeholders used to 
reach product selection decisions: were stakeholders using the developed guidelines on 
MDE procurement or relying on different decision-rules to support their choices? 
KD designed this study as an open-ended inquiry into MDE procurement in both 
settings. Bourdieu's theory of the logic of practice offered a theoretical lens for 
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interpretation, (17) suggesting that difficulties in the implementation of rational and 
systematic MDE procurement processes in LMICs may emanate from stakeholders 
attributing significant symbolic relevance to MDEs. The dynamics, constraints, 
motivations and incentives stakeholders face when engaged in such 'games' were 




Settings: The study sought to encompass one low- and middle-income country each to 
explore potential differences due to health system development. KD visited the Gambia 
and Romania, each for a two-week period, during September-October 2013. Specific 
country choice was dictated by practical considerations: KD had contacts in the 
ministries of health in both countries. The time frame was sufficient to visit all regions 
of the Gambia and two regions within Romania. Plans were put in place in collaboration 
with MN and IF in advance of fieldwork to visit a suitable range of health facilities and 
to recruit relevant participants. (Table 1) KD and MN/IF visited 11 health facilities 
across The Gambia and 7 facilities across the Sibiu and Alba regions in Romania (Table 
2). 
Interviews and focus groups: A topic guide for semi-structured interviews and focus 
groups was developed. (Appendix 4) KD and MN/IF conducted pilot interviews with an 
eligible participant in each country: the topic guide was appropriate for both settings. 
Interviews and focus groups were conducted in private offices/meeting rooms and lasted 
40 minutes on average; two Gambian participants and one Romanian participant were 
interviewed in an informal setting. Interviews with international consultants were 
conducted by phone and lasted approximately one hour. Participants were provided with 
a study information and consent sheet (Appendix 5), the latter being returned to KD 
prior to each interview. 
Participants and sampling: KD targeted participants from each stakeholder group 
identified as relevant to MDE procurement in the systematic literature presented in 
Chapter 1. (Table 1) Purposive and convenience sampling strategies were employed to 
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target professional groups with relevant experience (Table 3). A snowball approach was 
used to allow participants to recommend further individuals likely to be eligible for 
inclusion in the study; 75 health care professionals, managers and administrators, 
consultants and policy makers were recruited on the spot (Table 4). One Romanian 
hospital refused participation due to the manager's negative experiences with UK 
research institutions. Additionally KD approached and interviewed four international 
experts frequently consulted on issues of MDE procurement in high-level international 
organizations or consultancies. KD had no contact with participants before study 
commencement; participants had no prior knowledge of the interviewer. 
Ethics: The study was approved by the University of Birmingham Ethics Committee, 
the Gambian Special Cases Committee for Ethical Review and was cleared by the 
Regional Inspectorates for Public Health in Alba and Sibiu, Romania. (Appendix 6) 
Data collection: Interviews and focus groups were conducted until data saturation for 
each participant group was reached; saturation was discussed after each facility visit and 
phone interview with experts. Three repeat interviews were conducted with stakeholders 
at regional- and country-health system levels: two in the Gambia and one in Romania. 
All interviews/focus groups were audio-recorded and transcribed verbatim. Reflective 
field notes were written up after each interview/focus group. Transcripts were not 
returned to participants for checking. Interviews in Romania were conducted in 
Romanian (KD's native language) and one interview in Gambia was conducted in 
Spanish; a native Romanian speaker (Razvan Sandru - Gesellschaft fuer Internationale 
Zusammenarbeit) and Spanish-fluent researcher (Alice Kilpatrick - University of 
Edinburgh) verified transcript translations. 
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Potential barriers to obtaining a full, undistorted picture were noted in a field diary by 
KD and MN/IF and are acknowledged as study limitations. Where participants were 
interviewed at work, interviews were occasionally rushed. In the case of focus groups 
conducted in the presence of superiors, some participants did not take part due to 
discomfort. The effect of an English language barrier was minimal in The Gambia; IF 
decoded colloquialisms used by Romanian health care professionals. Analysis and 
interpretation of the decision-making dynamics in Romania may be colored by KD’s 
prior experiences in the country. 
Notably, only one focus group was conducted in Romania. Participants in Romanian 
health facilities were less likely to agree to focus group discussions due to an inherent 
resistance to information sharing. One-to-one interviews were welcomed, as participants 
did felt they could voice negative or critical opinions when senior staff members were 
not present. 
Analysis: A general inductive approach was used for coding and the framework method 
initially chosen for analysis.(18) NVivo was used for analysis; collections of Romanian, 
Gambian and international expert transcripts acted as cases for generating framework 
matrices. KD first familiarized herself with the data by listening to recordings and 
reading transcripts and field notes. KD, CC and SMH coded three transcripts from 
different participant groups, discussed and agreed a coding structure, which KD applied 
to all further transcripts. (Appendix 8) Relations between codes - including similarities 
and differences - were noted for further exploration and codes were grouped into 
categories and reduced iteratively. The constant comparison method was used to check 
code content and structure; coding, analysis and interpretation of data were conducted 
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simultaneously. (19) KD and AL critically discussed relations between codes and 
emerging themes; in discussions, Bourdieu's theory of the logic of practice was deemed 
a suitable lens for interpretation. (17) This theory was not consistently used from design 
to interpretation of findings: this was a novel study purposefully designed to be 
exploratory.  (20) 
Bourdieu’s theory was chosen for its unique combination of subjectivist and objectivist 
elements: it posits the existence of agents in a structured reality that agents co-structure 
via their participation. (17) Bourdieu's reality is made up of different 'fields': e.g. the 
field of scholarly inquiry. Fields are temporally and spatially bound, arbitrary in the 
goals set and principles followed (the nomos) and the rules and procedures enacted (the 
habitus). The dispositions and motivations of agents engaging with the field (the illusio) 
revolve around relations of power and ownership of capital. For Bourdieu, capital can 
be economic, cultural or symbolic - it is the bargaining chip used to substantiate the 
interactions and dynamics within each action field. (See Box 1 for an example) 
Research team and reflexivity: KD is a female PhD student at the University of 
Birmingham, where she trained in the use of qualitative research methods. KD designed 
the study, organized and conducted fieldwork in The Gambia and Romania. Prior to 
study commencement, KD had substantial knowledge of high-income country health 
technology assessment methods and systems: KD is familiar with NICE health 
technology assessment guidelines and resource allocation processes in the UK in 
particular. During field visits, she adopted a critical external "observer" point of view 
and wished to uncover the motivations and dynamics behind stakeholders' MDE product 
selection decisions: it was important to discern what "value commitments" participants 
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held.(21) KD did not adhere or advocate for any particular theory while conducting the 
study or first analysing the data: exploring the transparency and reproducibility of the 
decision-making processes and motivations of stakeholders was a first analytical 
priority. KD later employed Bourdieu's theory of the logic of practice to contrast 
behaviours and motivations of country participants (i.e. short-termist behaviours arising 
from specific cultural and political dynamics) to those of experts (i.e. views echoing 
long-term utility maximization and rational action theory). 
KD's interpretation of findings, as well as study participants' attitudes and responses 
towards KD, may additionally be coloured by KD's status as a Romanian national. In 
The Gambia, KD identified as Romanian and was therefore perceived as a citizen of a 
fellow-developing nation: this meant participants approached KD openly, in many cases 
affirming KD was not biased towards a "Western" attitude. In contrast, in Romania KD 
was frequently acknowledged as "not fully Romanian" due to belonging to a German 
minority and having chosen to study abroad in the UK; Romanian participants therefore 
viewed KD as a "Westerner". 
SMH, CC, RL and AL all assisted in study design, data analysis/interpretation and 
manuscript preparation; SMH additionally oversaw the first interviews and provided 
critical feedback on KD's performance. MN and IF, both public health professionals 
with experience in qualitative methods, acted as research assistants in the Gambia and 
Romania respectively; BC and AM facilitated the progress of the study by assisting in 
the ethical approval procedure. MN and IF were monetarily rewarded for their time 
assisting in data collection. 




MDE Procurement: How does it happen? 
Figures 1 and 2 outline procurement processes in The Gambia and Romania. In both 
countries, procurement is initiated by the requests of health care workers or medical 
personnel in health facilities. Requests for new products are based on clinical practice 
needs (clinicians decide on what to procure based on their experience) or demands of 
the local population. Health facilities usually do not possess the discretionary funds 
necessary to procure new products, thus relaying requests to regional or national level 
authorities. 
At regional levels, requests are centralized, verified and further relayed to national 
authorities. Differences in request handling at ministerial level were apparent: Gambian 
officials prioritize requests until funds are exhausted. In contrast, the Romanian 
Ministry of Health first allocates funds for outfitting eight national referral hospitals, 
considering requests from smaller municipal and city hospitals only after these 
investments. 
Legal restrictions apply in both countries; facilities and regional authorities are 
prohibited from procuring MDEs that cost more than 100,000 Dalasi in The Gambia 
and 30,000 Euro in Romania. Most minor MDE purchases - e.g. syringes, dressings, 
stethoscopes and minor diagnostic or monitoring equipment - fall below this threshold. 
Due to restricted funds, facilities in The Gambia usually enter donation arrangements 
with hospitals or universities abroad. In Romania, hospitals seek co-financing for 
investments from local councils or charities. Procurement based on public means must 
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be conducted publicly and transparently: in The Gambia, bids for government 
procurement contracts are placed in national newspapers; in Romania, an online bidding 
platform is used. The Gambian Public Procurement Authority and Romanian Office for 
Medical Devices and Equipment oversee and audit bids and processes. 
MDE Procurement Decisions: What Do They Mean? 
In conversation with participants, KD explored processes and methods behind product 
selection. During the analysis of this data, KD and AL became aware of the relevance of 
Bourdieu's theory on the logic of practice for interpretation. (Table 5) 
1. MDE procurement as a field of service delivery 
Discussions on procurement and product selection revolved around service delivery and 
the relevance of MDEs. Individual products are prized for their function in patient 
treatment and their role in the provision of safe and high-quality health services. 
Gambian participants noted that the absence of equipment might result in negative 
health outcomes and loss of patient confidence in facilities and their ability to provide 
care:  
 “Maybe sometimes you know you do have a review meeting on the outcome of a 
case that we are not very happy with, for example, the case of a maternal death. 
(...) We sit and debate on that day, just to find out, what went wrong. Sometimes 
also you might find out that certain equipment is lacking, so that is why.” 
(Nursing Officer, Major Health Centre, Gambia) 
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"Not having drugs or adequate equipment means the people lose confidence in 
the facility. They notice we do not have, so they do not come. Why would they?” 
(Officer in charge, hospital, Gambia) 
MDEs are an instrument by which the public and health system can place pressure and 
expectations on health care providers. Should facilities not have the equipment to 
diagnose or treat specific ailments, the facility's relevance in the overall system 
decreases, patients are referred elsewhere and public displeasure may follow: 
 “This hospital, it's a regional hospital, but here all patients come in from 
smaller hospitals. Then, what happens, since we can't do the studies [tests], well 
– (…) we refer to Banjul.” (Doctor, Cuban medical delegation, Major Health 
Centre, Gambia) 
"Each year we keep praying that nothing happens to this one [sterilizer], 
because if it does, it is another scandal." (Principal Nursing Officer, Hospital, 
Gambia) 
Romanian respondents viewed the possession of MDEs as a mark of quality: e.g. the 
availability of high-end complex equipment in facilities indicates that the country 
can/cannot rise to European/Western standards of care.  
 "So, at the level of, the priority of the ministry is to ensure the efficient 
functioning of a regional emergency hospital within each region. (...) With at 
least second-class equipment fit, to ensure coverage for multiple traumas, at 
European efficiency standards." (National policy maker, Romania) 
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“There are things, which exist in the West, but do not exist here, and we live 
very well even without those things. (…) It's a joke: we live.” (Medical director, 
Municipal Hospital, Romania) 
 
2. The nomos of MDE procurement: Why select this product? 
When asked for the reasons behind product selection, participants were apprehensive 
initially but a common understanding and articulation of motivations emerged in time 
(the nomos). 
Gambian health care workers indicated that the MDE requests submitted to health 
facility management or the Central Medical Store were in response to observed needs. 
Clinicians observed patient demands or need for a specific service and selected a 
suitable MDE for procurement based on their own clinical experience as opposed to 
external guidelines or international recommendations. 
“If someone has high blood sugar, so checking the blood sugar of that person is 
necessary, despite the machine not being available. It’s our responsibility to 
request it so that the authorities know that there’s a need for it.”(Interview, 
Ophthalmic nurse, Major Health Facility, Gambia) 
A similar discourse pattern was observed in Romania. Managers iterated that patient 
demand was the driving factor behind clinicians' procurement requests. 
“We realized that within the diagnoses put within the hospital, among the radius 
of this town, there were a lot of urological problems (…) We have patients. Now, 
 
94 
tell me what you [the doctor] need. (…) A scope like this. OK, we get that.” 
(Manager, Hospital, Romania)  
Managers had less altruistic motivations and requests were often prioritized based on a 
product's potential return on investment in order to ensure the facility's survival in a 
precarious and underfunded health system. Romania had undergone repeated health 
system reforms in recent years and most minor to medium sized hospitals had closed. 
Managers of remaining facilities were anxious over their facility's performance and 
relevance; continued development and expansion of clinical services (including the 
purchase or leasing of MDEs) became a vehicle for attracting funding, patients and 
staff, and remaining operational. Availability of high-end equipment in facilities ensures 
patients are not referred elsewhere and draws funding from the national health insurance 
provider (reimbursement for services can only be claimed by hospitals offering end-
treatments). 
 “I tried in the past years, since I am here - so three years - to improve the 
material base, it's very important for a hospital. (...) After the reform 3 years 
ago, when 2 years ago they[the ministry] reduced the number of hospitals, 
they[the ministry] have positioned themselves regionally, to cover an area of 
about 30-40km, if you look at the map of the country, what it looks like. (...) So 
then we said, as a strategy for the future, we tried to raise our “addressability” 
[ability to address population demands/service needs]. Because in the end this is 
it - health is a business too - it sounds ugly you know, business, but this is the 




At ministerial level, decision-makers had less difficulty in articulating motivations. 
Acknowledging patient needs and requests by individual facilities, decision-makers at 
this level were nonetheless bound to follow national policies on service delivery and to 
ensure financial sustainability for the health system: 
“As I said, we have to prioritize based on needs. And most of our priorities now, 
I think all countries, African countries are trying to target the Millennium 
Development Goals: improving maternal and child health. So, the priority is 
based on that, (...) so we do get equipment for providing services at the various 
level, yes.” (National Medical Stores, Gambia) 
“First of all, we are talking about following health policies, and after the 
policies, about investments, requests from the territories, investments in health. 
So, at the level of, the priority of the ministry is to ensure the efficient 
functioning of a regional emergency hospital within each region. So at least 8 
(...)As a second priority, we talk about ensuring outpatient clinics and main 
county hospitals - so, equipping all the county hospitals in all county capitals. 
Ensuring a minimal equipment fit, or standard (...)This fit was agreed by a 
committee of specialists in the field and discussed with the World Bank, it is 
within the available budget - or a potentially available budget - but which can 
ensure a pathway for the patient - an appropriate clinical pathway.” 
(Government official, Romanian Ministry of Health) 
Given resource constraints, procurement requests underwent further prioritization at 
different health system levels. Criteria listed as relevant to prioritization by participant 
groups in both countries are summarized in Table 6. Criteria mentioned are similar to 
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those identified in the systematic literature review presented in Chapter 1, with two 
notable exceptions. Participants did not discuss normative criteria such as cost-
effectiveness or value for money, but additionally considered implementation issues: 




3. The habitus of procuring: What dynamics frame stakeholder interactions? 
Bourdieu describes habitus as a socially constituted principle governing social 
interactions within the field; the habitus limits agents to a specific range of critical 
thought and action. (23) Breaking away from the habitus means adopting an external 
view of the field, one that KD and the study team was privileged to hold in The Gambia 
and Romania. 
Decision-making within the Gambia appears to be strongly influenced by duty of care 
towards patients. The dynamics observed and described by participants were team-
oriented, based on open dialogue and negotiation: e.g. KD noted that Gambian health 
care professionals frequently conduct team meetings to reflect on practice issues 
(including MDEs) in the bantaba - a round, central meeting place within each facility. 
Requests for MDE procurement still followed a specific chain of command and were 
reported to the Officer in Charge/CEO of each facility, but could additionally be 
discussed in an informal environment aimed at promoting dialogue.  
“When the heads of department request, we go through that requisition (...)At 
that point I don't know, but most of the time, what we think is ideal, is for 
example, if the head of departments make their requisition, then they sit as a 
team, and they see and prioritize the requisitions they need.”(Principal Nursing 
Officer, Major Health Centre, Gambia) 
Participants appeared to face severe resource constraints with a strong sense of 
camaraderie. This is reflected not only in their actions - e.g. by émigré Gambians 
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sending in support for the country - but by the terms used by participants - e.g. 'brothers 
and sisters': 
"The provision of the equipment, normally by the government, philanthropists 
and as well as some donor groups, for instances some of our brothers and 
sisters could be somewhere in the western world and form an association to help 
back home their families and their communities and their country, as a result 
they mobilize some funds to buy this equipment or going to some institutions like 
hospitals and gather some second hand materials." (Regional health authority 
representative, Gambia) 
However, severe resource constraints impede planning and result in un-coordinated and 
short-term practices. The Gambia does not have a MDE procurement policy and a 
working inventory of MDEs was only collated recently; there is no distribution plan for 
MDEs and products are given out on a per-request basis. The system is reactive and 
vulnerable to manipulation: 
“There’s no overall plan. For instance, if we - I remember we need blood 
pressure machines. I went to the main stores in Kotu, I couldn't find. But 
somebody gave me a drop that you know, the ministry has been donated some 
BP machines, you know. So, I went there, and he said no no no, this is for the 
provinces and I need to go there. So, I said, but you know, could you give me 5 
minutes? Then I was able to convince him and I got a few. But if I had not got 
that relationship, somebody else could not have had. These things are lined up.” 
(CEO, Hospital, Gambia) 
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This lack of central planning and monitoring results in an attitude of carelessness by 
individual MDE users and hopelessness in the minds of government decision-makers:  
"I will still advocate for transparency - more transparency, more accountability 
for resources. Because, what I actually realize is that - because it's government, 
many people don't tend to care much, so, yeah, that's what I also feel. 
Sometimes, they'll even tell you - ah it's not coming from your pocket - but it's 
actually coming from your pocket. Yeah, somehow, because you're being taxed, 
you're doing this, you're doing that. It's still your money - it's just the same 
money. Actually there is more transparency and accountability. And then, if the 
laws that are made by GPPA - that is the regulating body - are actually or 
strictly followed, I believe the mechanisms will be improving. (Government 
official, Gambia) 
Within Romania, decision-making is a hierarchy-driven process, framed by the laws 
governing the health system. Professionals in facilities noted that it was the hospital 
manager and the government that ultimately decided what was to be bought. Meetings 
between the medical director, accountant and manager at the hospital were described 
more as a formality rather than a decision-making mechanism. 
“Interviewer: I understand. So, is there discrimination between departments and 
wards? Who decides who is a priority: the gynecological ward or...? 




Managers expounded on their role in decision-making, and the powers held within 
facilities, while clinicians and accountants shied away from describing themselves as 
participants of the process: 
“The personnel being smaller and easier to control, as it's a small hospital, any 
problem that comes up I find out about the second day, in a little summary of 
priorities for me. I need to know what happens in the hospital, telemedicine isn't 
working, the oxygen station is broken, we miss something in the emergency care 
kit.” (Manager, Hospital, Romania) 
Managers’ role as final decision-makers also endangers them: managers lose their 
position should the hospital enter into debt for more than three consecutive months. 
This regulation constrains decision-making and inhibits managers from showing 
initiative: 
 “Let's say it like that, we do not have enough autonomy. But now I read they 
are modifying the laws, with penalties and so on. We live under constant threat 
of penalties and restrictions.” (Manager, Hospital, Romania) 
"When they are told, when it's put in the law. It's in the law, if from March, you 
have so many debts you are dead. You cannot think of something else, what 
creativity can you have." (Regional public health authority representative, 
Romania) 
Hospitals with little funds rely on the ministry for updating their stock. Participants 
viewed the ministry as both an adversary and benevolent patron able to fulfill facility 
requests, although few requests are honored: 
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"Yes, I can tell you a fortunate case from 2012, (...) We received a sum of money 
for the procurement of medical equipment - of course with the agreement that 
the local authority would co-finance these with a percentage between 5-10%. 
This was then. And then we finally felt like the Ministry acknowledged us. (...)We 
did the same last year, but in 2013 we unfortunately heard no echo. (...)I think 
they do acknowledge, and I am sure they listen, but there are no funds." 
(Financial Director, Hospital, Romania) 
4. MDEs: More than economic capital? 
The final concept relevant to this analysis is that of capital: Bourdieu distinguishes 
economic, cultural and symbolic forms of capital.(23,24) Capital determines and defines 
one agent’s position or domination over another. Participants across both countries 
ascribed symbolic relevance to MDEs due to their role in service provision and their 
ability to confer status and garner recognition for health facilities:  
“Every hospital should have their own sterilizing department and system if they 
want things [services] to really work and make the target of qualitative delivery 
of care. Service care.” (Principal Nursing Officer, Hospital, Gambia) 
The procurement and possession of devices substantiates the power of procurement 
stakeholders. Participants' accounts reflect that facility managers make the final 
decisions of what to request or procure at micro health system level, while ministry 
officials wield power over procurement at macro level. 
"You know, here, everything is administration. They decide on everything, every 
unit head, your only problem is if you need something you write it and request it 
 
102 
from them. If they have it, they will provide, if they don’t then well that’s what 
happens." (Dental worker, Major health centre, Gambia) 
"And then there is cardiology, similar, at this point still I say, why should my 
patients leave (this county), because I am a county with pretty powerful 
economic development and I have the possibility to keep them here in Sibiu, or 
to have the services here, why won't you [the Ministry] let me provide them? I 
have the ability, why not let me? Because you're [Sibiu county] cheating the 
other, and they [the Ministry] don't allow it. They [the Ministry] won't approve 
anything. (Representative regional public health authority, Romania) 
The second form of both economic and symbolic capital relevant to MDE procurement 
is funding. Across Romania and The Gambia, participants face severe constraints. 
MDEs cannot be purchased or maintained due to lack of financial resources: the 
availability of financial resources impacts facility 'survival'. 
"It's a problem until you don't have money. (…)If we had money we would 
procure, if we had money we'd get equipment, if we had money we'd buy drugs. 
So for example this year I cut the meal tickets [for staff]. (...)Probably we will 
have some sort of legal battle with the union but we will see what happens when 
they ask us to court. I don't know what to say - the situation in our system is 
horrible. "(Financial Director, Hospital, Romania) 
‘Technical capacity’ is a third form of economic capital relevant to selecting and 
maintaining MDEs: technical experts are needed to assist in technology inspection, 
procurement, maintenance or resource allocation planning. Within both the Gambia and 
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Romania biomedical engineers and health economists were largely absent. The Gambia 
had access to one technician and one qualified biomedical engineer within the UK 
Medical Research Council Centre and one health economist within the WHO country 
office. The scarcity of biomedical engineers and technicians results in impaired service 
provision: 
“The fact that there is no immediate engineers to fix them when they are down, 
so when they are down, they need to contact us. You can imagine the turnaround 
time, how long it takes for it to be fixed. (...)So we realize, we purchase them, 
fine. But we need to have somebody there to make sure that they are in good 
order.” (Biomedical engineering technician, Gambia) 
In Romania, KD found no health economists or biomedical engineers to interview and 
regional authorities noted that few members within the ministry were trained in public 
health. In contrast to The Gambia, participants rarely discussed MDE maintenance 
issues as hospitals purchasing MDEs are legally required to ensure services are 
available for preventive and corrective maintenance of equipment. Hospitals therefore 
require manufacturers to provide such services; maintenance costs are routinely 
included in MDE tenders. 
Technical expertise could also be disseminated/accessed via guidelines or 
recommendations. Few participants professed any knowledge of international MDE 
procurement guidance or health technology assessment methods. One Gambian 
clinician mentioned he was aware of guidance relating to MDEs for maternal, 
reproductive and child health. One Gambian technician and WHO country office 
representative additionally knew of procurement process and health technology 
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assessment guidance. In Romania, financial directors and managers said that they 
conducted an informal cost-benefit analysis before engaging in procurement; when 
prompted it became clear that these analyses did not explicitly consider clinical 
evidence or patient outcomes. 
5. Improving MDE procurement: international expert comments on field and habitus  
Chapter 1 highlighted that stakeholders at supra-national levels also influence 
procurement; such stakeholders include consultants in health policy, biomedical 
engineering and health economics in international organizations such as USAID, the 
World Bank or WHO. To explore experts' transnational experiences and reflections, KD 
conducted in-depth interviews with four such high-level consultants active across 
international organizations, consultancies and academia. 
In contrast to respondents in The Gambia and Romania, respondents in this group 
focused on the field of 'resource allocation'. Experts do not differentiate between 
investment decisions in MDEs, medicines, health services or programs: the nomos or 
end-goal is to maximize health utility given scarce resources. 
Consultants view MDE procurement in LMICs as an ad-hoc and uncoordinated resource 
allocation exercise susceptible to corrupt and collusive decision-making practices: 
“I think it’s really very variable what you see in the field. In general I would say 
that the default is a totally ad-hoc process that’s based on the influence of 
industry.” (Health policy and health economics consultant) 
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Opinions voiced by participants in this group suggest that corruption and collusion are 
part of the habitus of LMIC stakeholder interactions.  
“Another obvious indication of the problem [corruption/collusion] is when you 
look and see what they’re buying and you see: oh, ok, according to NICE 
guidelines - which have a certain spending envelope – a certain thing [device] is 
not cost-effective and then you see that Columbia and Romania are buying it. 
There’s a problem there.” (Health policy and health economics consultant) 
“Something that’s in the back of my mind is always the whole issue of 
corruption and collusion and so on. Because we know that that has happened 
many times in the devices business and it is not something we have very good 
defences against it. It’s part of our procurement challenge that when you look at 
the specifications you need to be able to see in the specifications whether they 
are wide enough to ensure competition but on the other hand specific enough so 
that the buyer gets something they can use.” (Consultant on health systems and 
financing) 
Such issues may be perpetuated by hierarchical decision-making structures, a lack of 
open communication and the wish of central level stakeholders to retain power and/or 
prestige: 
“Telling someone the state of your facilities – if it’s too bad it will look bad on 
you, if it’s too good you might not get what you want. (…) So your status is 
important and it affects how you relate to people and therefore what you give 
away to them. And that information I think is always the key block, because 
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giving away information, giving away power, control and it’s hard to do when 
that’s your responsibility.”(Biomedical engineer) 
Participants consider that these issues, coupled with the lack of knowledge of 
international guidelines or recommendations on MDE procurement, result in suboptimal 
procurement and resource allocation practices.  
When asked about solutions to this problem, experts indicate that development of a 
transparent and systematic decision-making system would be ideal. 
 “I think that you have to handle this [corrupt and collusive practices] in the 
context of the design of benefits plans. (…) There should be an effort depending 
on what the problem is, but starting with maybe the most expensive things or 
perhaps starting with what’s the big health problem (…) to look at what the 
most cost-effective alternative is.” (Health policy and health economic 
consultant) 
Participants acknowledge, however, that the success of such systems hinges on the 
availability of both decision-makers with the political capital to influence behaviors and 
analysts with the required technical expertise to advise on potential health system 
investments. In the case of MDEs, ministry stakeholders could thus empower 
biomedical engineers and health economists to advise on product selection given a 
country's unique care context. Examples of such efforts include the National Center for 
Health Technology Excellence in Mexico (CENETEC) (10) or the Health Intervention 
and Technology Assessment Program in Thailand (HITAP). (25) 
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Participant responses indicate that strengthening of technical expertise and capacity in 
biomedical engineering and health technology assessment is a first priority for LMICs, 
given that MDE procurement recommendations and tools already exist:  
"I think that there’s more of a political, technical, case to be made right now 
more than tools or capacity, which I believe exists. Of course they could be 
better, of course they could be tailored, but I think one is just making a case to 
decision makers that this is an essential function of the health system.[to 
appraise investments]" (Health policy and health economic consultant) 
Technical experts or analysts are therefore prized as a form of symbolic capital due to 
their role in staffing and creating rational resource allocation systems: 
"So I think it is almost, you almost need like, like a neutral broker. Someone 
who’s paid for the service and not in commission on the actual deal to find out 
what is the best way to buy a particular device or maybe even that might be the 
wrong question.”(Consultant on health systems and financing) 
Experts deplore the lack of human and financial resources to develop HTA systems 
across LMICs, resulting in minimal take-up of such methods: 
"High-income countries tend to use health technology assessment more and 
more compared to the others. Which is a shame because it should happen the 
opposite way. (...) But it’s not happening partly because of limited resources for 




Findings within this study suggest that technology procurement is a complex game 
wherein health care professionals endeavor to address patient needs and health facility 
managers act to strengthen and expand their institutions’ role within the health system. 
A user-buyer divide exists in both settings: while clinicians note patient needs and log 
procurement requests, it is health facility managers and/or policy-makers at central 
government levels that ultimately decide what products to purchase. The process and 
criteria for product selection and/or prioritization are not consistent or well defined. In 
The Gambia, product selection is discussed at ad-hoc governmental meetings. 
Stakeholders at this level have little to no knowledge of local needs or expertise relating 
to international MDE procurement recommendations or technical requirements (e.g. 
biomedical engineering and product technical specifications), methods (e.g. health 
technology assessment) or tools (e.g. checklists). Similarly, in Romania, the government 
relies on a group of clinical experts for decisions on outfitting the main eight referral 
hospitals but the criteria and decision-making process behind final MDE procurement 
for small and medium-sized facilities are unclear. 
In both countries, procurement is far from a rational and systematic resource allocation 
exercise. Instead, processes are driven by contextual and cultural factors such as 
hierarchical structures and the struggle of facility managers to ensure institutions’ 
‘relevance’ and ‘survival’. International experts acknowledge and deplore the effect of 
such issues on decision-making and draw attention to corrupt and collusive decision-
making practices in LMICs more generally. Experts note the difficulties LMICs face in 
contextualizing international recommendations and guidance in the absence of technical 
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expertise, local data and the political capital necessary to support transparent decision-
making. Biomedical engineers are needed to advise on or undertake product selection 
and maintenance, and economists should advise health ministries on medium to long-
term resource allocation and service planning. 
Barriers and facilitators to rational and transparent policy making 
It is pertinent to acknowledge barriers and facilitators to rational and transparent policy 
making and resource allocation. In both settings, the health system's lack of stable and 
predictable funding acts as the primary barrier to rational decision-making. The acute 
lack of funds to support health service delivery means that stakeholders cannot 
adequately plan future service delivery or resource allocation, or indeed have to 
overturn plans already made in order to cover basic services for which funds have 
become scarce. Participants in Romania, for example, reflected that funds for 
intervention delivery ran out in the third quarter of the year, making any plans for MDE 
acquisition moot. 
The opaqueness of decision-making structures and stakeholders' unwillingness to share 
information are further barriers to rational resource allocation. In Romania, health 
facility managers and staff were unclear on how and why the Ministry of Health would 
allocate MDEs to individual areas/facilities. No appeal mechanisms for rejected MDE 
requests exist and government officials were reticent to discuss the exact criteria for 
resource allocation, only indicating that expert committees made decisions to support 
national health policies. Interviewed regional representatives instead suggested that 
health policy played a minimal role and that political pressures or incentives 
predominantly influenced decisions. Expert consultants also identified the systemic lack 
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of transparency and stakeholders' unwillingness to share information - and thus to give 
up power and open oneself up for criticism - as barriers. Corrupt and collusive practices 
were also noted though no direct examples were offered in interviews. 
Wider literature on priority setting suggests participatory structures promoting open 
communication among stakeholders facilitate rational resource allocation. (21,26) 
However it is important to note that such structures need to cover all health system 
levels so that stakeholders are empowered to participate in all relevant deliberations. For 
example, Gambian stakeholders created participatory structures for health facility 
representatives to engage in resource allocation decisions at meso health system level, 
however local and regional representatives were still effectively excluded from ministry 
level meetings. The Gambian Permanent Secretary for Health, the representative of the 
National Medical Stores and Finance Ministry were instead responsible for resource 
allocation at ministry level. However, Gambian participants were more knowledgeable 
than Romanian counterparts when asked about the motivations behind MDE 
procurement, echoing The Gambia's emphasis on achieving the MDGs. 
Stakeholders acknowledged the presence of technical analysts - versed in health 
technology assessment and/or possessing relevant technical knowledge of biomedical 
engineering - as a further facilitating factor to rational policy making. When empowered 
to take part in resource allocation planning, such professionals can assist stakeholders in 
undertaking needs assessments or systematic evidence evaluations to inform product 
selection and use. Analysts of this type are additionally likely to possess the relevant 
knowledge of international methods and tools that may be helpful in product selection. 
For example, The Gambia has access to biomedical engineers and in those cases where 
 
111 
engineers have been consulted, MDEs with suitable specifications to The Gambian 
infrastructure were procured, and successfully adopted, used and maintained in health 
facilities. 
While the lack of knowledge of international resources on MDE procurement should 
certainly be acknowledged as a barrier to rational policy-making, it is worth noting that 
this is not the primary factor behind poor decision-making. The above sections 
emphasize that even should analysts and/or professionals with relevant knowledge be 
available, the lack of funding for the health system, opaqueness of decision-making and 
lack of suitably empowering participation structures will counteract any potential 
benefits professionals may bring unless these systems also change. 
Limitations 
Findings presented here should be interpreted with due caution. The study is restricted 
to two case studies of MDE procurement in LMICs, purposefully including a low-
income (The Gambia) and upper middle-income country (Romania) to capture 
maximum divergence. Conclusions reached apply to the public health sector: processes 
and/or stakeholder motivations within non-governmental, international organizations or 
the private sector were not explored. While contexts will differ across settings, the 
current study illustrates the potential use and relevance of Bourdieu's theory on the logic 
of practice for the contextualization of procurement decision-making processes and 
dynamics in LMICs.  
Study findings highlight the need for further capacity building within LMICs and for 
careful contextualization of international procurement guidance. Interventions targeted 
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at obtaining MDE procurement and management improvements need to focus on 
putting in place people able to understand, navigate and ultimately change the fields, 
nomos and habitus encountered among LMIC stakeholders. Methods, tools and 
guidance to empower these professionals are available. (10,15,16,27) To aid The 
Gambia in more systematic product selection, investments in local biomedical 
engineering capacity and the development of a national policy on medical devices could 
be a first step. Engineers would have recourse to internationally developed tools and 
guidance and could adapt this to the Gambian setting if empowered by the ministry and 
health system. In contrast, Romania may benefit more from capacity creation in health 
economics. The creation of a health technology assessment body to incorporate views 
from stakeholders and advise national decision-makers on procurement would foster 
dialogue, enhance transparency and promote rational resource allocation. The impetus 
for capacity building in biomedical engineering and health economics is rarely realized 
or acknowledged by country respondents: it is the responsibility of experts, high-level 





Informed by the preliminary findings of the systematic review, a qualitative study into 
the procurement processes of two contrasting LMICs – The Gambia and Romania – was 
planned and carried out. The aim of this study was to explore the empirical aspects of 
MDE procurement planning and decision-making.  
Key Finding 4: Fieldwork findings largely corroborate conclusions drawn from 
the literature review: procurement is a complex, multi-level, multi-stakeholder 
process driven by stakeholder experiences. Limited evidence is considered 
during product selection.   
The study found that across both the Gambia and Romania, MDE procurement is driven 
largely by the clinical and management experience of physicians and health facility 
managers or policy-makers. In line with systematic review findings, different 
stakeholders are involved with managing MDE procurement. Health facility managers 
and clinicians were able to influence the procurement of devices that fall below a 
specific cost-threshold (e.g. 30,000 EURO in Romania) at institutional level. National 
level stakeholders were instead responsible for the selection, purchase and distribution 
of high-cost technologies across national health facilities.  
Key Finding 5: Decision-making dynamics are strongly influenced by culture 
and considerations of power and prestige. These dynamics are substantiated by 
stakeholders equating MDEs to objects of symbolic relevance.  
Study participants across both settings recognized MDEs as indispensable elements of 
service delivery and prized technologies as symbolic forms of capital. The relevance of 
 
114 
MDEs results from participants conceptualizing the possession of technologies as 
proxies for institutional prestige or quality of care. Facilities with more up to date and 
varied MDEs are able to attract further funding both via reimbursement mechanisms, as 
well as directly via patient fees. Given this symbolic relevance attributed to MDEs, 
procurement decision-making does not take the form of rational resource allocation, but 
ad-hoc and prestige driven processes. Cultural and socio-political elements, such as 
health facility’s managers need to rigidly control asset purchases and the struggle for 
health facility survival in an underfunded health system, additionally influence 
stakeholder interactions and dynamics.  
Key Finding 6: The uncoordinated and socially constructed procurement 
environment is susceptible to manipulation; experts note the presence of corrupt 
and collusive practices across LMICs generally. 
Given the multitude of incentives and factors influencing MDE procurement – as well 
as lack of an evidence-based and transparent MDE selection and resource allocation 
framework - corrupt and collusive practices take hold. International experts with cross-
national experience iterate the presence of such issues across LMICs more generally. 
Experts therefore suggest that attempts to improve MDE procurement must include 
careful stakeholder management, including technical capacity creation, and perception 
negotiation to be successful.   
Key Finding 7: Changes in procurement systems can only be brought about by 
careful country-specific and sensitive implementation: this requires suitable 
professionals foremost. Frameworks, methods and tools to improve processes 
exist, the human resources to implement them in LMICs do not. 
 
115 
The fieldwork in both countries uncovered similarities across low- and middle-income 
settings. The main point of comparison is the dearth of biomedical engineering and/or 
health technology assessment professionals able to advise on MDE procurement issues. 
Knowledge of international procurement guidance was additionally poor across both 
settings. Notably, however, study findings suggest MDE procurement challenges are 
substantially different across low- versus middle-income settings: The Gambia is 
struggling with procurement and management of minor low-cost technologies (e.g. 
glucometers), whereas Romanian stakeholders mainly focus on the procurement of 
medium- and high-cost technologies (e.g. ultrasound and CT scanning machines). 
International expert opinions complement the in-country fieldwork and suggest MDE 
procurement differences between low- and middle-income countries exist. Experts 
advise that contextually relevant interventions must be designed to improve resource 
allocation processes. Investments into the human resource capacity of countries are at 
the forefront of improving MDE procurement. In this case, both countries would benefit 
from the availability of technical experts in biomedical engineering and health 
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Two teams of eleven players are engaged in a football game.  
Field: The overarching structure or process that frames agents’ actions: the 
competition or the football game itself. 
Nomos: The "fundamental law of a field" (28), the implicit or explicit tautology that 
prompts players to engage in the game:  each team's and player's desire to win and 
proceed to the national championship. 
Habitus: The rules of the game and the space to manoeuvre within and around the 
rules. Players are cognisant of the off-side rule, optimal goal scoring strategies, 
create new strategies and dynamics in the course of play. For example, players adapt 
to individual passing skills, enacting new tactics.  
Capital: The instrument around the possession of which the field is structured; 
capital can be economic, cultural or symbolic. The football is economic capital; the 
knowledge and skill in handling the ball, planning or enacting a strategy is cultural 
capital. Player status conferred by experience, skill or possession of the ball is 
symbolic capital. 





TABLE 1: PARTICIPANTS TARGETED FOR INCLUSION 
Participant type Justification 
Health care professionals in small or 
medium sized health facilities (up to 250 
beds). 
Clinicians are primary MDE users. 
Institutional, regional or national health 
facility, service and program managers 
Previous literature review notes 
stakeholders as relevant to the procurement 
process.  
Regional or national policy makers, 
including regulatory, public health and 
finance officials 
Stakeholders influence policy, financing 
and/or regulatory structures relating to 
devices. 
International consultants active in 
medical device procurement 
International organizations such as the 
WHO, World Bank and other think tanks 
and academic institutions offer medical 






TABLE 2: NUMBER OF INTERVIEWS AND FOCUS GROUPS CONDUCTED 
 The Gambia Romania International 
consultants 
Total 
Interviews 17 18 4 39 





TABLE 3: NUMBERS AND TYPES OF STUDY PARTICIPANTS 







42 5 0 47 
Health facility 
managers 




0 5 0 5 
Regional health 
authorities 
1 1 0 2 




















1 1 0 2 
International experts 0 0 4 4 




TABLE 4: NUMBERS AND TYPES OF VISITED HEALTH FACILITIES 
 The Gambia Romania 
Minor health centres 5 (all regions) NA: general practitioner 
practices 
Major health centres 2 (all regions) NA: Referral is GP to 
municipal hospitals. 









theory of the 
logic of 
practice 
Cases (transcript collections) 
The Gambia Romania Expert group 
Field Health service delivery Resource allocation 
Nomos Avoiding negative patient 
outcomes and meeting service 
needs 
Meeting patient demand 
and ensuring the 









Habitus Empathy and understanding 
between care providers 
Severe resource constraints 
leading to ad-hoc procurement 
and careless behaviors as 
providers lose hope in 
improving service delivery 




facilities as well as with 
the ministry 
Power game sustained 
via legislation which 
includes threats to 







Capital Medical devices and equipment 
Funding to procure medical technologies 
Technical capacity to select and maintain products 
Information and its communication/sharing 
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TABLE 6: PRIORITIZATION CRITERIA EMPLOYED BY DIFFERENT PARTICIPANT GROUPS 
Stakeholder group 
mentioning criteria 
The Gambia Romania 
Health care professionals Patient need 
Patient impact 
Urgency  
Avoidance of negative 
outcomes (e.g. death) 
Quality, maintenance and 
durability 
Ensuring service provision 





Managing patient demand 
Developing the health facility 
Addressing patient and 
physician demand 
Equipment durability, design, 
throughput, maintenance 
Increasing financing 
allocation through investment 
in new equipment 
Developing health facility 
Regional authorities  Service provision in region: 
timely, coverage 
Service provision in region: 
timely, coverage 
National level stakeholders Coverage 
Service provision 
Equipment durability, design, 
throughput 
Meeting targets: MDGs 
Coverage 
Service provision 
Rising to European care 



















CHAPTER 3: THE FEASIBILITY OF CONDUCTING HEALTH 
ECONOMIC EVALUATIONS FOR MDE PROCUREMENT: 
REFLECTIONS ON A GENERALIZED COST-
EFFECTIVENESS ANALYSIS CASE STUDY OF 
INTERVENTIONS FOR FEMUR SHAFT FRACTURE 
FIXATION IN SUB SAHARAN AFRICA 
Please see Appendix 9 (Electronic only) for ancillary files to this chapter.  
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3.	1.	INTRODUCTION		
The usefulness of health technology assessment (HTA) for informing resource 
allocation decisions is widely acknowledged across higher-income countries (1–5) and 
receiving increasing attention within low- and middle-income countries (LMICs).(6–9) 
Evidence on the efficacy, value for money and affordability of different health 
technologies – including medicines and medical devices and equipment (MDEs) – is 
critical to policy-makers and health system planners trying to achieve universal health 
coverage in resource poor settings.(6) While HTA has the potential to improve the 
allocative efficiency of health systems and increase the transparency of decision-making 
processes (10,11),  its use is severely hampered by the absence of reliable data, 
technical capacity and political support. (12)  
The WHO emphasizes that HTA systems, alongside regulatory and management 
frameworks, are key components of health systems, and should play an important role 
in MDE administration and policy-making. (13) Reports and research from resource 
poor settings, however, suggest 40-70% of MDEs fall into disuse due to undiscerning 
procurement efforts, lack of regulatory systems and absent maintenance and servicing 
capacity (14–17) – all issues that HTA frameworks should ascertain and address. 
Inconsistencies in the way HTA is implemented and used across LMICs may perpetuate 
such issues. (18) The 2015 Global Survey on HTA suggests that where present, HTA 
appears to focus on the evaluation of safety and clinical effectiveness of MDEs; factors 
such as cost-effectiveness, budget impact and/or implementation issues are considered 
infrequently. (18) LMIC specific health economic (HE) evaluations of MDEs, rather 
than medicines or intervention packages, are therefore also rare. (18–20) 
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This could be attributed to several issues. First, unlike medicines, MDEs are used across 
patients and clinical departments/units and routinely procured in sets: e.g. surgery kits, 
including instrumentation and minor devices such as oximeters. HE evaluations should 
therefore account for the shared resource use of MDEs. 
Second, decision-makers and analysts may not find it worthwhile to 
commission/conduct evaluations of single MDEs. Current practice assumes that cost-
effectiveness models implicitly consider the cost-effectiveness of MDEs and can 
therefore help inform procurement choices. For example, Ginsberg et al include surgical 
and diagnostic equipment for lumpectomies, colonoscopies and radiotherapy among the 
service packages evaluated for treatment of breast, cervical and colorectal cancers.(21) 
Screening interventions in combination with surgical treatment are shown to be highly 
cost-effective, potentially leading decision-makers to assume investments into the 
equipment considered to reach these estimates are cost-effective as well. This is 
particularly problematic due to the implementation challenges MDEs face in the 
eventual deployment setting. (See Chapters 1-2 and (20,22)) In the case of Ginsberg et 
al, it is furthermore unclear which specific devices were chosen for the hypothetical 
implementation of each intervention. Indeed, the authors issue a warning to policy-
makers to consider the available infrastructure and human resource mix carefully before 
embarking upon service implementation. 
There may be minimal value in evaluating basic, clinically efficacious and low-cost 
technologies such as stethoscopes and glucometers. (19) Such products are already 
included on the WHO’s Core Medical Equipment Lists and are deemed safe, 
appropriate and highly cost-effective for LMICs by expert consensus.(23) It is 
potentially more useful to conduct evaluations of MDEs which present contentious 
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investment decisions(19): e.g. see Burn et al. on pulse-oximetry (24) or 
Teerawattananon on laparoscopic surgery (10). However, there is a dearth of health 
economic analysts available to assist with such tasks in LMICs(18), with notable 
exceptions in countries that have made substantial efforts of integrating HTA into 
national policy-making and built human resource capacity in this area, for example, 
Thailand (25), Poland and Brazil. (7) 
Third, should health economists be available it may be considered that their time is 
better-spent contextualizing models and findings from studies conducted elsewhere. 
Contextualization and translation of study findings from one setting to another may 
however not be advisable; in addition to issues of heterogeneity in underlying 
population, setting characteristics or intervention implementation, the relevance, 
methodology or “application” of health economics to the overall health system may 
differ. (26) For example, the qualitative study presented in this thesis (see Chapter 2) 
suggests that The Gambia and Romania face substantially different challenges. Within 
the Gambia, infrastructure is currently so minimal that it may be most relevant to 
evaluate entire service or infrastructure packages. In Romania, it may instead only be 
worthwhile to evaluate the introduction of additional services. 
However, despite the above points, it remains pertinent to explore methods available to 
analysts or decision-makers for determining the relative value-for-money of different 
MDEs. This chapter explicitly focuses on exploring the applicability and feasibility of 
one such HE evaluation method for informing MDE procurement planning. 
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3.	2.	METHODS	
Chapter aims and structure 
The chapter proceeds in two parts. First, a case study exploring the cost-effectiveness of 
alternative treatment strategies for femur fracture fixation following generalized cost-
effectiveness analysis principles is presented. (See section below) The purpose of the 
case study is to ‘road-test’ the feasibility of generalized cost-effectiveness analysis 
methods and principles for the appraisal of interventions with substantial MDE 
procurement implications. Success in this endeavour is defined as the analyst’s ability to 
construct an appropriate economic model and obtain a cost-effectiveness estimate. 
In a second part, the challenges encountered in developing the case study will be 
discussed. In particular, comments on the feasibility of conducting such a study from 
the point of view of an economist not previously exposed to generalised cost-
effectiveness tools or methods will be presented. Critical reflection will focus on the 
following items: 
• Tools: are the software programs made available to LMIC and other analysts 
easy to use and suitable for modelling purposes? 
• Methods: what challenges arise during implementation of GCEA and 
development of the case study economic model? 
• Data and inputs: How easy is it to obtain relevant data to populate an economic 
model for a GCEA type analysis? What other type of inputs may be needed? 
• Expertise, effort and time-scale: When and how should GCEA be used?	
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The NICE Guide to Methods of Technology Appraisal 2013 will be followed to gage 
the relative success of the case study method and economic model for informing 
decision-makers. (5) Specifically, the usefulness of the case study will be considered in 
light of: 
• Strength of clinical evidence underpinning the model; 
• Appropriateness of the model, including consideration of the decision-problem 
modelled, plausibility of inputs and assumptions made, implications for current 
health service delivery/budget impact. 
To summarize, the purpose of this chapter is to explore if a MDE specific HE model 
using GCEA can be constructed and to document challenges arising during this process 
and propose further points of methodological research/development. 
Generalized Cost Effectiveness Analysis 
The WHO CHOosing Interventions that are Cost Effective (WHO-CHOICE) group 
endorses an economic evaluation method known as generalized cost-effectiveness 
analysis (GCEA). The hallmark of this method is the comparison of all potential 
treatments against a hypothetical null scenario where no treatment is available. (27) 
This type of sectoral cost-effectiveness analysis seeks to identify the most cost-effective 
treatment pathway under the assumption that LMIC policy-makers could reallocate all 
funds and resources towards the most cost-effective program.  
To aid in this type of evaluation, WHO-CHOICE developed a comprehensive guideline 
document and tool-set.(28) Tools are Excel based and consist of: a dynamic life-table 
population model known as PopMod (Part Two: 2 in (28)), a costing template able to 
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capture both health facility, regional and program costs – CostIt (29) and a tool for 
carrying out stochastic league table simulations for uncertainty analysis known as 
MCLeague. (30) 
The WHO-CHOICE guidelines state devices are to be considered integral parts of 
interventions: their full economic cost needs to be captured and the choice of products 
to be appraised within interventions be made explicit. GCEA additionally draws 
attention to program budgeting and marginal analysis which is better suited to deal with 
MDEs and infrastructure investment appraisals when these need to be considered 
separately to specific interventions or vertical programs.(31,32) GCEA adopts a societal 
perspective, endorses the use of the disability-adjusted life-year (DALY) for valuation 
of intervention effectiveness and proposes the use of an annual 3% discount rate of both 
costs and health effects. (28) 
In contrast, the Bill and Melinda Gates Reference Case (BMG-RC) for Economic 
Evaluation endorses the traditional incremental cost-effectiveness analysis already in 
use within the United Kingdom National Institute for Health and Care Excellence.(33) 
The BMG-RC proposes that decision-makers and analysts within LMICs focus on 
comparing the effectiveness and value for money of the main interventions that are 
feasible/of interest to the health system. Recommendations are to adopt a health system 
perspective (valuing all potential expenses that may befall the health system in future, 
including out of pocket expenses), use the DALY for valuation of intervention 
effectiveness and discount costs and effects at 3% annually. The GCEA-suggested 
comparison of interventions against a null scenario is to be carried out in additional 
analyses; exploring the effect of 3% discounting for health effects and a discount rate 
reflecting regional rates of government borrowing for costs is also recommended. (34) 
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While BMG-RC is not as comprehensive a document as the guideline issued to support 
GCEA, the reference case recommends a specific reporting standard that analysts 
should follow. Comprehensive guidance on how to carry out ICEA is already available 
elsewhere.(e.g. see (5,34) for a comprehensive list of materials) 
In practice, decision-makers may wish to consider more than just the cost-effectiveness 
or relative value for money of alternative interventions/programs when reaching 
investment decisions. Multi-criteria decision-analysis  (MCDA) methods draw upon 
quantitative and qualitative research techniques and allow for the consideration of 
further relevant factors, including: equity (3), feasibility, cultural acceptability and 
affordability of offering a service (9,35) and severity of disease (36). Using MCDA, 
decision-makers and analysts may transparently specify and consider all criteria 
pertinent to a decision-problem; individual expert value judgments are then aggregated 
to identify the best possible investment option. (37,38) Similar to HTA generally, the 
purpose of MCDA is to consider all relevant evidence including that provided by the 
Global Burden of Disease (39), cost-effectiveness analysis (27,34) and evidence based-
medicine. As illustrated in Chapter 1 (Tables 8 and 9), this is particularly relevant to 
MDEs: it is not only the cost and cost-effectiveness of MDEs that affects their uptake 
and use in health facilities, but also criteria relating to product design, and maintenance 
and decommissioning services available to manage technologies. The systematic review 
outlined in this thesis (Chapter 1) identified only one MCDA study relating to MDEs: 
Nobre et al (40) illustrate the use of the technique for a procurement problem in a public 
hospital in Brazil.  
Program budgeting marginal analysis (PBMA) may be of further relevance to decision-
makers contemplating MDE investment decisions. PBMA implies detailed review of a 
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current program budget (i.e. identifying how resources are spent) to inform further 
marginal analysis (i.e. how marginal gains in relevant outputs can be achieved subject to 
changes in resource allocation either within or across programs).(31) PBMA is 
supported by a seven step process where decision-makers are invited to establish the 
aim and scope of the exercise – i.e. allocation within or across programs, decide on a 
program budget, convene a marginal analysis advisory panel, elicit locally relevant 
decision-making criteria and assess options for service growth and resource gains from 
scaling back services or disinvestments. (ibid) The exercise concludes by evaluating all 
investment and disinvestment options, validating results and re-allocating resources. 
(32)  PBMA can be seen as holistic process rather than unique method, and can 
incorporate methods such as MCDA as well as other decision-making aides such as 
participatory action research and the accountability for reasonableness framework. 
(ibid) For MDE investment decisions, PBMA can be particularly useful if it 
incorporates cost-effectiveness analysis: considering the relative cost-effectiveness of 
MDEs and separately the opportunity costs associated with the procurement of different 
products can help decision-makers clarify which devices are best suited for investment. 
For example, when considering facility specific investments into surgery it may be 
beneficial to invest in comprehensive open-surgery kits rather than devices for 
laparoscopic surgery, considering the latter are more expensive and less likely to be 
indicated for use across all patient categories. 
Notably, the above methods necessitate the availability of both suitable data and 
sufficient financial resources and technical capacity (i.e. analysts with the relevant 
health economic modelling / social science methods knowledge). The aforementioned 
resources are particularly scarce across LMICs; in their absence, decision-makers may 
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turn to the use of heuristics to reach MDE investment decisions. One such method is 
described in detail by Lilford et al (including KD as a co-author) in: "An approach to 
prioritization of medical devices in low-income countries: an example based on the 
Republic of South Sudan." The approach involves specifying all potential MDE 
investment options; MDEs are first appraised at face value:  
• costly devices, which exceed available budgets, are ruled out;  
• basic technologies, which prove safe and effective, are purchased;  
• and remaining products undergo further appraisal. The latter involves 
consideration of available human resources to adequately use products 
(including training or hiring requirements) and maintenance services (including 
financial resources needed) for ensuring products reach full life expectancy. 
Should trained personnel and servicing capacity not be available (or obtainable), 
products are ruled out; remaining products then undergo a best evidence review 
exercise to determine they are the safest and most effective technology available 
for offering the desired service. Where the evidence review is inconclusive, a 
full health economic model is commissioned. 
The approach described is pragmatic and tailored specifically to decision-making under 
severe resource constraints. Such heuristic methods can prove particularly helpful when 
used in conjunction with resources listed in the systematic literature review on 




This study was carried out by one analyst (KD) and a series of pragmatic limitations 
therefore apply. First, the case study focused on identifying an area of clinical practice 
involving interventions with substantial MDE procurement implications.  Orthopaedic 
interventions for femur fracture fixation were chosen, informed by fieldwork conducted 
in Tanzania by A. Gummaraju (Appendix 2). As all interventions fall within the same 
program category (i.e. treatment of femur fracture – orthopaedic services) this 
endeavour does not fully correspond to the intended use of GCEA – that is, comparison 
of service packages/vertical programs. The case study presented here applies GCEA 
principles to an intra-sectoral set of interventions, rather than inter-sectoral programs. 
This restriction in scope, as well as other simplifying modelling choices set out in the 
next section (e.g. adopting a health service rather than societal perspective), was 
necessary to reduce appraisal complexity and ensure a manageable workload. This 
restriction however limits the potential usefulness and validity of reflective comments 
made here. It is, however, pertinent to note that decision-makers proceeding to set up an 
entire service (e.g. orthopaedic services) may well be interested in applying this type of 
intra-sectoral GCEA. 
Second, as the purpose of this case study was to explore how GCEA applies to MDE 
appraisals, the analyst chose not to proceed beyond initial model construction and 
calculation of a cost-effectiveness estimates. While the relevance of such analyses for 
decision-making in practice is not disputed, (20,41) data availability and quality was 
low in this case and analyses would have held little meaning in appraising the 
appropriateness of GCEA for the purpose selected here. A narrative overview of key 
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sources of uncertainty is provided to enable future analyses of this type if/when data 
becomes available. It should be noted that difficulties in undertaking sensitivity 







3. 3. 1. DEFINITION OF THE DECISION PROBLEM 
The availability and accessibility of safe anaesthetic and surgical care has received 
increasing global attention. At its 68th Global Assembly, the WHO passed a resolution 
on Strengthening Emergency and Essential Surgical Care and Anaesthesia as a 
Component of Universal Health Coverage. (42) Deliberations at the assembly were 
informed by findings of the Lancet Commission on Global Surgery.(43) The 
Commission notes that anaesthetic and surgical services were previously neglected in 
favour of disease or program specific issues and argues that such services should be 
recognized as essential components of resilient, responsive and functional health 
systems. (44) The effects in mortality and disability reduction of surgical services are 
likely to be particularly high in LMIC health systems. (45) Estimates from Sub-Saharan 
Africa and South Asia suggest only 13-31% of surgical need is currently met. (46) The 
associated loss in output is assessed at 2.5% of GDP for LMIC economies.(47)  
Similar to further research in this area (48,49), the commission's findings stress that 
LMICs need urgent and expansive investments into the surgical and anaesthesia 
workforce and appropriate hospital infrastructure and equipment. (43,50,51) Verguet 
and colleagues estimate investments into operating rooms for carrying out 5000 major 
operations per 100 000 population per year for 2012-30 at 300-420billion US$. (50) 
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While this represents 1-8% of total annual health expenditure across LMICs (50) 
surgery is still highly cost-effective, particularly when focused on the treatment of 
injuries, obstetric complications, timely management of abdominal and life-threatening 
conditions and elective care for hernias. (52–55) 
ORTHOPAEDIC SURGERY IN LMICS 
This case study focuses on orthopaedic surgery, more specifically surgery for the 
fixation of femur shaft fractures due to trauma or injury in adult non-elderly patients 
located in LMICs in Sub-Saharan Africa. Violence and injuries are among the top ten 
causes of death across Sub-Saharan Africa (56) and the tenth cause of disability 
worldwide. (57) The burden of disability due to trauma/injury in productive aged 
society members is particularly high in low-income countries due to road traffic 
accidents and self-inflicted, violent or occupational injuries.(53,57,58) Fractures alone 
account for 22 million years lived with disability in 2013, with musculoskeletal, fracture 
and soft tissue injuries estimated to contribute 20.8% of global years lived with 
disability, assessments ranging from 10.8% in Mali to 30.0% in South Korea. (39)  
Across Sub-Saharan Africa the availability of orthopaedic services able to cater to the 
volume of trauma and injury is low: across a sample of 267 hospitals, Chokotho et al 
estimate a mean of 1.4 orthopaedic surgeons available in district hospitals (n=185) and 
2.4 surgeons in tertiary or referral facilities (n=82). (59) Closed fracture care was 
available in 75% of district hospitals, 82% of tertiary and referral hospitals respectively; 
however, only 37% of district and 40% of referral hospitals had instrumentation 
necessary for surgical treatment of orthopaedic fractures; implants were available in 7% 
and 8% of district and referral facilities respectively. (ibid)  
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Information on the cost-effectiveness of orthopaedic services in LMICs – particularly 
the cost-effectiveness of femur-fracture care – is scarce.  Chao et al place the cost-
effectiveness of orthopaedic services, including treatments such as club-foot surgery 
and tibia fixation, at 381.15$US (2012) per DALY averted. (53,54) This indicates 
orthopaedic surgery is comparable in cost-effectiveness to ophthalmic surgery and 
caesarean deliveries; certain interventions may potentially be more cost-effective than 
antiretroviral therapy for HIV. (54) However, studies included in obtaining this estimate 
are likely to under-estimate the true cost of services as they focus on provision of 
surgery under the auspices of volunteer missions or emergency response in Haiti, 
Nicaragua and The Dominican Republic(60,61); follow-up treatment and salary costs 
may thus not be accurately captured and cost-effectiveness over-estimated. (53) The 
cost-effectiveness of alternative treatments for femur fracture fixation is still 
undetermined: Chen et al (60) do not include femur specific interventions within their 
study and Gosselin et al (61) include only a small number of patients afflicted by such 
injuries. 
SURGERY FOR THE FIXATION OF FEMUR SHAFT FRACTURES 
Fractures of the femur shaft result in loss of mobility and, depending upon treatment 
modality and extent of injury, may lead to mortality inducing complications such as 
adult respiratory distress syndrome, pulmonary embolism, pneumonia, systemic 
infection and organ failure.(62) Femur shaft fractures are particularly important when 
occurring in productive aged society members in LMICs as they are likely to result in 
work absenteeism, leaving entire households and families bereft of income.(62–64) 
Quick (less than 24 hour) and effective long-bone fracture stabilization (resulting in 
fracture union and full weight-bearing) is likely to result in increased patient mobility, 
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decreased morbidity due to lower rates of adverse treatment effects and lower hospital 
costs for patients and the health system.(62,64)  
In a recent qualitative study with femur and tibia fracture patients in Uganda, O’Hara et 
al note, however, that injured patients and family members may present late for 
treatment due to financial constraints. (63) While treatment and hospital stay may be 
subsidized by public funds, patients still bear the high costs of femur implants – whether 
plates or intramedullary nails; this is the main barrier to accessing high-quality 
treatment and patients are therefore routinely treated with traction. (63)  
Skeletal traction is the traditional treatment offered in low-income settings – the length 
of stay in hospital may extend to several months and complications are frequent; high-
income countries have long ago moved towards the use of plating and intramedullary 
nailing as a treatment standard. (65) With the advent of low-cost implants such as the 
SIGN nail (an orthopaedic implant designed for insertion into the femur with no power 
reaming or image intensification) these latter interventions for fracture fixation are 
declining in cost and an evaluation of the most cost-effective (or cost-minimizing) 
fracture treatment for LICs becomes relevant. (ibid) In particular, authors in the 
literature call for further research comparing skeletal traction, intramedullary nailing or 
plating and external fixation for fixation of femur shaft fractures. (62,64) 
The economic model presented in this chapter builds upon a previous study of which 
KD is one author (Appendix 2) which explored the barriers and facilitators to the 
adoption of an innovative orthopaedic implant device – the SIGN nail –in Tanzania. 
The main facilitators behind SIGN adoption by individual surgeons and health facility 
managers were technology cost (the nail is currently donated) and usability (the product 
144 
is routinely revised due to clinician feedback), endorsement/recommendation of fellow 
clinicians and the existence of a feedback loop between product users and 
developers/manufacturers. As in the case studies in The Gambia and Romania (See 
Chapter 2), health facility or national level stakeholders in Tanzania did not appear to 
consider HTA related evidence within their decisions-making process. Stakeholders 
reflected upon cost-savings ensured by the use of the SIGN nail, however did not 
consider the relative clinical effectiveness of the product or alternative interventions 
beyond standard care (traction). Considering Tanzania’s limited orthopaedic service 
delivery capacity (4 referral hospitals offer orthopaedic services for a population over 
44 million) and the potential for adoption of the SIGN nail or other similar orthopaedic 
products as ‘usual’ care, it would be relevant to evaluate alternative treatment strategies 
from the perspective of the health system. As other countries are likely to be in a similar 
position, further LMICs in Sub-Saharan Africa were also included. (59) 
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3. 3. 2. DATA AND METHODS 
 
AIM 
The aim of this evaluation is to determine cost-effective treatment strategies for the 
fixation of femur shaft fractures in adult non-elderly patients in LMICs in Sub-Saharan 
Africa. Boxes 1-2 briefly summarize population, interventions/comparators, outcomes 
and setting information.  
METHOD AND MODEL 
Generalized cost-effectiveness analysis amended where necessary due to data paucity or 
contextualization of the decision-problem.(28)  
A decision-tree was chosen as model structure as femur shaft fractures are acute 
conditions, likely to resolve in union or mal- or non-union in a relatively short period. 
Figure 1 illustrates a theoretical decision-tree developed with the assistance of 
clinicians; all potential fracture fixation interventions provided in LMIC settings have 
been included. Effectiveness estimates for several interventions included in Figure 1 
were not available - i.e. for open reduction definitive external fixation, closed reduction 
and internal fixation with plating, closed reduction with definitive external fixation. 
Figure 2 displays the reduced decision-tree used as a basis for modelling.
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TARGET POPULATION  
This study is restricted to adults aged 16-65 affected by fractures of the femur shaft and 
under-going first line treatment after injury; patients with substantial comorbidities, 
including cranial injury, were excluded from analysis. Patients under 16 were excluded 
as they are unlikely to be skeletally mature; elderly patients were similarly excluded as 
they are likelier to present with fractures of the femur head rather than femur 
shaft.(66,67)  
SETTING  
Consistent with previous health economic evaluations undertaken by the WHO under 
the auspices of the WHO-CHOICE group(21,68), this analysis is restricted to specific 
Global Burden of Disease sub-regions, namely Africa – D (AfrD) and Africa – E 
(AfrE). AfrD includes countries in Sub-Saharan Africa affected by high child and high 
adult mortality, e.g. The Gambia, Guinea, Niger, Mauritania and Sierra Leone. AfrE 
includes countries affected by high child and very high adult mortality, e.g. Cote 
D’Ivoire, Ethiopia, Rwanda, Malawi and Zimbabwe among others.  
It is estimated that 7% of the population within these regions has access to surgical 
services (Lancet commission, Meara et al 2015). The availability of orthopaedic 
services is additionally likely to be low: in a sample of 267 hospitals from east-central 
and southern Africa, a mean of 0.3 orthopaedic surgeons were available in 185 district 
hospitals, and a mean of 0.6 per referral or tertiary care facilities (n=82).(59)
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PERSPECTIVE  
The study is conducted from the perspective of the health service as per 
recommendations from the BMG-RC. While adopting a societal perspective is 
recommended as ideal practice by WHO-CHOICE, it was deemed impractical in this 
case because it would require additional data collection for estimation of indirect costs.  
(69) The systematic literature search undertaken (See Data and Evidence Sources 
below) identified only two articles including costs of treatment sought, however no 
indirect costs appear to be captured by either study. (70,71)  
Production and time losses incurred by patients seeking orthopaedic care specifically 
would need to be quantified via other means (41). To enable meaningful inclusion of 
such costs in the model, a range of costs  should be collected (potentially via survey) 
across the AfrD and AfrE settings, including estimates on the costs to care access, out of 
pocket expenses while seeking treatment, wages/profits foregone due to hospital stay. 
Debts incurred by the absence of family members (e.g. mothers) performing a caring 
role in the household would also need to be estimated.  
As orthopaedic specific literature is sparse in this area, it may be appropriate to capture 
at least some of these costs in the model from literature on other surgical interventions 
(e.g. see O’Neill et al on breast cancer care in Haiti(72), Nguyen et al on hospitalised 
injury in Vietnam(73)) and perform sensitivity analyses. As this was a feasibility study, 
and full access to papers and data collected by the aforementioned authors was not 
available, it was instead deemed more pragmatic to adopt a health service perspective at 
this stage. Informed by AG’s study in Tanzania and in line with BMG-RC, however, the 
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base case analysis includes implant costs, which are likely the highest out of pocket 
expenses sustained by patients.(34)  
TIME HORIZON AND DISCOUNT RATE  
In line with BMC-RC and WHO-CHOICE guidelines, base case analysis adopted a life-
time horizon for DALY calculations and assumed a 10-year implementation period for 
estimation of costs.(27,34) A 3% annual rate was used to discount both health effects 
and costs; additional analyses include no discounting of health effects.  
INTERVENTIONS AND COMPARATOR  
In line with WHO-CHOICE guidelines, this evaluation considers all plausible 
interventions for femur shaft fracture fixation.(27) The null scenario – i.e. patients not 
receiving any treatment – is the main comparator; additional analyses conducted 
according to BMG-RC guidelines compare the effectiveness of surgical interventions to 
the 'traditional' treatment on offer - i.e. traction. (34) To construct the null comparator, 
mortality rates associated with femur fracture were identified; surviving patients were 
all assumed to proceed to long-term disability in line with a no-treatment scenario. 
Operative and non-operative interventions modelled are described in more detail in Box 
2. Briefly, operative interventions consist of open and closed fracture reduction, further 
categorized into surgical procedures relying on internal, external or external-internal 
fixation with intramedullary nails, femur plates or external fixation devices. Skeletal 
traction with cast or brace application is the only non-operative intervention considered. 
The latter is currently the most frequently offered treatment in LMICs. (70) 
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The choice of interventions was informed by repeated consultations with orthopaedic 
surgeons with experience in low-income country health care delivery. Deepa Bose is a 
consultant at Queen Elizabeth Hospital in Birmingham and Secretary of the World 
Orthopaedic Concern. She contributed to the formulation and design of this evaluation. 
Informal discussions on the choice of interventions offered across Sub-Saharan Africa 
were held with Prof. Chris Lavy (University of Oxford). Choice of interventions was 
further informed by the BMedSci student project carried out by A. Gummaraju. 
(Appendix 2) 
OUTCOMES  
Health benefits of alternative interventions are quantified in DALYs averted. 
Calculations for Years of Life Lost (YLLs) and Years of Life Lived with Disability 
(YLDs) were conducted similarly to studies in the Global Burden of Disease series(74). 
Results are reported for four types of DALY to ensure sensitivity relating to 
methodological DALY calculation assumptions (75) are captured: 
i. Age weighted and discounted DALYs using standard Japanese life-expectancy 
(80 years of life for men, 82.5 years for women); 
!"" = 	 %&'
()
(+ + -)/ '
0 (12 31) − + + - " + 5 − 1
− '0 (12 ) − + + - 5 − 1  
!"7 = 78	 %&'
()
(+ + -)/ 	 '
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− '0 (12 ) − + + - 5 − 1  
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ii. Not-age-weighted and discounted DALYs, using standard Japanese life-
expectancy; 
!"" = 	9+ 	(1 − '
0(3) 




iii. Simple DALYs: not-age weighted, no discounting, using standard Japanese life-
expectancy; 
!"" = 9	×" 
!"7 = :	×78	×" 
iv. Age weighted and discounted DALYs using AfrD and AfrE standard life-
expectancy (formulas identical to i) using standard life expectancy of 57 years 
for men, 60 for women for Afr D). 
YLL = Years of life lost due to premature mortality. 
YLD  = Years of life lived with disability 
K  = Age weight modulation constant 1 or 0 
C = Adjustment constant 0.1658 
R = Discount rate 0.03 
a = Age of death 
β = Age weighting constant 0.04 
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L = Standard life expectancy (for YLL) or duration of disability (for YLD) at 
 time of death or injury 
N = Number of deaths 
I = Number of incident cases 
DW = Disability weights 
 
Disability weights for fractures of the femur (other than femur neck) from the Global 
Burden of Disease Study 2010 were used: 0.192 (uncertainty interval 0.121-0.280) for 
short term injury with or without treatment and 0.053 (uncertainty interval 0.035-0.079) 
for long term injury with or without treatment. (76)  
Clinical outcomes extracted from the literature to derive DALYs were mortality and the 
status of fracture union; DALYs were calculated in relation to the number of patients 
experiencing a mal- or non-union of the femur shaft fracture. Due to data paucity and 
irregular reporting, it was not possible to stratify outcomes into successful union, mal- 
and non-union; the latter two outcomes were instead aggregated. Incidence rates were 
converted to one-year probabilities as per Fleurence and Hollenbeak. (77)
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DATA AND EVIDENCE SOURCES 
Demographic data for the AfrD and AfrE Global Burden of Disease regions were 
obtained from the WHO. (78)  
EFFECTIVENESS ESTIMATES 
Parameter estimates for intervention effectiveness for use in base case analysis were 
sourced from best evidence available across the AO Foundation Surgery Reference 
database for clinical care and documents identified in a systematic evidence search. 
Table 1 includes all parameter estimates retrieved from documents and Table 2 provides 
a summary of study characteristics. 
The AO Foundation conducted systematic searches of Medline (last updated 2007) to 
identify comparative studies evaluating the effectiveness of fixation interventions. 
Studies were transparently classified into four classes of evidence; for the purposes of 
this case study, only studies within classes I-III were to be used, i.e. randomized control 
trials, cohort or case control studies. 
To identify further relevant evidence, KD also conducted a systematic literature search 
to identify studies on long-bone (femur, tibia, humerus) fracture fixation effectiveness 
and costs in the target population. (Box 3) A. Gummaraju and KD independently 
reviewed titles and abstracts for relevance according to a pre-established algorithm. 
Studies were included only if they:  
1. Mention any intervention/comparator pair of interest:  plating, traction, 
casting, intra-medullary nailing, and progression of fracture when no treatment 
is administered. 
153 
2. Document any or all: 
a. Clinical outcomes of interest, clinical or radiographic: union 
(mal- or non-union), functional outcomes (mobility, range of motion, 
weight bearing, leg length discrepancy) etc. 
b. Utility outcomes: DALY or QALY. 
c. Intervention costs. 
Studies were excluded if they: did not refer to the interventions of interest, the 
population was not over 16 and no outcomes of interest were reported. 
The search strategy identified 361 studies of potential relevance, 207 abstracts were 
appraised and 118 found relevant for use in potential evaluations of the tibia, humerus 
or femur. (Figure 3) 30 articles related specifically to the femur; KD extracted data from 
the 19 articles for which full text versions were available to the University of 
Birmingham. (Appendix 9) KD categorized studies into three classes of evidence and 
only used estimates from references classed A-B: A – for randomized control trials or 
trials, B – for cohort or case control studies, C – for case series and studies with no 
comparator group. 
Mortality estimates for the null treatment scenario or following intramedullary nailing, 
for the populations age group of interest, were not available across results from the 
above searches. Mortality estimates following intramedullary nailing were sourced from 
a multi-centre cohort study in India; and mortality estimates for the null treatment 
scenario were extracted from a prospective cohort study by Enninghorst et al.(79) 
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Incidence estimates for femur shaft fracture were also obtained from the latter study. 
(ibid) 
COST ESTIMATES 
Costs were obtained from diverse sources. Due to data paucity, an ingredients approach 
could not be used. Instead KD extracted cost data from the articles identified via the 
above literature search and references from the Lancet Commission on Global Surgery 
to estimate costs for operative and non-operative treatments. All documents appraised 
ignored or excluded the costs of implants: KD obtained estimates for such costs by first 
searching the UNICEF online product catalogue (no estimates were available) and then 
searching Alibaba (a global trading website) for femur compression plates and 
intramedullary nails from manufacturers that have obtained both CE and ISO 
13485:2003 certifications specifically. Domestic taxes applicable to the import of such 
items were excluded from the analysis. All costs were converted to international dollars 
as per guidance issued by WHO-CHOICE and using published purchasing power parity 
conversion factors. (80)Table 3 details costs sourced from the literature and 
assumptions used for cost calculation. Opportunity costs were excluded from the 
analysis. (See also Appendix 9)  
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ASSUMPTIONS  
Due to data paucity and the complexity of the theoretical decision-model considered 
(See Figure 2 for the final decision tree), a number of simplifying modelling decisions 
and assumptions were made: 
• Only patients undergoing first-line treatment after injury were considered; 
patients undergoing surgery or stabilization following an initial negative fracture 
fixation outcome (i.e. non-union or mal-union) were not included. 
• To ensure integration of all available data, the decision tree was constructed to 
consider the following outcomes for each intervention node: potential death 
(mortality estimate obtained from literature) and potential non-union or mal-
union (estimate obtained from literature). 
• Where mortality estimates were not available, i.e. following open reduction with 
intramedullary nailing or plating and open reduction with intramedullary nailing 
after temporary external fixation, a baseline all-cause mortality following 
musculoskeletal trauma and surgery was used. (Lancet Commission on Global 
Surgery: Foote et al 2015)  
To construct the available model further simplifying assumptions relating to the 
modality of fixation were made. For example, our model does not distinguish between 
reamed vs. unreamed fixation, or fixation undertaken with or without image 
intensification during surgery.(81) Considering such factors would have doubled the 
size of decisions to be modelled for the intramedullary nailing interventions.  
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HETEROGENEITY  
Differences in the clinical effectiveness and costs of treatments due to diversity in 
fracture and patient characteristics could not be explored due to data paucity. 
Classification of patients into subgroups according to the type of fracture sustained 
(simple, wedge, complex) was not possible, as the literature did not consistently report 
relevant outcomes at this level of detail. Heterogeneity due to differences in patient 
groups – as appraised by the injury severity score of patients – could also not be 
investigated. Patients with a high injury severity score (ISS above 25 points) present 
with life-threatening injuries and are frequently managed consistent with the principle 
of ‘damage control orthopaedics’. (DCO) The latter involves prioritizing the treatment 
of urgent conditions and temporarily managing the femur fracture via external fixation; 
surgeons only proceeding to final fracture fixation upon patient stabilization. (82) In 
contrast to patients characterized by a high ISS, patients with limited injuries are 
routinely treated using ‘early treatment care’ – i.e. fixation of femur shaft injury up to 
24 hours after admission. (82) Mortality is likely to be high in the former patient group 
(ISS over 25) and health outcomes likely better in the latter group (ISS under 25). A 
further source of heterogeneity is setting specific: it is likely that the incidence rate of 
femur fracture varies in settings exposed to high levels of armed violence (e.g. civil 
wars or conflicts)(67) or settings with minimal traffic regulations. (58) Variations in 




 Deterministic and probabilistic sensitivity analyses relating to second order parameter 
uncertainty (69) were conducted as follows: 
• Deterministic analyses:  
o capacity utilization rates of operating rooms were varied at 50 and 95% 
as per WHO-CHOICE recommendations reflecting likely surgical 
service utilization in the femur fracture population; 
o costs were discounted at 6 and15% as per WHO-CHOICE 
recommendations reflecting different discounting scenarios - in the first 
case, double to base case, in the second the rate reflects the regional bank 
bond lending rate in Kenya; 
• Probabilistic analyses: 
o Monte Carlo simulations (1000 iterations) were conducted to generate 
cost-effectiveness estimates and calculate the net monetary benefit of 
each intervention (and ancillary likelihood of the intervention being cost 
effective): 
§ effectiveness was estimated by calculating DALY values 
corresponding to mortality and non-union estimates repeatedly 
randomly sampled from beta distributions corresponding to the 
mortality and non-union data extracted from the literature; 
§ population level intervention costs were similarly estimated using 
cost estimates repeatedly randomly sampled from gamma 
distributions corresponding to all costs extracted from the 
literature. 
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Distributions for all parameters were estimated using the method of moments as per 
Briggs et al. (83) 
Using the above estimates, cost-effectiveness was estimated by calculating costs per 
DALY averted in comparison to both the null scenario and traction. To reflect the 
regional Africa D-E decision-problem most accurately DALYs were calculated using 
African life expectancy; similar to base case analyses, DALYs were age-weighted and 
used 3% cost discounting. The net monetary benefit method was used to estimate the 
probability that interventions are cost-effective at different cost-thresholds ranging from 
I$1- 10,000. 
Limitations 
Results of sensitivity analyses should be interpreted with due caution: substantial issues 
around data availability and quality apply. Parameter point estimates for non-union 
probabilities were derived from studies in the AO registry and documents identified via 
systematic literature searching. For studies from the AO registry, full text articles could 
not be accessed – i.e. references (84–86). The point estimates obtained from the AO 
database were converted to one-year probabilities (where follow-up time was not 
specified this was assumed to be one year). Notably, effectiveness estimates obtained 
thusly correspond to average incidence from underpowered studies not studying the 
exact interventions of interest – for example, the Canadian Orthopaedic Society point 
estimate extracted reflects the overall incidence of union across patients treated with 
both reamed and unreamed intramedullary nailing. It is likely that Mclaren’s meta-
analysis up to 1987 would be the only high-powered study relevant for data extraction, 
however no full text for this was available and no information on included populations 
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is provided in the AO database. Non-union estimates for the traction comparator were 
sourced from Gosselin et al, a study identified via systematic literature search.(87) The 
study is a retrospective study conducted within one hospital. The risk of bias is high: 
authors are evaluating the use of the SIGN nail (likely introduced by them into the 
health facility) versus skeletal traction using Perkins method.(87) Estimates from 
Opondo et al could have alternatively been used, however the risk of bias is similarly 
high here; in this “quasi-experimental” study patients were given a choice of 
treatment.(70) 
The potential quality of estimates sourced from studies where no full text was available 
is under question; the risk of bias in other studies (e.g. (70)) is also high. The initial 
point estimates obtained from either these studies therefore do not appear robust enough 
to yield the sensitivity analyses conducted here meaningful. Variation in union-rates due 
to types of technology used (e.g. with or without reaming) may of course be a used as a 
proxy to explore the uncertainty around the union estimates included, however, it is 
unlikely that this would be relevant to decision-makers.  
Higher quality data from sufficiently powered head-to-head trials comparing one or 
more of the interventions modelled could allow for extraction of meaningful high-
quality point estimates and calculation of relevant confidence intervals around which to 
undertake sensitivity analyses.  
To construct the null scenario it would also be relevant to estimate the probability of 
non-union after surviving a femur fracture. Information on union outcomes in patients 
not presenting for treatment was not deducible from available literature - all patients 
were therefore assumed to progress without treatment.  In further studies it may be 
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appropriate to consult expert opinion and gage the range of union/non-union estimates 
likely to be observed in this population. 
The costing approach adopted here combines bottom-up and top-down costing(88). The 
set-up costs of operating rooms were obtained from a modelling study (50). The model 
proceeded on the assumption that operating rooms would need to be set up to offer 
orthopaedic services (50); in practice, even should such rooms be built and equipped, 
they are likely to be used across clinical areas. The final per patient costs included in the 
base case here may therefore be over-estimated; deterministic analyses where operating 
room capacity use was varied to 50% may therefore offer a proxy for the likely cost-
effectiveness of services in practice.  
Implant costs included are averages obtained from a cursory search of digitally available 
online catalogues. While only ISO and CE approved implants were chosen, it would 
still be recommended to conduct further searches and include potential domestic taxes 
in future models before exploring any cost uncertainty. Demand and supply constraints 
could additionally be built into a model (20) given the limited availability of 
orthopaedic services in Sub-Saharan Africa more generally. (59) 
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REPORTING 
The CHEERS checklist is followed for reporting (89). All items in the checklist are 
addressed except items 20a, 20b and 21 as these explicitly relate to results of 
uncertainty analyses. This study had no dedicated funding and no conflict of interest is 
applicable. 
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3. 3. 3. RESULTS 
EFFECTIVENESS 
DALYs resulting from each of the interventions included in the decision tree (Figure 2) 
are outlined in Table 4a; calculated estimates for Africa D, Africa E and Sub-Saharan 
(regions Africa D and E) are provided. Table 4b outlines DALYs averted as compared 
to the null no-treatment scenario and to the traditional treatment on offer (traction). The 
null scenario reflects all surviving patients hypothetically progressing to non-union, 
valued using a long-term disability weight of 0.053. DALYs for all other interventions 
involve the use of 0.192 as a disability weight. 
Across all scenarios, traction is dominated; assuming African life expectancy, traction 
exceeds the no-treatment scenario by 30,786 DALYs. Calculation of DALYs for 
traction assumes the same mortality as for the null scenario – this is due to lack of 
mortality data for this intervention and assuming that traction is not able to avert 
mortality by itself. DALYs for this intervention may further be inflated due to the initial 
parameter value used for non-union probability. The parameter was sourced from a 
case-series study conducted by the SIGN-IM nail manufacturers to compare the use of 
intramedullary nailing to traction in Cambodia. The study is relatively small (n=87), and 
the traction comparator group consisted of the last 50 patients treated with traction 
within the specific hospital setting. The study may therefore suffer both from observer 
and selection bias. 
In comparison, DALY estimates for operative treatments rely on parameter estimates 
sourced from higher-quality evidence. Across operative treatments, closed-reduction 
with intramedullary internal fixation (CRIF) appears most clinically effective. 
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Assuming African life expectancy, CRIF averts 251,166 DALYs in comparison the no-
treatment scenario and 281,952 DALYs in comparison to traction across Sub-Saharan 
Africa. The dominance of CRIF is clinically plausible: similar to IM-nailing 
interventions, union-rates are high and mortality estimates are additionally lower than 
for open-surgery. (0.0126 vs. 0.017 probability of death) However, total DALY averted 
estimates for all operative interventions are similar, ranging from 235,730-251,166 in 
comparison to the no treatment scenario and 265,939-281,952 in comparison to traction. 
The similarity in DALY estimates obtained is due to similarity of input parameters: 
mortality estimates for ORIF-IM, ORIF-P and ORIF-IM following EF are identical. The 
AO reference database and systematic search failed to identify suitable high quality 
mortality estimates for these interventions and estimates from an Indian prospective 
cohort study were therefore used.  
INTERVENTION COSTS 
The total patient costs for each of the interventions considered in the decision tree 
(Figure 2) are outlined in Table 5. Costs were calculated using references identified via 
the systematic literature search or from the Lancet Commission on Global Surgery. 
Equivalent annual costs for the operating room make up more than 80% of the final per 
patient cost. Operating room costs were calculated based on Verguet et al’s estimate of 
likely construction and MDE investments for surgery rooms. (50)The current model 
assumes operating rooms are used solely for orthopaedic surgery – this is an implausible 
assumption and implies costs are overestimated. Costs for low-, low-middle and upper-
middle income countries were presented by Verguet and colleagues; the model assumes 
that 2 operating rooms would need to be constructed for each 100,000 population and 
calculates necessary investments for low-income countries only. 
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Estimates incorporate costs for procedures and hospital stay sourced from a study in 
Kenya (70) and implant costs sourced from MDE manufacturers. The latter may be 
underestimated as no taxes were included. The highest costing intervention is ORIF-IM 
after EF due to the high external fixator cost (200$I). Of all compared treatments, 
traction costs the least, incurring health systems only 714$I per patient. The null-
scenario assumes the health service incurs no costs on behalf of patients: this is likely a 
gross-underestimation of costs as patients may need to access pain-management and 
physiotherapy services. While physiotherapy services may be rare across LMICs (given 
relatively low access to orthopaedic services in general), it is likely that pain-
management at least is available via minor or major health centres. Traction costs 
already include such services and can therefore also act as a proxy for the null scenario 
costs. 
COST-EFFECTIVENESS  
Table 6 notes the cost/DALY averted for each intervention considered in comparison to 
the no-treatment scenario and traction respectively. CRIF-IM is the most cost-effective 
service against both comparators, costed at 1087$I/DALY averted. The second most 
cost-effective intervention is ORIF-P, costed at 1143$I/DALY averted. ORIF-IM-EF 
and ORIF-IM are similarly valued, suggesting neither strategy clearly dominates. The 
cost-effectiveness of all interventions as compared to the 1* GDP/capita threshold 
advised by the WHO-CHOICE group are presented in Table 7 (assuming age-weighted 




Results of the deterministic analyses varying cost discount and capacity utilization rates 
are presented in Table 8. The cost-effectiveness of traction as compared to the null 
treatment scenario does not vary: no fixed costs relating to fracture treatment were 
included in the model. The cost data available from Opondo et al. (70) included costs 
relevant to hospital capacity utilization (e.g. bed usage and investigation fees), however 
no infrastructure or MDE costs were otherwise included. In contrast, surgical 
interventions are sensitive to variation in discount rates and capacity utilization; this 
variation is expected as total per patient costs are driven largely by operating 
room/infrastructure/MDE costs: i.e. the latter make up 85-88% of the total per patient 
cost per surgical intervention. 
Table 9 presents statistics describing the estimates generated via Monte Carlo 
simulation. Notably, confidence intervals for surgical interventions are relatively 
narrow, suggesting the interventions are likely to be cost-effective against both the no 
treatment comparator on traction. This should be interpreted with due caution however 
as costs for both the null and traction are likely to be underestimated in this model. See 
notes above on traction costs included and additionally: no costs for the null comparator 
could be sourced - e.g. costs for pain management after musculoskeletal injury in Sub-
Saharan Africa should be included in future model versions. Sensitivity analyses 
suggest traction has the most variable cost-effectiveness: however, this may simply be 
driven by the high uncertainty underpinning both the traction and null treatment 
estimates included in the model. Results could be refined should higher quality 
estimates for the latter scenarios become available. 
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To graphically illustrate simulation results, cost-effectiveness planes were generated. 
Figures 4 and 5 illustrate that surgical interventions achieve relatively similar effects 
(DALYs averted) for the same costs: the clustering of these estimates reflects the 
similarity in parameters used to calculate DALYs - interventions achieve similar rates of 
non-union and mortality. In contrast, the cost-effectiveness of traction is more variable: 
parameter estimates for this intervention are more uncertain and given the high 
uncertainty in the comparison of this treatment against the null the spread of estimates 
on the CE plane is to be expected. 
Figure 6 additionally presents the cost-effectiveness acceptability curves of all 
interventions against the null comparator at different cost thresholds. (Note that 
probabilities of mutually exclusive interventions sum to 1 as per Briggs et al. 
(83)recommendations on presenting such CEACs)  The likelihood of interventions 
being cost-effective increases abruptly up to a threshold of I$1000 for surgical treatment 
options with only marginal increases and consistent decreases being recorded thereafter. 
I.e. while the probability of CRIF-IM being cost-effective continues to increase, the 
probability of ORIF-IM, ORIF-P and ORIF-IM after EF being cost-effective decreases 
beyond I$2150 and tends towards a probability of 0.2. The graphic supports base case 
findings, which suggest CRIF-IM is the most cost-effective surgical treatment option on 
average, followed by ORIF-IM after EF. Notably however, the CEACs suggest that 
traction appears as the most cost-effective option for the lowest cost thresholds (i.e. 
thresholds under I$550). Traction may of course be beneficial in specific patient groups: 
while in the base case model traction incurred more DALYs than the null (therefore did 
not avert any DALYs), MC simulations suggest traction may avert DALYs in 49% of 
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cases. For cost thresholds beyond I$550 traction is clearly less cost-effective than 
surgical interventions.  
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3. 3. 4. DISCUSSION 
 
The study presented here employed GCEA methods for exploring the cost-effectiveness 
of femur fracture fixation in the adult populations of AfrD and AfrE Global Burden of 
disease regions. Study findings suggest CRIF-IM and ORIF-IM after EF are the most 
cost-effective services for this decision-problem in the LMICs of considered regions; 
however, the services cannot be considered cost-effective for all countries within the 
region at the 1* GDP/capita threshold.(28) (Table 7) Results are reassuring given that 
closed-fracture is currently frequently on-offer across Sub-Saharan Africa,(59) although 
implants for the procedure may need to be sourced and budgeted for by health systems, 
rather than patients, to ensure better service-take up.  
Previous studies have placed the cost-effectiveness of orthopaedic interventions at 
361$I/DALY averted in Haiti, 381$I/DALY averted in the Dominican Republic and 
502$I/DALY averted in Nicaragua. However, all these studies are based on cost 
estimates of high-income country volunteer missions abroad and are critiqued by the 
Disease Control Priorities (Version 3) project for not including relevant staff-time, 
surgical equipment and infrastructure, implant and patient follow-up costs. Estimates 
obtained here include such costs and are therefore more realistic given the decision-
problem in AfrD and AfrE; this would imply orthopaedic surgical fixation with IM 
nailing would be of similar cost-effectiveness to glaucoma surgery (54). 
The usefulness of findings is limited, however, given the likely cost-inflation due to 
inclusion of operating room-costs. The model presented here assumes operating rooms 
would be set-up solely for orthopaedic use – this is likely to be inaccurate, although 
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further operating rooms would need to be constructed given current levels of availability 
and need for orthopaedic surgery. (59) 
It is likely that both operating room construction and procurement of implants would 
not be affordable for LMICs. NICE Guidelines suggest budget impact should not play a 
determining role in the adoption of interventions(5), however LMIC policy-makers 
dispose of incredibly limited budgets for service delivery in general. Surgical 
interventions in particular – when involving scale-up of surgical infrastructure – are 
likely to take-up a significant proportion of health care budgets.  
While it was possible to construct a GCEA model for the above set of interventions, it 
was incredibly difficult to obtain high-quality comparative data for populating the 






The purpose of this chapter was to explore the feasibility of using GCEA for the 
evaluation of interventions relying on the substantial presence/procurement of MDEs. 
Key problems encountered in this process relate to the availability and appropriateness 
of HE modelling tools, insufficient methodological guidance on model construction, 
including difficulties with implementing the societal perspective, and difficulties in 
sourcing suitable parameter data. 
Availability and appropriateness of HE modelling tools 
Although GCEA software - that is the software suite including PopMod and MC League 
- is publicly available and free, the WHO-CHOICE group requires analysts to request 
access to the software. In the case of this analysis, the software was provided after more 
than nine months from the initial request, during this time model development 
continued and it was no longer deemed pragmatic to switch to the use of PopMod. 
While GCEA methods are extensively described in the WHO Guide to Generalized 
Cost-Effectiveness Analysis, the software manual is rather brief and pre-supposes a 
relatively high level of health economics knowledge. The WHO-CHOICE group 
cautions this is the case and supplies training in the use of the method or software via a 
tutorial (analysts that have timely access to the software will find this helpful). Queries 
can additionally be sent to the WHO-CHOICE group.  
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PopMod is constructed as a dynamic life-table model - while this may be recommended 
for evaluation of complex interventions or vertical programs it may prove too complex 
for the evaluation attempted here. WHO-CHOICE guidelines specify that GCEA is 
suited to exploring regionally efficient mixes of interventions and that more complex 
decision-problems should be approached using a mix of ICEA and GCEA. In that sense, 
reflections collected via the use of this case study must be interpreted with due caution: 
the case-study does not reflect the intended GCEA-use scenario envisioned by WHO-
CHOICE. 
Insufficient guidance on model construction 
Several shortcomings of GCEA became apparent during the construction of the health 
economic model. First, if PoPMod is used, GCEA is restricted to one specific type of 
economic model. The model resembles a Markov model for evaluation of complex 
interventions for long-term conditions with recurring events. The PoPMod model 
accounts for births, deaths and disease interactions.  This requires analysts to be 
discriminant in the disease areas and interventions chosen for modelling. The case study 
presented here is not suitable for such an approach as it focuses on the evaluation of 
interventions for an acute condition. Simplifying the GCEA-designed-model - as was 
done here via the use of a decision tree - is only theoretically mentioned in the GCEA 
methods guide (see above on mixing ICEA and GCEA) and no further guidance on 
using GCEA given different or more specific decision-problems than set out in the 
original document is available. Following GCEA methods was therefore quite difficult 
in this case. 
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GCEA guidelines endorse the use of age-weighted and discounted DALYs, however, 
fail to advise analysts on how to explore differences in DALY estimates given different 
assumptions, e.g. no age weighting or use of the simplified DALY. In line with 
recommendations by Fox-Rushby et al (75), the case-study calculated DALYs averted 
using all relevant formulae. The guideline document similarly proposes the use of 
regional cost-effectiveness thresholds, set in relation to GDP per capita. Shortcomings 
of such methods have been summarized elsewhere.(90) 
Analysts may encounter additional difficulties while conducting sensitivity analyses for 
GCEA models. For example, in the case study presented here it was particularly 
challenging to calculate relevant confidence intervals for the Monte Carlo simulation 
estimates. In particular, surgical intervention cost-effectiveness estimates did not follow 
a normal distribution - this may certainly arise as an issue in any type of modelling 
(83)but may apply to multiple intervention comparators in a GCEA scenario. Guidance 
on how to deal with this skewness or any other similar statistical challenges (e.g. 
estimation of parameter distribution via method of moments) is not provided in the 
WHO-CHOICE handbook. 
Most importantly, using GCEA relies on the construction of a null-treatment 
comparator scenario. Articles using WHO-CHOICE methods fail to provide substantial 
insight into how this is done and the methods guide provides only a theoretical outlook 
on how to proceed. Supposing the use of PoPMod, the null may potentially be easily 
constructed, however in the absence of this, the method is particularly challenging to 
implement. Guidance should be issued not only on ‘how to’ construct this sort of 
comparator but also on what issues to expect, or pitfalls to avoid, while doing so. For 
example, due to limited data, analysts may be tempted to use null probabilities in their 
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analysis – this is unlikely to reflect the reality of the decision-problem and is an over-
simplification applied to the concept of ‘no treatment’. Guidance should specify how 
analysts can determine what interventions are to be considered lifesaving and also 
include recommendations on disability weights to use in the construction of the null. 
The implementation of a societal perspective was additionally difficult. Particularly in 
the case of traction – an intervention likely to result in substantial production time loss 
for individuals affected – production costs should be captured. A discussion on how to 
include such costs is presented in the WHO-CHOICE manual. (28) Details on how to 
estimate such costs, however, or what proxies one may use if these costs are not 
available and data collection improbable, should also be included. GCEA further 
advises analysts to use an ingredients approach for costing and to include programme 
costs in analyses. While this may be useful for vertical programme appraisal, it is 
unlikely to be of particular use in situations where resources are shared not only across 
interventions but also further across health system areas more generally. This is the case 
for MDEs, and for the case-study presented: construction costs for operating rooms 
were included in the analysis although this assumed operating rooms being constructed 
and used solely for the treatment of fractured femurs. 
Difficulties in sourcing suitable parameter data 
GCEA is particularly data-intensive: inputs for all potentially relevant interventions 
must be sourced to enable a GCEA-type comparison. In this case, the analysis had to be 
simplified and outcomes negative outcomes (e.g. non-union and mal-union) aggregated 
to account for gaps in available data.  
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The high data collection/data use burden is particularly challenging for LMIC 
stakeholders or analysts due to data paucity, but HIC stakeholders will also find this 
particularly onerous. Little guidance is given on pragmatic methods for data sourcing 
given resource constraints in LMICs and generally limited research literature; e.g. the 
use of surveys or expert opinion elicitation methods may be useful in such cases. 
Guidance on how and when to use such methods would be helpful for further 
development of GCEA. Little guidance is further devoted to data appraisal. 
Implementation of GCEA assumes analysts have a background in epidemiological or 
health service research more generally and are able to make sensitive and relevant 




Developing a GCEA specific HE model focused on the appraisal of MDE-intensive 
interventions is indeed possible, however, not necessarily feasible. The study presented 
here suggests that GCEA studies are time-consuming and data-intensive and therefore 
may be best targeted to evaluations where sufficient quality data is available. While the 
WHO-CHOICE issued methodological guidance is a robust and comprehensive guide 
on how to design a GCEA evaluation, further guidance on how to conduct and then use 
GCEA findings is needed. It is necessary for GCEA conducted analyses to meet 
international methodological standards (e.g. (89)) and to include all relevant details on 
model construction, in particular the null scenario constructed to represent natural 
disease progression and management. 
The key features that set apart the NICE methodological guidance(5), and indeed the 
BMG reference case(34), are the focus (and guidance) on integration of findings into 
decision-making paradigms. This includes recommendations on contextualizing 
findings where possible, considering budget impact and also identifying sources for 




Chapter 3 explored the feasibility and relevance of HE/HTA for MDE procurement 
using a case study economic evaluation on orthopaedic interventions for femur fracture 
fixation. The methods and challenges for undertaking HE/HTA have been recently 
discussed in more detail elsewhere(18,91,22)however, to the author’s (KD) knowledge, 
this is the first study to reflect on MDE related HE/HTA for procurement decision-
making in particular.  
The chapter critically reflects on the use of generalized cost-effectiveness analysis – 
GCEA (27,28), while also making reference to the traditionally popular incremental 
cost-effectiveness analysis - ICEA used in the UK, Canada and Australia (1,92,2) and 
endorsed by the Bill and Melinda Gates Foundation. (34) 
Key Finding 8: Undertaking MDE specific evaluations using GCEA is a very 
labour intensive and complex process challenged by lack of appropriate data 
and insufficient guidance. Alternative methods, including heuristics or multi-
criteria decision analysis may be more suitable for evaluating MDEs and/or 
narrowing down where HE evaluations (using GCEA/ICEA) are needed. 
The case study compared the use of several MDE intensive interventions for femur 
fracture fixation in Sub-Saharan Africa: surgical interventions (including internal and 
external surgical fixation with plates, intramedullary nails and external fixators) were 
compared to standard care (traction) and a no-treatment scenario.  The lack of suitable 
and high-quality comparative effectiveness data and contextually relevant cost-data was 
extremely challenging. While such issues equally impinge on the use of GCEA and 
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ICEA, GCEA is particularly vulnerable to such issues due to two reasons. First, GCEA 
implies a higher workload: compared to a traditional comparison of two interventions 
and associated evidence appraisal/retrieval and HE modelling, GCEA involved the 
comparison of six alternative scenarios for the case study presented here. Second, 
GCEA requires the construction of a no-treatment comparator scenario – i.e. a null 
scenario. Limited guidance is available on how such a scenario should be constructed in 
the absence of data: information on natural disease progression without any intervention 
is rarely available. While GCEA appears promising for the comparison of vertical 
programs and multiple macro-interventions therein (e.g. see (68)), it appears un-
manageable and largely un-suitable for MDE evaluation when used for intra-sectoral 
purposes. Heuristics(19),  multi-criteria decision analysis or program budgeting 
marginal analysis (37,38,20), may instead prove more favourable for implementation as 
they consider multiple issues (e.g. demand and supply constraints (22)) and can narrow 
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BOX 1: POPULATION, INTERVENTIONS/COMPARATORS, OUTCOMES AND SETTING 
Population: Patients affected by fractures of the femur shaft (not femur head), aged 
16-65, not presenting with contra-indication to surgery or life-threatening comorbidity 
(e.g. significant head-injury). 
Interventions/Comparators: Relevant surgical and non-surgical interventions for 
which effectiveness data is available compared to a no-treatment baseline. Figure 1 
illustrates all relevant interventions and Box 2 defines the content of each 
intervention. Figure 2 illustrates all interventions for which effectiveness data was 
available and which were included in the model. 
Outcomes: Mortality and fracture union versus mal- and non-union.  




Open reduction involves dissecting soft tissue surrounding the fractured bone in order to insert fixation devices. Open reduction is recommended for complex fractures 
where multiple bone fragments need to be re-aligned or for severe trauma, when wound debridement needs to occur. Open reduction is routinely faster than closed reduction, 
but may lead to infections and delayed union/non-union due to reduced blood supply to the fracture site. 
ORIF-IM Definitive internal fixation with intramedullary nails: Muscle is opened to achieve insertion of a load-bearing nail into the bone canal. The canal may 
(reamed IM nailing) or may not (unreamed IM nailing) be widened before nail insertion; the latter can occur in antegrade or retrograde fashion. Titanium nails are 
currently preferred. Usually requires specialized surgical equipment (e.g. for reaming) and fluoroscopy; the SIGN-IM nail is an interlocking nail not requiring the 
latter additions. Weight-bearing may be attempted before union.  
 
ORIF-P Definitive internal fixation with plates: Muscle is opened to enable insertion of a titanium plate close to fractured bone. Plates are secured with multiple 
screws. Contra-indicated for patients with multiple injury, coagulopathy and cranial injury (Buchholz and Brumback 1996). Weight-bearing is only attempted after 
fracture union. 
 
ORIF-IM or ORIF-P following EF Temporary external fixation and definitive internal fixation with intramedullary nails or plates: Used when patients are not 
clinically stable enough to be treated with internal fixation directly and/or when fracture is unstable. An external fixator device is used (e.g. Wagner device) and 
pins are applied to stabilize the fracture externally.  Upon patient stabilizations, surgeons proceed to definitive internal fixation via IM nailing or plating (see 
above). Pin infection may set in depending upon time spent with temporary fixation, risks as for internal fixation apply. 
  
ORIF-EF Definitive external fixation: External fixator device is used to secure stabilization of fracture. World War II developments initially saw the insertion of 
pins proximal and distal to fracture; further devices were then designed – most commonly used in the Wagner device version. Murphy 1988 reports vastly superior 
outcomes following IM-nailing compared to external fixation, thus definitive external fixation is not routinely recommended. 
 
Closed reduction implies the manipulation of fractures without opening adjoining soft tissue – see above and brief notes below. 
CRIF-IM Definitive internal fixation with intramedullary nails: IM-nail is inserted through end of bone. Risk of infection is low, haematoma is not disturbed 
therefore aiding healing. 
CRIF-P Definitive internal fixation with plates: Plates are inserted through a minimally invasive technique via proximal and distal incisions into the extraperiosteal 
tunnel. Current system in use is the Less Invasive Stabilization System. 
CRIF-EF Definitive external fixation: Fracture is stabilized via minimally invasive insertion of pins and fixated externally. 
 
Non-operative treatments: 
Traction with cast or brace support: Performed as skin traction in children mainly, however may be used as both skin or skeletal traction on adults when other treatments 
are not available. Involves the insertion of a percutaneous pin in the affected bone – this is then secured to a weight which ensures lengthening and stabilization. Patients 
need to remain supine for a minimum of 6 weeks. A Spica cast or brace may be applied as aftercare for several months to ensure weight-bearing. Union outcomes are 
unsatisfactory compared to surgical interventions. Note that casts may also be used after surgical treatments to promote earlier weightbearing. 
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Description: Strategy for Ovid MEDLINE(R) <1946 to January Week 4 2015> 
1     economics/ (26542) 
2     exp "costs and cost analysis"/ (183857) 
3     exp "economics, hospital"/ (19797) 
4     economics, medical/ (8583) 
5     economics, nursing/ (3911) 
6     economics, pharmaceutical/ (2538) 
7     (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab. (431744) 
8     (expenditure$ not energy).ti,ab. (17597) 
9     (value adj1 money).ti,ab. (23) 
10     budget$.ti,ab. (17480) 
11     or/1-10 (555515) 
12     randomized controlled trial.pt. (381609) 
13     controlled clinical trial.pt. (88411) 
14     random allocation.sh. (81683) 
15     double blind method.sh. (126945) 
16     single blind method.sh. (19689) 
17     or/12-16 (546657) 
18     animal/ not human/ (3881514) 
19     17 not 18 (497354) 
20     ((femor$ or femur) adj2 fracture$).mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier] (22699) 
21     ((humer$ or humerus) adj2 fracture$).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, 
unique identifier] (7340) 
22     ((tibi$ or tibia) adj2 fracture$).mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier] (13235) 
23     (long bone adj2 fracture$).mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier] (1268) 
24     or/20-23 (40817) 
25     ((femor$ or femur) adj2 neck$).mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier] (18782) 
26     24 not 25 (32322) 
27     exp Fracture Fixation/ (47033) 
28     (manage$ adj2 fracture$).mp. (1680) 
29     or/27-28 (47910) 
30     26 and 29 (15338) 
31     (child$ or pediatr$ or paediatr$).mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier] (1907302) 
32     (elder$ or older or geriat$).mp. [mp=title, abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier] (436517) 
33     exp Child/ (1556226) 
34     exp Aged/ (2373638) 
35     or/31-34 (4165456) 
36     30 not 35 (8051) 
37     19 or 11 (1033663) 
38     36 and 37 (259) 
39     remove duplicates from 38 (257) 
BOX 3: SEARCH STRING FOR SYSTEMATIC EVIDENCE SEARCH FOR PARAMETER ESTIMATES 
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3.	9.	TABLES	
TABLE 1: CLINICAL EFFECTIVENESS AND MORTALITY ESTIMATES OBTAINED FROM LITERATURE* 
Intervention or 
Comparator 






ORIF-IM Probability of 
non-union 
0.0446 NR AO: Canadian Orthopaedic Trauma Society (2003) Nonunion following 
intramedullary nailing of the femur with and without reaming. Results of a 
multicenter randomized clinical trial. J Bone Joint Surg Am; 85-A:2093-6.  
ORIF-IM Mortality 0.017 (1.4,2.25) Lancet Commission: Foote et al (2015): Musculoskeletal trauma and all-cause 
mortality in India: a multicentre prospective cohort study 
ORIF-P Probability of 
non-union 
0.047 NR AO: Varjonen L, Majola A, Vainionpaa S, et al (1990) Problems associated with 
longitudinal fractures of the femoral shaft in adults. A comparison between 
intramedullary nailing, interlocking intramedullary nailing and plating. Ann 
Chir Gynaecol; 79:46-9 
ORIF-P Mortality 0.017 (1.4,2.25) Lancet Commission: Foote et al (2015): Musculoskeletal trauma and all-cause 





0.0434 NR AO: Stephen DJ, Kreder HJ, Schemitsch EH, et al (2002) Femoral 
intramedullary nailing: comparison of fracture-table and manual traction. a 
prospective, randomized study. J Bone Joint Surg Am; 84-A:1514-21. 
ORIF-IM after 
EF 
Mortality 0.017 (1.4,2.25) Lancet Commission: Foote et al (2015): Musculoskeletal trauma and all-cause 











CRIF-IM Mortality 0.0126 NR AO: Canadian Orthopaedic Trauma Society (2006) Reamed versus unreamed 
intramedullary nailing of the femur: comparison of the rate of ARDS in multiple 
injured patients. J Orthop Trauma; 20:384-7. 
CRIF-IM Probability of 
non-union 
0.0039 NR AO: McLaren AC, Roth JH, Wright C (1990) Intramedullary rod fixation of 
femoral shaft fractures: comparison of open and closed insertion techniques. 
Can J Surg; 33:286-90. Davlin L, Johnson E, Thomas T, et al (1991) Open 
versus closed nailing of femoral fractures in the polytrauma patient. Contemp 
Orthop; 22:557-63. 
Traction Probability of 
non-union 
0.4276 NR Systematic search: Gosselin RA, Heitto M, Zirkle L Cost-effectiveness of 
replacing skeletal traction by interlocked intramedullary nailing for femoral 
shaft fractures in a provincial trauma hospital in Cambodia (Provisional 
abstract) 
Traction Mortality 0.1666667 NR *Author's assumption: minimum estimate for mortality in traction group is 
identical to null scenario as the intervention cannot be life-saving 
Null Mortality 0.1666667  NR J Trauma Acute Care Surg. 2013 Jun;74(6):1516-20. Population-based 
epidemiology of femur shaft fractures. Enninghorst N1, McDougall D, Evans 




0.8333333  NR *Author's assumption: all surviving patients with fracture continue without 
treatment to create the null  




TABLE 2: STUDY CHARACTERISTICS  
Reference Study type Objective Setting Population Follow-
up 







nailing of the femur 
with and without 
reaming. Results of a 
multicenter 
randomized clinical 











224 skeletally mature 
patients, excluded if: 
time to surgery less 
than 24 hours,  femoral 
canal less than 9mm, 
medical 
contraindication to 
surgery, previous joint 
dislocation, grade IIIb 
or all IIIC open 
fractures, MI history, a 
pathological fracture, 
femoral neck or inter 
trochanteric fracture, 
not able to return to 
follow up, unwilling or 
intra artical fracture 
6cm close to physeal 
scar. 
























Take into account 
ISS as potential 




Foote et al (2015): 
Musculoskeletal 
trauma and all-cause 













India – 14 
hospitals 
4612 patients (96% of 
sample) presenting 
with musculoskeletal 
















Reference Study type Objective Setting Population Follow-
up 
Outcomes Notes on quality 
assessment 
study 
AO: Varjonen L, 
Majola A, 




of the femoral shaft 





nailing and plating. 











NR 64 patients with 55 




Union status Only abstract 
available; estimate 
from AO used  
AO/Systematic 
search: Stephen DJ, 
Kreder HJ, 




of fracture-table and 
manual traction. a 
prospective, 
randomized study. J 
Bone Joint Surg Am; 
84-A:1514-21. 




and table traction 
Canada – 
Toronto 
87 patients with AO 
type 32 fracture, 
exclusion of poly 


















table + IM used as a 
proxy for likely 
nailing following 




Reference Study type Objective Setting Population Follow-
up 








nailing of the femur: 
comparison of the 
rate of ARDS in 
multiple injured 
patients. J Orthop 
Trauma; 20:384-7. 
RCT Comparing 
incidence of adult 
respiratory 
distress syndrome 
in patients with 
reamed vs. 
unreamed nailing 
of the femur 












F/U rate of 85%+ 
Adequate sample 
size 
Intention to Treat 
Analysis Used 
AO: McLaren AC, 
Roth JH, Wright C 
(1990) 
Intramedullary rod 
fixation of femoral 
shaft fractures: 
comparison of open 
and closed insertion 
techniques. Can J 
Surg; 33:286-90.  
Meta-analysis 






NR 3243 fractures: CRIF 






range of motion 
Meets class II AO 
evidence standard 
criteria: Violation of 
any of the criteria 





assessment in a 
prospective study or 
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195 
Reference Study type Objective Setting Population Follow-
up 
Outcomes Notes on quality 
assessment 
use of reliable data* 
in a retrospective 
study 







Gosselin RA, Heitto 






nailing for femoral 
shaft fractures in a 
provincial trauma 






of the SIGN 
intramedullary 






87 patients: 50 patients 
(52 fractures) treated 
by Perkins traction, 37 
by IM nailing. Patients 
undergoing second line 













selection bias as last 
50 patients make up 
the comparator 
group. Outcome 
assessment may be 
biased – conducted 
by SIGN 
developers. Not all 
patients were 
followed up. 










NR Patients presenting 
with femur shaft 
fracture in catchment 







Classified as level 
III study by authors. 
195 
196 
Reference Study type Objective Setting Population Follow-
up 
Outcomes Notes on quality 
assessment 
epidemiology of 
femur shaft fractures. 
Enninghorst N, 
McDougall D, Evans 
JA, Sisak K, Balogh 
ZJ. 
population including 























traction: cost per 
patient 
13594 400-40000 2011, 
Kenyan 
Shilling 
Kenya Costs of ward bed, drugs, 
radiographs, laboratory 
investigations, physiotherapy 
and theatre fees are included; 
fixed costs such as infrastructure 
and depreciation value of the 
initial equipment costs were not 
considered, same with implants 
(SIGN nail was used). Base year 
assumed was end of study 2011.  
Opondo et al: Cost effectiveness 
of using surgery versus skeletal 
traction in management of 
femoral shaft fractures at Thika 














per case of early 
mobilization 
59561 (38,618 - 
106,780) 
2010, USD USD Retrospective study collecting 
data over 9 years, unclear what 
costs were included and how 
changes in cost make-up were 
accounted for. 
Harvin et al: Early femur fracture 
fixation is associated with a 
reduction in pulmonary 
complications and hospital 
charges: a decade of experience 























Costs estimated via 
mathematical modelling given 
initial expert and survey 
responses. Costs do not include 
Verguet et al: Timing and cost of 
scaling up surgical services in 
low-income and middle-income 






















implants  but include equipment 

















IM nail costs*  150 50-250 2015, USD NA All costs refer to devices 
certified under  ISO 13485:2003 



















































TABLE 4A: AFRICA D, AFRICA E AND TOTAL DALYS INCURRED IN THE NULL SCENARIO 
AND UNDER INTERVENTIONS MODELLED 
Population and 
Interventions 




















Null 159,431 1629549 279,711 125,223 
Traction 177,747 2461490 311,845 139,611 
ORIF-IM 19,211 300331 33,706 15,088 
ORIF-P 19,556 315989 34,311 15,359 
CRIF-IM 10,010 33723 17,558 7,886 




Null 181,196 1,854,741 317,885 142,836 
Traction 201,989 2,801,320 354,361 159,234 
ORIF-IM 21,873 341,834 38,374 17,241 
ORIF-P 22,265 359,613 39,062 17,548 
CRIF-IM 11,423 38,263 20,041 9,007 




Null 340,628 3,484,290 597,596 268,059 
Traction 379,736 5,262,811 666,206 298,845 
ORIF-IM 41,084 642,165 72,080 32,329 
ORIF-P 41,821 675,602 73,373 32,906 
CRIF-IM 21,434 71,985 37,598 16,893 
ORIF-IM -
EFafter EF 
37,876 496,356 66,452 29,807 
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TABLE 4B: AFRICA D, AFRICA E AND TOTAL DALYS AVERTED BY EACH INTERVENTION COMPARED TO THE NULL SCENARIO 



































Africa D  
 
Comparator Null: no treatment Comparator: Standard care 
Traction -18,316 -831,941 -32,134 -14,388 
ORIF-IM 140,220 1,329,218 246,005 110,135 158,536 2,161,159 278,139 124,523 
ORIF-P 139,875 1,313,560 245,400 109,864 158,191 2,145,501 277,534 124,252 
CRIF-IM 149,421 1,595,826 262,153 117,337 167,736 2,427,768 294,287 131,725 
ORIF-IM after EF 141,726 1,397,609 248,647 111,318 160,042 2,229,551 280,781 125,706 
Africa E Comparator Null: no treatment Comparator: Standard care 
Traction -20,793 -946,580 -36,476 -16,398 
ORIF-IM 159,323 1,512,907 279,510 125,595 180116 2459486 315986 141993 
ORIF-P 158932 1495128 278822.96 125288 179724.36 2441707.08 315299 141687 
CRIF-IM 169773 1816478 297844 133828 190566 2763058 334320 150227 
201 
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ORIF-IM after EF 161026 1590324 282497 126934 181818 2536904 318973 143333 
Africa D 
and E 
Comparator Null: no treatment 
Comparator: Standard care Traction -39,108 -1,778,521 -68,610 -30,786 
ORIF-IM 299,544 2,842,124 525,515 235,730 338,652 4,620,645 594,125 266,516 
ORIF-P 298,807 2,808,687 524,223 235,152 337,915 4,587,208 592,833 265,939 
CRIF-IM 319,194 3,412,304 559,997 251,166 358,302 5,190,825 628,607 281,952 




TABLE 5: INTERVENTION COSTS USED IN MODELLING 





Open reduction Closed 
reduction 
Traction 





Africa D Surgery room/per 
patient 
4037 4037 4037 4037 0 0 
Surgical implant 150 80 200 150 0 0 
Procedure and 
hospital stay 
513 513 513 513 714 0 
Total cost per 
patient 
4700 4630 4750 4700 714 0 
Total costs - 
treatment 
128154900 126246210 129518250 128154900 19468638 0 
Africa E Surgery room/per 
patient 
4036 4036 4036 4036 0 0 
Surgical implant 150 80 200 150 0 0 
Procedure and 
hospital stay 
513 513 513 513 714 0 
Total cost per 
patient 
4699 4629 4749 4699 714 0 
Total costs - 
treatment 





4037 4037 4037 4037 0 0 
Surgical implant 150 80 200 150 0 0 
Procedure and 
hospital stay 
513 513 513 513 714 0 
Total cost per 
patient 
4700 4630 4750 4700 714 0 
Total costs - 
treatment 
272957200 268891880 275861000 272957200 41466264 0 
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TABLE 6: COST-EFFECTIVENESS OF ALTERNATIVE INTERVENTIONS IN COMPARISON TO NULL SCENARIO AND STANDARD CARE (I$/DALY 
AVERTED) 










































Comparator Null: no treatment Comparator: Standard care 
Traction -6997 -154 -3988 -8907 
ORIF-IM 914 96 521 1164 686 50 391 873 
ORIF-P 903 96 514 1149 675 50 385 859 
CRIF-IM 858 80 489 1092 648 45 369 825 
ORIF-IM after 
EF 
914 93 521 1163 688 49 392 875 
Africa 
E 
Comparator Null: no treatment Comparator: Standard care 
Traction -1058 -23 -603 -1341 
ORIF-IM 909 96 518 1153 682 50 389 865 
ORIF-P 897 95 511 1138 671 49 383 851 
204 
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CRIF-IM 853 80 486 1082 644 44 367 817 
ORIF-IM after 
EF 




Comparator Null: no treatment Comparator: Standard care 
Traction -1060 -23 -604 -1347 
ORIF-IM 911 96 519 1158 684 50 390 869 
ORIF-P 900 96 513 1143 673 50 384 855 
CRIF-IM 855 80 487 1087 646 45 368 821 
ORIF-IM after 
EF 




TABLE 7: COST-EFFECTIVENESS OF TREATMENTS MODELLED COMPARED TO THE 1* 













Estimates Africa D 626.17 3601.73 3623.22 626.17 3601.73 3623.22 
Africa 
D  
Comparator Null: no treatment 
Comparator: Traction Traction ˟ ˟ ˟ 
ORIF-IM ˟ ü ü ˟ ü ü 
ORIF-P ˟ ü ü ˟ ü ü 
CRIF-IM ˟ ü ü ˟ ü ü 
ORIF-IM 
after EF ˟ ü ü ˟ ü ü 
Estimates Africa E 554.56 1953.01 3205.45 554.56 1953.01 3205.45 
Africa 
E 
Comparator Null: no treatment 
Comparator: Traction Traction ˟ ˟ ˟ 
ORIF-IM ˟ ü ü ˟ ü ü 
ORIF-P ˟ ü ü ˟ ü ü 
CRIF-IM ˟ ü ü ˟ ü ü 
ORIF-IM 
after EF ˟ ü ü ˟ ü ü 
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TABLE 8: RESULTS OF DETERMINISTIC SENSITIVITY ANALYSES VARYING DISCOUNT RATE AND CAPACITY UTILIZATION 
Intervention 
Discount rate Capacity utilization Discount rate Capacity utilization 
6% 15% 50% 95% 6% 15% 50% 95% 
Comparator: Null Comparator: Traction 
Traction -860.96 -860.96 -860.96 -860.96 
ORIF-IM 1316.09 1853.66 784.92 1344.42 946.75 1393.12 505.70 970.28 
ORIF-P 1302.03 1840.93 769.56 1330.44 934.33 1381.61 492.38 957.91 
CRIF-IM 1235.21 1739.74 736.69 1261.80 897.93 1321.28 479.62 920.24 




TABLE 9: DESCRIPTIVE STATISTICS OF PROBABILISTIC SENSITIVITY ANALYSES  
Comparator 














Null ORIF-IM 0.08 473.54 1079.39 2225.26 14071.90 1622.29 990.08 1191.19 1158.14 
ORIF-P 1.43 463.47 1117.87 2210.87 20967.51 1644.02 1034.40 1211.14 1143.65 
ORIF-IM 
after EF 
0.33 479.23 1174.95 2405.27 14790.40 1702.42 1062.78 1277.90 1157.96 
CRIF-IM 0.33 456.79 1094.64 2206.47 14003.24 1605.08 1012.13 1209.30 1087.29 
Traction -
426899.70 
-846.84 -16.92 718.70 916271.40 261.13 -2052.84 2575.11 -1347.39 
Traction ORIF-IM -1438.13 234.09 870.00 2099.51 11017.53 1388.86 789.17 968.00 868.63 
ORIF-P -2762.30 232.32 905.37 1994.78 11387.43 1396.21 783.09 1013.23 855.20 




























FIGURE 2 DECISION TREE USED FOR MODELLING
212 
FIGURE 3 PRISMA FLOW DIAGRAM OF SYSTEMATIC SEARCH 
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CHAPTER 4: MEDICAL DEVICE AND EQUIPMENT 
PROCUREMENT PLANNING: AN APPRAISAL AND 
RECOMMENDATIONS FOR THE REVISION OF THE ONE 
HEALTH TOOL 
 
KD designed and conducted the research presented here during an internship at the 
World Health Organization (WHO) in March-May 2015. Mrs. Adriana Velazquez 
Berumen (Senior Advisor for Medical Devices) supervised the project and provided 
critical feedback and support alongside staff within the WHO Medical Devices Unit; 
Ms. Karin Stenberg (Advisor on the One Health Tool) additionally reviewed research 




Sustainable and effective health service delivery relies on judicious, transparent and 
realistic health care planning.(1) While MDEs are critical components of health systems 
and services, findings presented in Chapters 1-2 suggest that MDE procurement 
planning in LMICs is fraught with challenges.  
First, product selection is frequently undiscerning. LMICs lack the necessary technical 
experts in biomedical engineering and health technology assessment (health economics 
in particular) to advise what products are appropriate and cost-effective for use in 
settings with limited infrastructure and human resource skills. (Chapter 2) Additionally, 
no generally agreed and unified set of criteria exists to assist/guide stakeholders in 
product selection. (Chapter 1) Stakeholders could use existing tools or checklists, 
developed for specific clinical or service delivery areas (e.g. 2,3), however knowledge 
of such resources among LMIC decision-makers is limited. (Chapter 2)  
Second, MDE costing for planning purposes frequently neglects expenses associated 
with user training and product servicing. (Chapter 1) Such costs should ideally be 
captured at the product selection and procurement stage to ensure products are used 
safely and to full capacity. Products for which no maintenance or training budget is 
available may be inappropriately handled and prematurely fall into disuse. (4,5) Value-
for-money should also be considered at product selection stages: considering the cost-
effectiveness of alternative purchases and interventions before embarking on investment 
decisions may lead to improved patient outcomes and more efficient resource allocation. 
(Chapters 2-3) 
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Third, MDE procurement processes may be un-coordinated and opaque. Findings of the 
qualitative study presented in Chapter 2 suggest that procurement decisions are driven 
by socio-political considerations of health facility prestige and competitiveness. In the 
absence of transparent and rational resource allocation processes, informed by evidence-
based criteria and/or technical expertise, health systems are left susceptible to corruption 
and collusion. (Chapter 2)  
Careful and informed MDE investment planning may mitigate such issues via the use of 
well-designed planning tools. For example, procurement checklists can prompt 
decision-makers to consider all potential factors impacting upon product selection, 
distribution, use and decommissioning of individual devices.(6) Tools may additionally 
provide guidance on how to undertake specific planning steps, e.g. to assist planners in 
product life cycle costing or consideration of value-for-money.(7) 
The aim of this chapter is to appraise one such planning tool - the One Health tool 
(OHT), specifically its MDE components and functions. OHT is a UN developed 
costing tool intended for use in LMIC health system planning efforts. (See Box 1) The 
appraisal presented here aims to determine whether OHT and its functions accurately 
capture relevant planning considerations related to MDE costing domains (e.g. product 
maintenance and user training) and MDE procurement/use recommendations set out in 
Chapters 1-3 within this thesis (e.g. availability of biomedical engineers for product 
selection and maintenance service provision).  
While OHT was designed for costing of horizontal or vertical health service plans, the 
tool is currently also used for costing of MDE procurement options. (8) Given its 
popularity among international organizations and analysts, and potential to influence 
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LMIC decision-making behaviour, it is relevant to consider whether the tool is designed 
to address the various procurement challenges outlined in this thesis. The chapter 
proceeds by introducing the methods and findings of ann appraisal of OHT and 





The current study was undertaken within an internship at the World Health Organization 
(WHO) Medical Devices and Equipment Unit between March-May 2015. KD proposed 
the project during the internship application process, and later refined this with 
assistance from Adriana Velazquez Berumen – WHO Focal Point and Senior Advisor 
on Medical Devices. 
AIMS AND RESEARCH QUESTIONS 
The aim of this study was to appraise OHT's planning functionality and inputs, 
specifically as they relate to MDEs. Documenting the tool's MDE related features, 
strengths and shortcomings will enable improved MDE costing to the benefit of 
stakeholders engaged in MDE resource allocation planning - or health system planning 
more widely. 
Informed by Chapters 1-3 in this thesis, in particular the findings of the systematic 
review and qualitative study, KD devised two main research questions applicable to 
OHT's appraisal: 
1) What is the medical device and equipment related content of OHT? 
2) How can OHT be used for medical device and equipment oriented planning? 
The above questions relate to two key appraisal concepts: 1) appraising OHT inputs and 
2) appraising OHT functions. This appraisal does not consider the general ease of use of 
the tool - rather it considers whether OHT is 'fit for purpose' when used for MDE 
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resource allocation planning. Feedback on OHT user experiences is routinely collected 
by the product developers/WHO following training sessions. (9)   
CHECKLIST DEVELOPMENT PROCESS 
The two main research questions posed above served as a starting point for the 
development of an appraisal checklist. (See Box 2) KD first specified a draft list of 
question items and iteratively refined these in collaboration with the biomedical 
engineers within the Medical Device and Equipment Team, including Yael Rodriguez 
Guadarrama, Gabriela Jimenez Moyao, Didier Mukama, Ying-Ling Lin. All engineers 
had experience in MDE management within public health care systems, including 
within LMICs across Asia, Sub-Saharan Africa and Latin America. 
CHECKLIST CONTENT: RATIONALE FOR INCLUSION OF QUESTION ITEMS 
The rationale for inclusion of individual question items and corresponding questions are 
listed in Table 1. 
Question items relating to OHTs MDE inputs: KD devised appraisal questions relating 
to OHT's MDE inputs by referring to the systematic review data extraction template 
presented in Chapter 1 (Question items 2) and the findings of the systematic review 
(Question items 1). (ibid)  
 Questions relating to OHTs MDE planning functionality: Reflecting on the findings 
noted in Chapter 1-2, KD further developed question items relating to OHTs planning 
functionality.   
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APPRAISAL PROCESS 
Before applying the appraisal checklist, KD familiarized herself with the structure and 
content of OHT. Technical manuals and the software itself were studied and test 
projections created to visualize how OHT operates. Specifically, KD attempted 
projections relating to health system recovery planning for Sierra Leone and Liberia 
given the recent Ebola Virus Disease outbreak. (Box 3) Using the developed question 
list (Box 2), KD then proceeded to appraise OHT and document its features. 
Best practices synthesized from the international literature (Chapter 1) are used as 
benchmarks for gaging OHT performance. (Table 1) Devices should only be selected 
for procurement when their technical specifications allow for storage and functioning in 
unfavourable ambient conditions (e.g. settings with high temperature, interrupted or 
minimal electricity supply, unclean water, no sewage) and use by potentially low-skilled 
health care workers. (10) Investments in user training or infrastructure upgrades are also 
relevant to MDE selection and should be carefully considered during planning. (ibid and 
Chapter 3)  
The appraisal was conducted independently of OHT developers and appraisal findings 
were presented in an internal seminar at the WHO and refined iteratively in light of 
expert comments by the Senior Advisor for Medical Devices (Adriana Velazquez 
Berumen) and the Technical Officer on Costing and Priority Setting within the Health 
Systems Governance and Financing Unit (Karin Stenberg). In discussion with the two 
units, KD proceeded to formulate recommendations for the revision of OHT.
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4.	3.	FINDINGS	
4. 3. 1. OHT: An overview 
OHT is a freely available software program meant to support resource-poor countries in 
costing and planning efforts. Given user input, OHT estimates the investment 
requirements of different health programs, interventions and policies and links these to 
health outcome and budget impact projections. The tool aims to inform decision makers 
of the cost, clinical effectiveness and value for money of alternative policy or program 
options(11).  
OHT consists of separate easily editable modules (Figure 1) – e.g. for infrastructure, 
health financing – that facilitate the interaction of multiple stakeholders including 
clinical experts, financing professionals, logisticians and health care managers. The 
modules allow planners to provide baseline and target assessments describing the 
current and future (desired) health system structure, outputs and services, as well as 
financial resources available.  The tool adopts a short to medium-term health system 
perspective and by default uses a 5-year planning period; this can be shortened or 
lengthened by users as needed. OHT relies on both impact and costing modules (See 
Box 1) to complete individual planning projections. 'Bottlenecks' - e.g. financing or 
other resource gaps, which impede the delivery of a service (e.g. low availability of 
health care workers) - can be flagged by the tool and thus inform decision-makers of 
key health system development constraints. 
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4. 3. 3. MDEs within OHT  
Descriptive findings: Several OHT modules contain MDE related inputs (MDE template 
lists) and utilities (functions to estimate the number of MDEs to purchase and their 
overall costs). 
The configuration screen and logistics module allow users access to one general 'Drugs 
and Supplies' list that includes MDEs. (Figure 6) Users can edit this list by adding or 
deleting items or can alternatively upload their own list. This list additionally includes 
editable fields for product unit costs, safety stock and wastage estimates. 
Within the infrastructure module users have access to health facility specific MDE lists; 
five separate lists exist for health post, health centre, district hospital, provincial hospital 
and central hospital. (see Figure 7 for an example of a health post list ) These OHT lists 
build upon past lists developed by the WHO (Figure 8 and Box 3) and include additions 
corresponding to the disease programs specific to OHT, i.e.: Child health; Reproductive 
and maternal health; Immunization; Nutrition; Water and Sanitation (WASH); HIV; TB; 
Malaria; NCDs and Mental Health Services. For example, a review of the health post 
and health center lists reveals that rapid diagnostic tests for TB and malaria diagnosis 
were added to the WHO's original MDE lists for health post and health center (Box 4) to 
form the OHT health facility specific input lists. (12) 
Separate lists exist for Medical Equipment and Facility Furniture. All items on these 
lists are included in the general ‘Drugs and Supplies’ list that can be accessed via the 
tool configuration screen. (Figure 6) OHT lists include columns for the generic medical 
device name, quantity of items needed per health care facility, device cost (in national 
currency) and device working life (in years). For target setting purposes, an additional 
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column (tick-box only) allows the user to specify whether devices are to be purchased in 
USD rather than national currency. All MDE lists available in OHT are editable: users 
can add or remove items from the lists. OHT further allows users to upload their own 
MDE input list in Excel or CSV format, provided a specific template is followed. 
The infrastructure and logistics modules additionally have predefined variables able to 
capture: 
• Health facility rehabilitation costs, including costs for the maintenance and 
replacement of medical devices and equipment; (Figures 9-10) 
• Estimates for safety stock (as percentage of need at the end of each year) and 
wastage (percentage of drug or supply that will be lost, ruined or expired within 
a year). (Figure 6) 
The former costs are specified as overall general estimates per health facility, while the 
latter are to be specified for each item included on the 'Drugs and Supplies' list. (In the 
case of consumables, a single item may refer to a set, e.g. a set of disposable gloves.) 
The human resource module includes editable tables where users can input the number 
of health care workers (e.g. nurses, doctors, program managers) needed to carry out a 
specific intervention/program or policy. OHT includes a field for technicians here. 
(Figure 11) Users have the option of adding different types of staff. 
Critical appraisal: A full account of critical appraisal findings is presented in Table 1. 
There are two main issues that limit OHTs functionality and planning accuracy: 
i) MDEs included within OHT are linked to individual health care facilities rather than 
interventions. This restricts the tools functionality for vertical program planning.  This 
issue can be traced back to previous WHO-MDE lists that were designed to be facility 
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specific. (Box 4) Experts developed these original lists by identifying the common 
procedures, and clinical departments included in different types of health care facility 
and then defining what MDEs would be needed to undertake said procedures. Without 
an accurate account of what interventions experts considered when producing the lists, 
it is difficult to link individual products to interventions. 
More recently, the WHO has proposed an alternative approach to MDE selection: the 
'availability matrix' method relies on listing devices needed for carrying out specific 
interventions, further grouped into clinical areas. For example, for the area of 
reproductive, maternal, newborn and child health and within this, the intervention 
named ‘diagnosis of complications', products such as pulse-oximeters and examination 
gloves are listed among others.(13) This approach has been used in the development of 
the Interagency List of Medical Devices for Reproductive, Maternal, Newborn and 
Child Health (13) and is currently used to develop device lists specific to cancer 
management interventions. (ibid and (12))  
The 'availability matrix' approach, however, has three shortcomings that make its use 
impractical for planning within OHT. First, many MDEs are generic to several clinical 
areas and interventions, e.g. medical furniture, gloves and injection equipment as well 
X-ray machines. Using the availability matrix alone for MDE selection may thus result 
in double counting: ideally, an MDE planning tool should distinguish between products 
intended for shared or dedicated use by different clinical departments.  
Second, depending upon the spending envelope, several variants of the same MDE 
could be purchased to undertake the same intervention: e.g. a surgical monitoring and 
anesthesia unit may be suitable to surgery in high-resource settings, but a pulse-
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oximeter and robust but low-tech anesthesia machine may be more suitable for use in 
low-resourced settings. The availability matrix fails to specify how MDEs are selected 
in such cases; biomedical engineering expertise is needed to conceptualize such 
decisions.  
Third, when selecting MDEs it is prescient to consider the human resource skills, 
infrastructure and maintenance capacity of eventual deployment settings (Chapters 1-3 
and(10)): it is unclear if/how the availability matrix approach accounts for these issues. 
ii) MDE related information is captured in separate OHT modules 
In its current format, OHT captures information related to devices in several different 
modules; this makes MDE related planning a lengthy process, as several inputs need to 
be crosschecked. For example, OHT requires users to specify wastage and safety stock 
estimates for each product in the logistics module. Maintenance and rehabilitation costs 
are meanwhile specified in the infrastructure module as general costs per health facility, 
rather than per device. This is problematic as wastage estimates depend upon the type of 
maintenance procedures put in place: e.g. preventive maintenance and careful 
calibration of minor devices such as oximeters may result in longer product life spans. 
OHT currently assigns all products on MDE lists a generic 5-year life span - this is 
obviously inadequate for consumables, however may be a realistic reflection of the life 
span of electronic equipment given unfavourable deployment settings. Additionally, 
problems may arise due to conflicting user input: e.g. logisticians may input different 
data from biomedical engineers/MDE managers. Where possible, information such as 
this should therefore be collected in one central module. 
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4. 3. 4 Recommendations for OHT revision 
The following recommendations may assist in OHT revision:  
1) Development of the following product lists: 
• A generic list of medical furniture for different types of health care 
facility, including furniture, stationery items and cleaning materials. 
Products detailed in this group would correspond to the shared resources 
necessary for various facilities to function and quantification criteria 
based on facility size, number of beds and/or population numbers should 
be provided. 
• Two types of MDE lists: 
i. Core equipment lists for each type of health care facility, 
including: consumables such as syringes, gloves, needles and 
basic devices shared across clinical areas – e.g. stethoscopes, 
weighing scales, simple laboratory equipment. This should also 
include, where necessary, the information systems relevant for 
managing patient records or samples. Currently, OHT does not 
include laboratory information systems or electronic records 
management systems (Table 1), however, such digital resources 
are now recommended as standard and cost-saving practice. (14) 
ii. Condition/clinical area specific medical device and equipment 
lists. These could be developed using the availability matrix 
approach as detailed and exemplified above. (15) Interventions 
corresponding to one specific clinical area and subsequently 
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devices associated to these should be identified using a 
transparent decision algorithm. It will be necessary to link 
interventions to the specific devices needed for carrying out 
services and to program filters into OHT to allow users to choose 
MDEs suited to specific programs and interventions. As best 
practice, safe, cost-effective products suited to the infrastructure 
and human resource skills encountered in deployment settings 
should be included in these lists. (See (10) for a MDE selection 
algorithm)  
 
2) When using the above lists for planning purposes within OHT, tool developers 
should:  
• Make available a master MDE list (including all products specified in 
lists in point 1) as a default option. Users should be encouraged to use up 
to date functional inventories of equipment and devices present within a 
country’s health care facilities for baseline assessment. This is to ensure 
current, contextual, country-specific information is entered into the tool. 
For target setting purposes, users should be encouraged to plan and select 
products for procurement as per the principle employed in point 1). Users 
should first be encouraged to select vertical programs, subgroups or 
interventions to be provided. OHT should automatically identify medical 
devices and equipment corresponding to the latter 
programs/interventions and compare this to information provided at the 
baseline assessment stages to inform users of further investments 
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required. The tool should flag the purchase of any financially 
unsustainable purchases as bottlenecks. While a universal cost-threshold 
may be inappropriate, it is important to consider a relative threshold - for 
example, the purchase of MDEs which exceed half a country's health 
care budget. 
In summary, the development of three list groups is recommended: 
a) Generic lists of medical furniture 
a. For Health Post 
b. For Health Centre 
c. For District Hospital 
d. For Provincial  
e. Central Hospitals 
b) Core lists of medical devices and equipment:  
a. For Health Post 
b. For Health Centre 
c. For District Hospital 
d. For Provincial  
e. Central Hospitals 
c) Clinical area specific lists of equipment and devices. 
To ensure MDE specific information is collated and easily accessible, all lists should 
include the following headings (including the general 'Drugs and Supplies' list): 
I. Generic device name (Optional separate columns for GMDN(16) or 
UMDNS(17) codes to allow for quick cross-checking) 
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II. Units per health care facility (for furniture and core lists) or quantification 
criteria for intervention/clinical area specific lists 
III. Unit costs (ideally local currency, local prices if data is available) 
IV. Year that costs were specified, last updated and the original currency of costs 
indicated 
V. Life-span of devices (in months) 
VI. Replacement time-frame (in months or fractions thereof)    
VII. Purchase in USD necessary (tick-box) 
VIII. Type of maintenance necessary (choose among health facility specific or 
specialist, each to be costed out separately and link to the infrastructure upgrade 
requirement screen for costing out infrastructure investments) 
IX. User training (tick-box - if yes, a reminder to include such costs in the Human 
Resources module as appropriate under training) 
X. Safety stock necessary per health care facility 
XI. Wastage estimate per health care facility 
Items IV-VI and VIII-IX are optional and present additions/alterations to OHTs current 
functionality. Item IV (year costs were specified, last updated and currency specified in) 
is useful in understanding where/how cost-data for individual products was last obtained 
and updated - an older date provided in this column may encourage users to seek up-to-
date pricing information. Item V (life span of devices in months) is a modification of the 
current life-span field (life-span in years) already included in OHT: as smaller items 
such as consumables or reagents may be usable for periods shorter than a year, a 
monthly life span is more appropriate for planning. Item VI (replacement time-frame in 
months - or fractions thereof) refers to the period after which MDEs are required to be 
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replaced by national/international policy: i.e. an X-ray unit may need to be replaced 
every 10 years due to national regulation to ensure the health and safety of health care 
staff and patients. Product replacement time may therefore differ from life span. Items 
VIII-IX are self-explanatory and prompt users to consider which products may require 
additional investments for user training or maintenance. 
Lists should be developed in shareable and editable format, ideally in a template file 
that can be uploaded to OHT (the tool currently provides guidance on how such lists 
should be structured). (9) 
The methodology supporting product selection for inclusion on the MDE lists 
mentioned above needs to be distinguished from methods used to select medicines 
within the Essential Medicines List. (18,19) To be accepted onto the Essential 
Medicines List, medicines undergo a rigorous and transparent selection process: items 
selected as part of the ‘core list’ correspond to priority health conditions and are 
reviewed for safety, efficacy and relative cost-effectiveness and affordability. Such a 
rigorous review would be impractical for the static medical furniture or core health 
facility equipment lists proposed here – most items on these lists are likely to be safe 
and uncontentious investment options; lists developed by expert consensus informed by 
the MDE selection/prioritization criteria outlined in Chapter 1 may be used instead. 
However, safety, relative cost-effectiveness and affordability should guide discussions 
for the development of intervention/clinical area specific lists of equipment. For 
example, resource-stratified clinical guidelines for breast cancer (2,20) may be used to 
create resource-level stratified MDE lists.  
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4.	4.	DISCUSSION	
This chapter includes the first MDE specific appraisal of OHT - the main health system 
planning tool available free of charge to LMICs. The descriptive and analytical findings 
presented here illustrate that OHT is a comprehensive planning platform, able to capture 
health service planning inputs relating to infrastructure, human resources and financing 
among others. OHT is a helpful starting point for costing out MDE purchases; however, 
its structure is currently too rigid to deal with the peculiarities of MDE procurement and 
relevant planning given specific health programs or services. 
OHT possesses a basic set of functions and inputs necessary for assisting LMIC 
decision-makers in health system planning and resource allocation. The tool currently 
allows users to edit generic health facility specific MDE lists to indicate what products 
are present in the health system and which are yet to be purchased. The tool further 
prompts users to specify other MDE-related investments: e.g. relating to safety stock 
and wastage and health facility maintenance - including a nominal sum for MDE 
specific maintenance. OHT can thus be used as a starting point for MDE related costing 
exercises and planning purposes, however, two main issues limit its planning 
functionality. 
First, although OHT allows users to engage in program specific planning and tailor what 
interventions are/are not to be offered in the health system, the tool cannot link selected 
interventions to specific MDEs. This means that in addition to intervention or program 
selection, users must engage in a fairly labour intensive process of reviewing OHTs 
generic MDE lists during both baseline assessment and target setting stages. Challenges 
arise as decision-makers involved in planning and/or logisticians do not possess the 
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necessary clinical or biomedical engineering related knowledge to complete this 
process. (21) Second, OHT captures information related to MDEs in several different 
modules, making the tool difficult to navigate and increasing the reporting burden on 
users. Further points where OHT may require revision are outlined in Table 1. 
To mitigate these issues, further development of OHT input lists is proposed. A first 
step is the creation of static lists for medical furniture and basic MDEs for each type of 
health care facility. The current OHT and WHO lists could serve as a basis for this. 
(Box 1) Additionally, clinical area and/or intervention specific lists should be created 
and linked to specific programs or intervention sub-groups. Users should thus be able to 
select a specific program or intervention sub-group and be presented with a 
correspondingly tailored list of products. This approach is similar to that within the 
Integrated Healthcare Technology Package (IHTP) (22) and within the availability 
matrix used for product selection by the WHO(15).  Additionally, MDE related 
information should all be captured in individual lists on a per product basis: this will 
prompt users to consider product features, including maintenance and training necessary 
for safe deployment, and logistical challenges at early procurement stages. 
Only one other (complete) tool for MDE related planning currently exists. (8) IHTP was 
developed under the auspices of the WHO and focuses solely on health technologies 
and projecting procurement and management scale-up given local epidemiology and 
service scale-up. IHTP is not freely available for use.(22) The tool adopts a bottom-up 
approach to the selection of health technologies; this is similar to what is proposed here: 
i.e. users first select what services are to be offered and based on this IHTP offers 
suggestions for the types of products to be considered for procurement. IHTP is not 
suitable for impact analysis, however, thus limiting its use for resource allocation. 
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The findings of this appraisal must be interpreted with due caution. Although KD 
formulated appraisal questions transparently, the appraisal of OHTs current 
functionality and potential for further use included substantial subjectivity. The 
appraisal process has been iterative and the team  involved in this exercise cautions that 
they have not been extensively involved with OHTs (or know of data evaluating OHTs) 
use in LMIC settings.  Furthermore, the appraisal checklist specified here was not 
previously piloted on any other planning tool or MDE resource allocation planning 
method. While KD attempted to obtain access to IHTP to first pilot the checklist, access 
was not granted by the WHO in this case. To further develop and refine the checklist, 
planning experts, biomedical engineers and health technology managers should be 
consulted. DELPHI or other consensus methods may prove particularly useful in such 
endeavours and may help identify any further concepts of relevance to the MDE 
specific appraisal of OHT. To validate the checklist, surveys engaging MDE resource 
allocation planning stakeholders with experience of using OHT should be conducted 
and responses compared to findings and recommendations outlined here. 
Notably however, the appraisal checklist presented here draws upon recent relevant 
evidence on MDE procurement planning as outlined in Chapters 1-3. Concepts relating 
to MDE affordability and costing, maintenance and servicing in deployment settings, 
quantification of stock (including estimation of wastage and safety stock) were probed 
via multiple questions. Findings of the research presented in Chapters 1-3 have not only 
been integrated into the checklist but have also served to guide OHT's appraisal; leading 
experts on MDE management for LMICs were additionally consulted during the 
appraisal checklist development and appraisal process.
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4.	5.	CHAPTER	SUMMARY	AND	KEY	FINDINGS	
Despite difficulties in using health technology assessment and economic evaluation 
methods in LMICs, MDE investment decisions must be reached in practice. To prevent 
MDEs falling into disuse, it is therefore crucial to ensure all product purchases are 
appropriate costed. 
Chapter 4 summarizes a critical appraisal of the One Health Tool (OHT) for MDE 
related investment planning, management and costing. Use of OHT is promising as it is 
able to capture both health and budget impact information and evaluate investments 
associated to different health service expansion plans. The tool is relatively easy to use, 
however proves too rigid to assist in sensitive and context-specific MDE procurement 
planning. For example, OHT is currently unable to link individual interventions to 
MDEs required to carry out services and additionally includes simplistic technology 
management assumptions (e.g. a uniform 5-year life span of all MDEs).  
Key Finding 9: Regardless of planning tools used to inform/reach MDE 
investment decisions, information relating to shared/dedicated resource use, 
user training, maintenance and servicing capacity, safety stock and wastage 
must be captured. For information to be meaningful and easily accessible, 
MDEs should be linked to interventions where necessary and presented in a 
centralized database/list. 
Issues with the tool can be traced back to inappropriate input materials. Device lists 
input into OHT do not link individual products to interventions but to health service 
level or health facility type. The tool therefore assumes users have considerable and 
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detailed knowledge of linkages between individual devices, interventions and health 
facilities. Planning is additionally complicated by lack of information of which devices 
fall into different product categories: e.g. facility furniture and common necessities (e.g. 
delivery beds and stethoscopes), clinical area specific technologies (e.g. dental 
equipment), or intervention critical products (e.g. colonoscopes for colonoscopies). 
Such information would for example allow users to determine what MDEs constitute a 
dedicated or shared resource across clinical areas: e.g. an ultrasound machine can be 
shared by the internal medicine and paediatric department. Recommendations for 
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 Background To enable a standardized health systems approach to costing, Avenir Health 
developed OHT under the direction of the United Nations Interagency Working Group on 
Costing. (11,23) OHT has been used in over 25 countries. (23) 
Configuration: Users choose a region or country to initiate new planning projections; 
projections include several planning modules (Figure 1). Country databases, including 
demographic and disease incidence/prevalence estimates, are available for download from 
Avenir Health. OHT can project costs for two planning scenarios: horizontal delivery  
(Figure 2) or vertical program planning (Figure 3). Users select programmes and health 
services/interventions to model - these may already be provided within the health system, 
be subject to re-development or newly introduced. By default, OHT includes a list of 
programmes and services focused on achieving the Millennium Development Goals: e.g. 
Water and Sanitation (WASH) and Human Immunodeficiency Virus. Interventions 
included in OHT reflect WHO guidelines or evaluations by the WHO-CHOICE (Choosing 
interventions that are cost-effective) group - e.g. see Ginsberg et al. (24)  
Users can add or delete interventions from this list as well as upload their own context 
specific intervention lists. Interventions are assigned to a relevant vertical program and 
further classified according to the health care level at which they are carried out – i.e. 
outreach, community, clinic and hospital level. This classification scheme links program 
and delivery channel oriented planning. (Figures 4-5)  
Baseline assessment: In individual planning modules (Figure 1), users first perform a 
baseline assessment of the health system and its capacity to offer health services by 
specifying the type of interventions already offered, availability of health care 
professionals/associated staff and of physical resources, i.e. facilities, medicines and 
medical devices and equipment.  
Target setting and planning: Users set policy objectives and/or formulate health system, 
sector or disease specific development plans. For each plan users must specify the 
interventions for which costs and outcomes need to be modelled - i.e. interventions to be 
phased out, introduced or augmented.  Each alternative plan is saved by OHT as a 
projection. The projections include the costs and likely health outcomes incurred by the 
interventions selected by users. (See Box 2 for examples) 
Costing: OHT supports programme specific and sector wide costing, budgeting and 
financing analysis and uses an ingredients approach for cost-estimation. (25) Variable costs 
are estimated using population numbers and a database of disease incidence. Costs are 
editable and standard cost lists for infrastructure, medicines, MDEs and human resource are 
included. Program management/ monitoring activities are estimated by specifying the type 
of health care professionals to be employed, a standard salary per professional and the 
relative time needed for activities. 
Data and impact projections: DemProj is the software used to link the health outcome and 
costing modules of OHT. (26) The health impact modules used by OHT are condition or 
program specific tools previously developed to model intervention health impact (e.g. the 
AIDS Impact Model, TB Impact and the Lives Saved Tool (LiST) among others).  
 
BOX 1: ONE HEALTH TOOL: PLANNING PRINCIPLES AND FUNCTIONS 
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Part 1: Inputs 
What is the medical device and equipment related content of OHT? 
1. Identify and discuss any and all medical device input lists within the tool.  
a. What devices and equipment are considered by OHT?  
b. What methods were used for list development?  
c. Are additions or deletions necessary? 
2. What information on devices is captured by OHT, e.g. are the following included: 
a. Device characteristics: 
i. Unique device identifier or device name. 
ii. Technical specifications or functional group (i.e. are devices grouped 
by clinical area, location within health facility or departments, 
function, size, cost or other characteristics?) 
b. Maintenance requirements (including routine and corrective maintenance, 
need for user training). 
c. Specifications for user training. 
d. Specifications for safety stock and wastage. 
e. Device life-cycle costs: product cost, distribution, maintenance, spare parts, 
training, decommissioning. 
Part 2: Planning functionality 
How can OHT be used for medical device and equipment oriented planning? 
1. Can OHT accommodate medical device and equipment procurement planning for: 
a. Single interventions (or packages) 
b. Vertical programs 
c. Horizontal programs or per health care delivery level 
d. Specific health facility types 
2. Does OHT include estimates to aid in specifying safety stock and wastage of devices? 
3. Can OHT calculate device coverage levels per regions or facilities? 
4. What does OHT consider a “bottleneck in service delivery” in relation to devices?  
I.e. will OHT alert planners to the need to: specify safety stock, wastage; attain specific 
coverage levels based on population or facility estimates; specify training components 
for staff; specify maintenance and decommissioning components? 
5. Does OHT include variables related to: 
a. Biomedical engineering capacity within a country or region/per clinical area 
b. Technical capacity for medical device and equipment repair 
c. Health system infrastructure and necessary building-works or upgrades to 
infrastructure to enable device functioning (e.g. water, electricity, sewage 
systems) 
d. Electronic health system infrastructure to aid in device management and/or 




BOX 1: OHT APPRAISAL QUESTIONS 
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BOX 3: USING OHT FOR SIERRA LEONE RECOVERY PLANNING AFTER EBOLA VIRUS DISEASE OUTBREAK 2014 
OHT was proposed as a recovery-planning tool for countries affected by the 2015 Ebola Virus Disease outbreak. Two specific projections relating to 
recovery planning in Liberia and Sierra Leone were attempted to appraise OHTs applicability to MDE procurement planning. These exercises are ‘test 
scenarios’ – as such KD attempted to use the tool given only generically available information and guidance to gage the tools functionality and data input 
requirements. 
1) Projecting equipment costs for one tertiary hospital including CT scanning ability in Liberia.  
This was a costing exercise, hampered only by data paucity in OHT. Default population and cost data for Liberia was uploaded to OHT and the default 
input list of MDEs for a central level hospital used to project costs. Initial estimates suggested 26,051,666 Liberian Dollars (LRD) would be needed, 
excluding CT which is costed at 0 in OHT. Excluding further equipment (a linear accelerator and equipment necessary for radiotherapy were excluded 
upon communication with Liberian partners) and adding a CT scanner with 10 year operating life(Google search: $USD165,000), estimates for the 
medical equipment within the hospital reached 39,266,568 LRD. This excludes servicing costs. 
2) Projecting MDE related costs for 20% expansion of TB diagnostic services in Sierra Leone: This task could not be completed as OHTs functions do 
not extend to this level of planning and further expert input and data were needed.  
Current data from Sierra Leone suggested TB diagnosis via microscopy, tissue culture and X-ray were not available. Initially, the following were chosen 
for projection: i) Microscopy: diagnostic test for active TB case finding and ii) Microscopy: test to monitor treatment for pulmonary TB cases; both 
services were expanded from 0% coverage to 20%. Issues arose after services were chosen for projection: OHT does not link the intervention to specific 
medical devices; biomedical engineers and clinical experts would be needed to advise on the laboratory equipment relevant to TB microscopy. When 
consulting MDE lists for district and central hospitals it additionally became apparent microscopy equipment had no reference cost attached: TB 
laboratory equipment for microscopy was costed out at 0 in OHT. 
Considering recent WHO recommendations, microscopy was replaced by genotypic molecular testing, carried out via the use of Xpert MTB/RIF assay. 
Only Xpert cartridge costs were available: 49,445.242438 Sierra Leonean Leone (SLL). OHT did not include Xpert cartridges in the facility MDE lists. 
Further expertise would be needed to specify the number of cartridges per facility rather than population (population per facility can be specified 
elsewhere) – additional data relating to health facility coverage/population and likely throughput of tests per cartridge is needed to complete this task.  
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BOX 4: WHO CORE EQUIPMENT LISTS: DETAILS ON THEIR DEVELOPMENT, CONTENT, ORGANIZATION AND PRESENTATION 
	 	
WHO Core Equipment Lists 
Development and content: The WHO Technical Advisory Group on Health Technologies developed Core equipment lists in 2010. (27,28)Biomedical engineers, 
clinical specialists, health technology managers and infrastructure/logistics professionals from across LMICs mapped out the different rooms and service areas 
routinely included in specific health facilities and identified what furniture and equipment is necessary for each type of health care facility and the services 
generally provided therein. (8) No written account of methods used for the development of these lists exists and it is additionally unclear what criteria or factors 
experts considered during product selection.  
 
The WHO further states(29):  
“WHO has not reviewed the safety, efficacy, quality, applicability, or cost acceptability of any of the technologies referred to hereafter. Therefore, inclusion of 
the aforesaid lists herein does not constitute a warranty of the fitness of any technology or of any resulting product and any future development thereof, for a 
particular purpose. Besides, the responsibility for the quality, safety and efficacy of each technology or each resulting product remains with its developer, owner 
and/or manufacturer.” 
 
Organization: Lists are organized by health care facility type. Five separate lists exist for health post, health centre, district hospital, provincial hospital and 
central hospital. All baseline lists can be found on the WHO’s website and are freely downloadable. (29) 
Presentation: Medical device lists include columns for device location (area, unit and subunit), device type (medical equipment, furniture, 
instrument or accessory), a generic device name, and term names and unique numeric identifiers corresponding to GMDN (30)and UMDNS 
nomenclatures(17). Lists were provided in a PDF format for consultation until 2015; they are currently available for download as editable Excel 
files. 




TABLE 1: OHT APPRAISAL CHECKLIST: QUESTION ITEMS AND RATIONALE FOR QUESTION INCLUSION 
Appraisal Question Rationale and supporting evidence 
Section 1: What is the medical device and equipment related content of OHT? 
1. Identify and discuss any and all medical device input lists within 
the tool.  
The systematic review highlighted that different types of MDE lists 
are used for planning purposes: it is relevant for planners to 
understand what product categories are included/excluded from lists 
and how lists were developed (i.e. do included items correspond to 
'gold standards'). 
1a. What devices and equipment are considered by OHT? 
1b. What methods were used for list development? 
1c. Are additions or deletions necessary? 
2. What information on devices is captured by OHT, e.g. are the 
following included: 
The systematic review noted the importance of uniquely identifying, 
and clearly categorizing, MDEs. In the absence of unique product 
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Appraisal Question Rationale and supporting evidence 
2a. Device characteristics: i. Unique device identifier or device 
name.        ii. Technical specifications or functional group (i.e. are 
devices grouped by clinical area, location within health facility or 
departments, function, size, cost or other characteristics?) 
identifiers or a clear categorization system, MDE procurement 
planning is increasingly difficult: e.g. products with 
similar/inappropriate specifications may be acquired and stock 
tracking/verification is challenging.  
2b. Maintenance requirements (including routine and corrective 
maintenance, need for user training). 
Absence of maintenance services, whether preventive or corrective, 
and training on safe MDE use lead to products breaking or falling 
into disuse prematurely; this directly results in lost resources and 
impairs health service provision. 
2c. Specifications for user training. 
2d. Specifications for safety stock and wastage. Health care professionals in The Gambia and Romania frequently 
mentioned stock outs of MDEs (referring to consumable items) as 
well as wastage of products due to MDE transport in unfavorable 
conditions (i.e. hot humid countries - referring to products such as 
blood pressure machines and laboratory reagents which react 
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Appraisal Question Rationale and supporting evidence 
adversely to protracted heat exposure). 'Stock out' or 'wastage' 
estimates may not be relevant for all items, however OHT should 
minimally require the specification of such estimates for 
consumables/single-use products. 
2e. Device costs or prices, including an indication for which 
devices should be procured. 
To judge whether MDEs are affordable, details on all MDE life-cycle 
cost components must be specified; if only one total cost is specified, 
details on whether this accounts for shipping, distribution, installation 
and calibration, maintenance and spare parts, training and 
decommissioning are needed.  
 
The health economic analyses presented in Chapter 3 highlight the 
difficulty of sourcing adequate cost-data relating to MDEs; data on 
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Appraisal Question Rationale and supporting evidence 
MDE servicing and ancillary infrastructure are particularly difficult to 
obtain. (See Chapter 3 - estimation of costs for alternative 
interventions modelled, specifically operating room costs) 
Section 2: How can OHT be used for medical device and equipment oriented planning? 
1. Can OHT accommodate medical device and equipment 
procurement planning for: 
Interviews with health facility managers and regional/national health 
service planners/MDE management personnel in The Gambia and 
Romania emphasized the importance of adopting a unified 
perspective when selecting, procuring and managing MDEs. Planning 
should account for shared resource use and additionally consider 
which health facilities are best positioned and equipped to use and 
maintain specific MDEs; this ensures both improved service delivery 
and enables timely patient referral to better equipped facilities as 
relevant.  
1a. Single interventions (or packages) 
1b. Vertical programs 
1c. Horizontal programs or per health care delivery level 
1d. Specific health facility types 
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Appraisal Question Rationale and supporting evidence 
 
It is worth noting however that professionals engaged in MDE 
procurement and resource allocation frequently work at either health 
facility or regional/national horizontal or vertical program level 
(Chapter 1): OHT should therefore enable the capture of multiple 
planning perspectives. 
2. Does OHT include estimates to aid in specifying safety stock 
and wastage of devices? 
Interview and focus group participants across The Gambia and 
Romania noted MDEs frequently broke or were used up without 
replacement stock being available (e.g. in case of consumables). In 
the absence of an electronic MDE management system (See also 
question 5d) it was difficult to adequately monitor and quantify how 
many products would be needed to enable minimal service delivery. 
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Appraisal Question Rationale and supporting evidence 
3. Can OHT calculate device coverage levels per regions or 
facilities?  
Policy makers and national procurement representatives in both The 
Gambia and Romania mentioned the use of 'informal' coverage 
targets for different MDEs: e.g. 1 Magnetic Resonance Imaging 
machine per 150,000 people. Should policy makers indeed set such 
MDE coverage targets, it is relevant to explore how this is accounted 
for in OHT 
4. What does OHT consider a “bottleneck in service delivery” in 
relation to devices? I.e. will OHT alert planners to the need to: 
specify safety stock, wastage; attain specific coverage levels based 
on population or facility estimates; specify training components for 
staff; specify maintenance and decommissioning components? 
This question item was included after a first cursory review of OHTs 
functions.  
 
OHT is able to flag 'bottlenecks' in service delivery/funding/capacity: 
i.e. identify points where insufficient resources are provided to ensure 
service delivery. Findings in Chapter 1 and 2 suggest several such 
'bottlenecks' could apply to devices, including: specifying insufficient 
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Appraisal Question Rationale and supporting evidence 
safety stock and wastage for consumable/single use devices; inability 
to attain specific coverage levels based on population or facility 
estimates as per national policies (see Item 3 above); not specifying 
costs for MDE relevant user training or product maintenance and 
decommissioning. 
5. Does OHT include variables related to: Interviews in The Gambia emphasized how, in the absence of MDE 
manufacturers within LICs, as well as obligatory MDE maintenance 
contracts, MDEs frequently fall into disuse. The publicly funded 
health system therefore needs to compensate for shortcomings in the 
availability of maintenance services and trained servicing personnel. 
Depending on the complexity of MDEs, only specifically trained 
engineers may be able to ensure product maintenance - e.g. medical 
physicists for brachytherapy.  
5a. Biomedical engineering capacity within a country or region/per 
clinical area 
5b. Technical capacity for medical device and equipment repair 
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Appraisal Question Rationale and supporting evidence 
5c. Health system infrastructure and necessary building-works or 
upgrades to infrastructure to enable device functioning (e.g. water, 
electricity, sewage systems) 
The systematic review in Chapter 1 emphasized that when selecting 
MDEs for procurement, stakeholders assign foremost relevance to the 
ambient conditions encountered in the eventual deployment setting. 
Availability of electricity, clean water, and temperature controlled 
storage/treatment rooms are relevant both for MDE selection and 
continued use.  
5d. Electronic health system infrastructure to aid in device 
management and/or patient management (e.g. electronic patient 
records, laboratory information systems) 
To accurately account for MDE stock and appropriately manage this 
at regional and national scales, functional inventories or information 
systems are needed. Interview participants in both The Gambia and 
Romania emphasized the need for such systems: they could serve to 





TABLE 2: ONE HEALTH TOOL APPRAISAL  








1. Identify and discuss any and all medical 
device input lists within the tool.  
a. What devices and equipment are 
considered by OHT?  
b. What methods were used for list 
development?  
c. Are additions or deletions 
necessary? 
 
MDE lists developed 
using a transparent 
product selection 
algorithm and including 
sufficient information for 
linking MDEs to specific 
interventions or health 
facilities 
OHT uses the following 
MDE lists: 
• One general 
'Drugs and 
Supplies' list 




• Separate health 
facility specific 
lists for Medical 
Equipment and 
Facility Furniture 






MDE lists within 
OHT are static: i.e. 
products listed are not 
linked to the health 
interventions they 
perform. If lists were 
dynamic, MDEs on 
lists would be added 
or deleted depending 
upon the interventions 
or programs users 
select within a 
projection.  
2. What information on devices is 
captured by OHT, e.g. are the following 
included: 
MDEs grouped according 
to transparent decision-
algorithm 
OHT - MDE input lists 
include: 
a. Device characteristics 
i) Information on 
MDEs is disparately 
presented in OHT: 
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 Appraisal Question Notes on best practice OHT Inputs and 
functions 
Notes 
a. Device characteristics: 
i. Unique device identifier 
or device name. 
ii. Technical specifications 
or functional group (i.e. 
are devices grouped by 
clinical area, location 
within health facility or 
departments, function, 
size, cost or other 
characteristics?) 
b. Maintenance requirements 
(including routine and corrective 
maintenance, need for user 
training). 
c. Specifications for user training. 
d. Specifications for safety stock and 
wastage. 
e. Device costs or prices, including 
an indication for which devices 




including preventive and 
corrective maintenance 









including consideration of 
safety stock and wastage 
where necessary 
Indications of product 
cost and components 
reflected in cost (e.g. 
maintenance, warranty); 
information on how up to 
i. Device name - 
this is a unique 
text identifier. 
ii. Devices are 
classified into 
either equipment 
or furniture and 
are grouped 
according to the 
health care 
facility they are to 
be used in. 
b. Maintenance of 
devices is captured via 
the infrastructure module 
- users can specify 




c. User training is not 
considered. 
d. Users can specify the 
necessary safety stock 
e.g. users specify 
maintenance, safety 
stock, wastage in 
different modules of 
the tool. A potential 
improvement, for 
example, would see 
safety stock and 
wastage for individual 
devices placed 
alongside the MDE 
health facility specific 
lists. 
ii) It is unclear how 
the devices on the 
preloaded MDE lists 
were chosen for 
inclusion in OHT. 
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functions 
Notes 
date costs are and projected wastage of 
devices within the 
logistics module, using 
the 'Drugs and Supplies' 
list. 
e. Device costs for each 
MDE are included in 
each of the lists 
presented. During 
baseline assessment users 
can indicate what devices 
are already present 
within the national health 
system; during target 
setting users can choose 
what MDEs are still to be 
procured and also 
indicate whether 
products are to be 





in OHT  
1. Can OHT accommodate medical device 
and equipment procurement planning for: 
a. Single interventions (or 
packages) 
b. Vertical programs 
c. Horizontal programs or per 
Transparent planning 
methods  
Users can use the OHT 
MDE lists to select what 
MDEs are to be 
procured. The lists 
indicate what products 
are generally required for 
MDE lists are static 
rather than dynamic: 
i.e. user selections of 
the types of programs 
or health interventions 
to offer do not 
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functions 
Notes 
health care delivery level 
d. Specific health facility 
types 
each type of health care 
facility. Users can also 
select what MDEs are to 
be procured from a 
general Drugs and 




the MDE lists. For 
example, even should 
users select to offer 
only TB services, 
OHT will not restrict 
the MDE list to items 
only needed for the 
management of TB. 
2. Does OHT include estimates to aid in 
specifying safety stock and wastage of 
devices?  
Realistic estimates of 
safety stock and/or 
wastage to be included to 
ensure service can be 
provided sustainably even 
in periods of high demand 
or financial difficulty 
OHT allows users to 
specify their own 
estimates for safety stock 
needs and wastage. 
Background research 
into frequently used 
estimates for safety 
stock and wastage 
may be warranted. 
This would allow 




3. Can OHT calculate device coverage 
levels per regions or facilities? 
MDE coverage per region 
and nation can be 
calculated 
This function is not 
automatic in OHT, 
however, this could be 
deduced: MDEs are 
assigned to different 
health care facilities and 
OHT calculates health 
The Global Health 
Observatory now 
includes indicators 
and for the 
availability of certain 
MDEs (e.g. CT 
scanners). The WHO 
256 
257 




for coverage purposes. 
and other UN 
organizations also 
propose benchmarks 
for MDE availability; 
benchmarks could be 
presented as 
informational sources 
for users wishing to 
procure specific types 
of MDEs. 
4. What does OHT consider a “bottleneck 
in service delivery” in relation to devices?  
I.e. will OHT alert planners to the need to: 
specify safety stock, wastage; attain 
specific coverage levels based on 
population or facility estimates; specify 
training components for staff; specify 
maintenance and decommissioning 
components? 
 MDE procurement costs 
are included in the 
overall investment 
estimate of a specific 
health program/policy. 
Should a financing gap 
exist - i.e. should OHT 
calculate insufficient 
resources to meet the 
investment requirement - 
the tool will alert users to 
a 'bottleneck'. 
Additional 
bottlenecks could be 
specified, in particular 
relating to:  
i. low coverage levels 
of basic technologies 
(indicators for basic 
technology 
availability in 
countries are included 
in the Global Health 
Observatory) 
ii. No provision for 
user training in 
equipment use: this is 
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and control in 
particular. 
 
5. Does OHT include variables related to: 
a. Biomedical engineering 
capacity within a country 
or region/per clinical area 
b. Technical capacity for 
medical device and 
equipment repair 
c. Health system 
infrastructure and 
necessary building-works 
or upgrades to 
infrastructure to enable 
device functioning (e.g. 
water, electricity, sewage 
systems) 
d. Electronic health system 
infrastructure to aid in 
device management and/or 
patient management (e.g. 
Health systems to employ 
biomedical engineers and 
technicians to advise on 
MDE management and 
conduct MDE 
maintenance respectively. 
Where resources permit, 
information systems for 
MDE management and 
patient/record/sample 
management should be 
present.  
 
a-b. In the human 
resource module, users 
can specify the number 
of technicians needed 
within the health system. 
 
c. In the infrastructure 
module, users can 
specify what 
infrastructure works are 
to be carried out within 
the planning cycle. This 
includes building and 
equipping new health 
care facilities. Users can 
specify building costs 
a-b. The Global 
Health Observatory 
will include estimates 
of the international 
availability of 
biomedical engineers. 
It may be useful for 






d. The WHO strongly 
recommends 
investments in health 
information systems 
for laboratories and 
258 
259 
 Appraisal Question Notes on best practice OHT Inputs and 
functions 
Notes 
electronic patient records, 
laboratory information 
systems) 
and use MDE lists as 
explained above. Users 
can also enter estimates 
for water, sewage and 
electricity works and 
utilities - this can be 
either as a % of building 
costs or overall 
estimates. 
d. In the health 
information systems 
module, users can 
specify the type of IT 
infrastructure to be 





































FIGURE 7: OHT HEALTH CARE FACILITY SPECIFIC LIST 
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FIGURE 9: DELIVERY CHANNELS AND HEALTH SYSTEM INFORMATION, INCLUDING 


























This thesis explored medical device and equipment (MDE) procurement in low and 
middle-income countries (LMICs), specifically procurement planning methods and 
processes. The thesis assumes that given improved methods and processes, difficulties in 
the uptake and use of MDEs in LMICs may be pre-empted. Four original research studies 
were undertaken and key findings are outlined further below. 
Research presented here should be interpreted with due caution. Study limitations are 
summarized in detail in individual chapters; however, two crosscutting limitations are 
noteworthy. First, this thesis has focused exclusively on MDE procurement in the public 
health care sector of LMICs. A considerable volume of health service delivery in LMICs 
falls on the private sector and MDE procurement may occur substantially differently 
therein.(1) Second, research presented here did not explore the role of regulatory, financing 
or tendering system differences on MDE procurement.  (E.g. see (2,3)) Studies presented 
here were not designed to explore such issues, although the relevance of these factors in 
procurement and procurement planning is noted across chapters.  
The MDE procurement landscape: From the normative to empirical 
Chapter 1: Systematic literature review on MDE procurement methods 
A systematic review of the literature on LMIC-specific MDE procurement methods is 
presented; 250 individual documents were appraised. Documents were identified following 
a thorough search of both bibliographic and grey literature and application of strict 
inclusion and exclusion criteria. Materials included research articles, procurement reports, 
recommendation documents as well as guidelines or checklists. Across documents, a 
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diverse set of recommendations on how MDE procurement should be undertaken emerges; 
recommendations and notes on best practice were synthesised using both narrative 
synthesis and qualitative meta-summary.  
Key Finding 1: The literature suggests two main methods are used (either solely or 
in combination) for product selection; stakeholders are either guided by past 
procurement experience or focus on identifying products to address a high priority 
condition. 
Experience based-methods imply the review and/or evaluation of historical procurement 
trends and updating procurement practices as needed on a case-by-case basis. The opinions 
and personal experiences of stakeholders, of both the procurement process and products 
selected, form the foundation of this method. (E.g. see (4,5)) Needs-based methods in 
contrast rely on stakeholders first identifying a health area of need and then products 
necessary for service provision in this area. (E.g. see (6))  Methods are likely to be 
combined in practice. 
Key finding 2: MDE cost and technical specifications/alignment to ambient 
conditions are the primary factors influencing product selection. Evidence sources 
such as health needs assessments are also relevant, however, health technology 
assessment is mentioned in few documents.  
The systematic review also explored what factors, issues or evidence sources were noted as 
relevant to procurement planning. Authors noted that cost is the most significant factor 
affecting MDE selection: high product costs are prohibitive for resource constrained 
settings and decision-makers therefore procure cost-minimizing technologies. Authors of 
reviewed documents emphasise, however, that decision-makers may neglect to consider 
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the full life-cycle cost products are likely to incur; costs for user training, maintenance and 
servicing are frequently not considered. Where such costs have not been accounted for 
during product selection, devices are likely to remain unused during deployment.  
Use of relevant evidence may improve procurement planning; the systematic review 
therefore documented the types of evidence sources decision-makers may turn to when 
selecting MDEs.  Notably, the review suggests health needs assessments play a major part 
in procurement planning. In contrast, health technology assessment (HTA) reports/health 
economic (HE) evaluations are referenced in a minority of cases, suggesting the relevance 
and potential of such methods is not widely realized across stakeholders. 
Key Finding 3: The literature suggests MDE procurement is a complex process 
where stakeholders acting at different health system levels undertake different 
actions. 
Authors of reviewed documents emphasize that a multitude of stakeholders are engaged in 
MDE procurement. Macro-level stakeholders for example may set the overall direction or 
scope for MDE related resource allocation; meso-level agents (e.g. regional planners) may 
instead be responsible for the tendering and distribution of products. End-users – that is 
clinicians and patients – are mainly consulted on issues of clinical need and product 
experience. The involvement of multiple stakeholders and tendering at meso-level by 
planning decision-makers, rather than clinicians, creates a user-buyer divide. This divide 
leaves room for discoordination when stakeholders do not realize effective and efficient 
communication channels between decision-making levels. 
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Chapter 2: A qualitative study exploring MDE procurement in contrasting settings 
Informed by the preliminary findings of the systematic review, a qualitative study into the 
procurement processes of two contrasting LMICs – The Gambia and Romania – was 
planned and carried out. The aim of this study was to explore the empirical aspects of 
MDE procurement planning and decision-making.  
Key Finding 4: Fieldwork findings largely corroborate conclusions drawn from the 
literature review: procurement is a complex, multi-level, multi-stakeholder process 
driven by stakeholder experiences. Limited evidence is considered during product 
selection.   
The study found that across both the Gambia and Romania, MDE procurement is driven 
largely by the clinical and management experience of physicians and health facility 
managers or policy-makers. In line with systematic review findings, different stakeholders 
are involved with managing MDE procurement. Health facility managers and clinicians 
were able to influence the procurement of devices that fall below a specific cost-threshold 
(e.g. 30,000 EURO in Romania) at institutional level. National level stakeholders were 
instead responsible for the selection, purchase and distribution of high-cost technologies 
across national health facilities.  
Key Finding 5: Decision-making dynamics are strongly influenced by culture and 
considerations of power and prestige. These dynamics are substantiated by 
stakeholders equating MDEs to objects of symbolic relevance.  
Study participants across both settings recognized MDEs as indispensable elements of 
service delivery and prized technologies as symbolic forms of capital. The relevance of 
MDEs results from participants conceptualizing the possession of technologies as proxies 
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for institutional prestige or quality of care. Facilities with more up to date and varied 
MDEs are able to attract further funding both via reimbursement mechanisms, as well as 
directly via patient fees. Given this symbolic relevance attributed to MDEs, procurement 
decision-making does not take the form of rational resource allocation, but ad-hoc and 
prestige driven processes. Cultural and socio-political elements, such as health facility’s 
managers need to rigidly control asset purchases and the struggle for health facility 
survival in an underfunded health system, additionally influence stakeholder interactions 
and dynamics.  
Key Finding 6: The uncoordinated and socially constructed procurement 
environment is susceptible to manipulation; experts note the presence of corrupt 
and collusive practices across LMICs generally. 
Given the multitude of incentives and factors influencing MDE procurement – as well as 
lack of an evidence-based and transparent MDE selection and resource allocation 
framework - corrupt and collusive practices take hold.  International experts with cross-
national experience iterate the presence of such issues across LMICs more generally. 
Experts therefore suggest that attempts to improve MDE procurement must include careful 
stakeholder management, including technical capacity creation, and perception negotiation 
to be successful.   
Key Finding 7: Changes in procurement systems can only be brought about by 
careful country-specific and sensitive implementation: this requires suitable 
professionals foremost. Frameworks, methods and tools to improve processes exist, 
the human resources to implement them in LMICs do not. 
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The fieldwork in both countries uncovered similarities across low- and middle-income 
settings. The main point of comparison is the dearth of biomedical engineering and/or 
health technology assessment professionals able to advise on MDE procurement issues. 
Knowledge of international procurement guidance was additionally poor across both 
settings. Notably, however, study findings suggest MDE procurement challenges are 
substantially different across low- versus middle-income settings: The Gambia is 
struggling with procurement and management of minor low-cost technologies (e.g. 
glucometers), whereas Romanian stakeholders mainly focus on the procurement of 
medium- and high-cost technologies (e.g. ultrasound and CT scanning machines). 
International expert opinions complement the in-country fieldwork and suggest MDE 
procurement differences between low- and middle-income countries exist. Experts advise 
that contextually relevant interventions must be designed to improve resource allocation 
processes. Investments into the human resource capacity of countries are at the forefront of 
improving MDE procurement. In this case, both countries would benefit from the 
availability of technical experts in biomedical engineering and health technology 
assessment to advise on technical design and value-for-money of alternative devices. 
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Improving MDE procurement: the role of health technology assessment, health 
economics and planning tools 
Both of the above studies tangentially touched on the role of HTA methods and HE for 
MDE procurement selection. The studies highlight that HTA and HE are not frequently 
considered in product selection. In contrast, feasibility criteria, i.e. as relating to product 
technical specifications or design characteristics that would ensure favourable deployment 
in LMICs, are cited as the main issues considered in product selection.  
The qualitative study suggests that social dynamics, cultural and political factors also play 
a substantial part in procurement by shaping the decision-making landscape. Stakeholders 
across both the Gambia and Romania, and across LMICs generally in the opinion of 
experts, have limited to no knowledge of HTA/HE methods for product selection.  The 
2015 WHO Global Survey on HTA similarly suggests cost-effectiveness of alternative 
products is rarely considered in HTA exercises and MDE investment decisions more 
generally. (7) This may be due to the low availability of analysts to help implement such 
methods. (ibid) 
Chapter 3: Exploring the feasibility of using HTA and generalized cost-effectiveness 
analysis for informing MDE procurement 
Chapter 3 explored the feasibility and relevance of HE/HTA for MDE procurement using 
a case study economic evaluation on orthopaedic interventions for femur fracture fixation. 
The methods and challenges for undertaking HE/HTA have been recently discussed in 
more detail elsewhere(7–9)however, to the author’s (KD) knowledge, this is the first study 
to reflect on MDE related HE/HTA for procurement decision-making in particular.  
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The chapter critically reflects on the use of generalized cost-effectiveness analysis – GCEA 
(10,11), while also making reference to the traditionally popular incremental cost-
effectiveness analysis - ICEA used in the UK, Canada and Australia (12–14) and endorsed 
by the Bill and Melinda Gates Foundation. (15) 
Key Finding 8: Undertaking MDE specific evaluations using GCEA is a very 
labour intensive and complex process challenged by lack of appropriate data and 
insufficient guidance. Alternative methods, including heuristics or multi-criteria 
decision analysis may be more suitable for evaluating MDEs and/or narrowing 
down where HE evaluations (using GCEA/ICEA) are needed. 
The case study compared the use of several MDE intensive interventions for femur fracture 
fixation in Sub-Saharan Africa: surgical interventions (including internal and external 
surgical fixation with plates, intramedullary nails and external fixators) were compared to 
standard care (traction) and a no-treatment scenario.  The lack of suitable and high-quality 
comparative effectiveness data and contextually relevant cost-data was extremely 
challenging. While such issues equally impinge on the use of GCEA and ICEA, GCEA is 
particularly vulnerable to such issues due to two reasons. First, GCEA implies a higher 
workload: compared to a traditional comparison of two interventions and associated 
evidence appraisal/retrieval and HE modelling, GCEA involved the comparison of six 
alternative scenarios for the case study presented here. Second, GCEA requires the 
construction of a no-treatment comparator scenario – i.e. a null scenario. Limited guidance 
is available on how such a scenario should be constructed in the absence of data: 
information on natural disease progression without any intervention is rarely available. 
While GCEA appears promising for the comparison of vertical programs and multiple 
macro-interventions therein (e.g. see (16)), it appears un-manageable and largely un-
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suitable for MDE evaluation when used for intra-sectoral purposes. Heuristics(17),  multi-
criteria decision analysis or program budgeting marginal analysis (18–20), may instead 
prove more favourable for implementation as they consider multiple issues (e.g. demand 
and supply constraints (9)) and can narrow down which technologies should undergo HE 
evaluations.  
Chapter 4: MDE procurement planning using the One Health Tool 
Despite the difficulties documented above, MDE investment decisions must be reached in 
practice. To prevent MDEs falling into disuse, it is therefore crucial to ensure all product 
purchases are appropriate costed. 
Chapter 4 summarizes a critical appraisal of the One Health Tool (OHT) for MDE related 
investment planning, management and costing. Use of OHT is promising as it is able to 
capture both health and budget impact information and evaluate investments associated to 
different health service expansion plans. The tool is relatively easy to use, however proves 
too rigid to assist in sensitive and context-specific MDE procurement planning. For 
example, OHT is currently unable to link individual interventions to MDEs required to 
carry out services and additionally includes simplistic technology management 
assumptions (e.g. a uniform 5-year life span of all MDEs).  
Key Finding 9: Regardless of planning tools used to inform/reach MDE investment 
decisions, information relating to shared/dedicated resource use, user training, 
maintenance and servicing capacity, safety stock and wastage must be captured. 
For information to be meaningful and easily accessible, MDEs should be linked to 
interventions where necessary and presented in a centralized database/list. 
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Issues with the tool can be traced back to inappropriate input materials. Device lists input 
into OHT do not link individual products to interventions but to health service level or 
health facility type. The tool therefore assumes users have considerable and detailed 
knowledge of linkages between individual devices, interventions and health facilities. 
Planning is additionally complicated by lack of information of which devices fall into 
different product categories: e.g. facility furniture and common necessities (e.g. delivery 
beds and stethoscopes), clinical area specific technologies (e.g. dental equipment), or 
intervention critical products (e.g. colonoscopes for colonoscopies). Such information 
would for example allow users to determine what MDEs constitute a dedicated or shared 
resource across clinical areas: e.g. an ultrasound machine can be shared by the internal 
medicine and paediatric department. Recommendations for restructuring available medical 
device lists to take into account such considerations are set out. 
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Overarching conclusions 
Two issues not directly addressed by this thesis are of additional relevance to LMIC 
decision- and policy-makers.  
Human resources for MDE management 
Studies presented here suggest MDE procurement in LMICs is conducted in the absence of 
trained technical experts with relevant knowledge of biomedical engineering and HTA.  
The systematic review presented in Chapter 1, highlighted that MDE costs and technical 
specifications are the primary factors considered during product selection. Similarly, 
findings in Chapter 3 emphasize that it is necessary to apply health economic methods 
pragmatically in LMICs, e.g. by restricting evaluation of MDEs to products which can be 
feasibly introduced, adopted, used and maintained in LMICs. Findings in Chapter 4 
corroborate the above findings and suggest that both biomedical engineers and HTA 
professionals have important roles to play in health system planning. While HTA 
professionals and biomedical engineers could separately advise on issues of value for 
money and maintenance/product selection and procurement technical specification, 
coordination of advisory efforts is still needed to ensure optimal MDE selection. In 
practice, professionals should therefore combine skills from these two domains; 
analysts/engineers/professional units trained in multi-disciplinary methods could thus help 
bridge the user-buyer divide experienced by clinicians and resource allocation planners. 
Sound training in biomedical engineering, including contact with clinicians would ensure 
clinical and patient care perspectives are considered. Similarly, training in HTA and HE 
methods will ensure biomedical engineering professionals are not solely influenced by 
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'impressive, high-tech' specifications and instead seek to ensure products present value for 
money and are used towards achieving overall health maximization. 
The above conclusions are also substantiated by findings of the qualitative study conducted 
in The Gambia and Romania. Findings here highlighted the low availability of engineers 
and also their restricted role in decision-making. In The Gambia, only one biomedical 
engineer was present in the public health care system; however, their role was confined to 
training technicians for product maintenance and offering ad-hoc advice on high cost MDE 
procurement. Similarly, a biomedical engineer in a non-governmental Gambian 
organization and expert biomedical engineer emphasize that the role of engineers is not 
acknowledged as relevant within health systems; the biomedical engineer appears to be 
equated to a technician rather than a trained professional of engineering and management.  
Similarly, health technology assessment professionals were largely absent across both 
settings and few participants recognized the role/importance of such professionals for 
procurement. Committees made up of ministry of health officials, public health 
professionals, economists and service coordinators met in both settings to evaluate service 
packages or programmes to offer to populations. Participants did not mention the use of 
MDE-related HTA evidence - including review of technical specifications and cost-
effectiveness – for decision-making. 
Both biomedical engineers and HTA analysts are therefore largely absent across The 
Gambia and Romania. Interviewed participants emphasized however that such 
professionals would play a great role in resource allocation planning and MDE 
management, should they be available.  
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Two recent surveys into biomedical engineering and HTA capacity in LMICs also suggest 
such professionals come in low supply and are not used to full potential.(7,21) The 2015 
WHO Biomedical Engineering survey highlights the relatively low availability of 
engineers per 10,000 people in low-income settings compared to middle and high-income 
countries. (Table 1) In contrast to biomedical engineering expertise, health technology 
assessment professionals and units are better represented across LMICs, although the 
recent WHO survey into global HTA capacity notes that the lack of qualified human 
resources is the main barrier to the use of such methods. (7) Survey findings suggest two 
out of three countries use some form of HTA for decision-making. (ibid) The survey 
findings emphasize however, that HTA processes are largely focused on issues of safety 
and clinical effectiveness rather than value for money or budgetary impact. Following 
HTA recommendations is not mandatory for decision-makers and survey findings 
emphasize that little consideration is given to issues of ethics, equity and (health service 
delivery) feasibility. (ibid) 
Recommendations distilled from the global literature on MDE procurement and best 
practices therein additionally emphasize the key role of biomedical engineers and health 
economists in MDE procurement. (3,22–24)Engineers are crucial to MDE procurement 
and management as they identify products with LMIC appropriate technical specifications 
and assist in their overall management, including user training, maintenance and 
decommissioning. (ibid) In turn, health economists are needed to ensure the full budget 
impact of MDEs is recognized before procurement is initiated; value for money should be 
considered at this stage of the procurement cycle. In contrast to the focus of country level 
HTA initiatives, international efforts such as WHO-CHOICE (11)and Disease Control 
Priorities (25) focus on the value for money of different services and interventions; 
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difficulties in service implementation due to  feasibility issues and necessary product 
procurement/infrastructure upgrades are frequently acknowledged as limitations in such 
studies. 
Leveraging the knowledge base around MDE procurement resources 
To improve the current procurement and use of MDEs in LMICs, and ultimately health 
service delivery, it is necessary to promote the uptake and development of available tools, 
methods and guidelines. Relevant instruments to assist MDE procurement decision-makers 
in LMICs exist but stakeholders are not sufficiently aware of them. The lack of awareness 
may be due to tool specificity (e.g. different tools focus on different clinical areas – e.g. 
(26,27)), lack of transparency (e.g. detail on how ‘core’ or ‘essential’ lists were 
developed(4)) or due to tool complexity (e.g. One Health tool). 
This thesis identified several instruments that LMIC stakeholders may use when facing 
issues of MDE selection and procurement. Core equipment lists(4,28), guides on the set-up 
of specific service areas including MDE selection recommendations(26) as well as 
checklists for guiding MDE procurement stakeholders(29) exist. However, materials are 
specific to diverse health care areas and rarely acknowledge that procurement officials in 
LMICs are non-experts that procure across specialties.  
In the absence of technical experts, MDE procurement is frequently relegated to 
pharmacists or clinicians with little experience in MDE management and associated 
challenges. Pharmacists and clinicians are often not experienced enough (or too focused on 
their own clinical area) to select products with LMIC appropriate technical specifications, 
and estimate the necessary user training or servicing requirements of products. The 
primary reason for MDEs falling into disuse is that their technical specifications are not 
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appropriate for LMICs. (Chapter 1) Products selected are often not robust enough to 
withstand high temperatures, arid environments, or require a stable electricity supply or 
clean water for functioning. Replacement of spare parts and maintenance is quasi 
impossible due to underdeveloped supply chains and low availability of technicians. 
Absent or lacking user training and high product utilization rates further complicate this 
issue.  
This inexperience, coupled with the strong influence of industry in LMICs and lack of 
formal mandatory HTA systems, encourages corrupt and collusive procurement decision-
making practices.(30) International experts interviewed for the study in Chapter 2 suggest 
that collusive/corrupt practices occur primarily when decision-makers restrict procurement 
to one specific company/manufacturer.  
To discourage this, and provide all procurement stakeholders with a baseline level of 
expertise needed to develop a product profile for contextually specific procurement, this 
thesis provides pragmatic recommendations and syntheses of decision-relevant 
information. These recommendations are a reflection of recent rigorous research, relevant 
specifically to stakeholders and decision-makers in LMICs; however, implementation of 
any recommendations/use of suggestions made here should be conceptualized and 
implemented in a fair, publicly defensible and legitimate manner. (31) In particular, 
decision-makers should be aware of the "Accountability for Reasonableness" framework 
developed by Daniels and Sabin when designing/developing an MDE 
procurement/resource allocation system.  (ibid)  
Daniels and Sabin insist that resource allocation of public funds should be a legitimate, 
transparent and public process, open to participation of all relevant stakeholders. 
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Professionals at all health system levels should therefore be made aware of 
national/regional MDE management processes and feel empowered to feed into these. 
Processes should be transparent, draw upon publicly defensible resource allocation criteria 
and be conducted in the interest of the public good (32); criteria for MDE selection and 
resource allocation should be grounded in up to date, contextually appropriate, evidence.  
The MDE resource allocation system should be responsive to change and accountable to 
all: a fair and publicly accessible system for enabling and resolving appeals must therefore 
also exist. The system should further encourage the voicing of diverging opinions and 
create pathways for logging appeals; the process for considering and resolving appeals 
must also be clearly set out. All of the above steps must be cemented in regulation: 
national health policies and health laws can firmly define the MDE procurement decision 
space and ensure only relevant 'rules' feed into this particular resource allocation 'game'. 
(See Chapter 2) Failing to abide by legally binding processes, or failure to transparently 
disclose decision-making practices/amend decisions as relevant upon receipt of new 
evidence could therefore be challenged. 
The next sections briefly detail resources decision-makers in LMICs may find useful in 
MDE resource allocation.  
Chapter 1 lists design characteristics specific to MDEs intended for deployment in LMICs. 
The WHO and other international agencies have initiated similar efforts to support MDE 
procurement, albeit this has been trialled for emergency response situations – e.g. see 
personal protective equipment specifications for use during the recent Ebola Virus 
outbreak(33). UNICEF, USAID Grand Challenges and MSF similarly support the use and 
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development of generic product profiles to advise non-expert procurement stakeholders. 
(34)  
Guidance for non-expert procurement stakeholders has also been developed – Chapter 1 
acts as a resource repository for this. The WHO Global Forums on Medical Devices(1,35) 
additionally provide the opportunity for LMIC stakeholders to exchange ideas on best 
practices and common pitfalls encountered in MDE management. 
Chapters 3 and 4 additionally provide comments on two further resources available to 
LMIC stakeholders for assisting in MDE product selection, more specifically GCEA and 
the One Health Tool (OHT) for health system planning. While GCEA sets out guidance for 
conducting cost-effectiveness analyses,(11) it is a complex and data-intensive method 
requiring substantial expert input for model design. Methodological guidance fails to 
advise analysts on consideration of MDE associated deployment challenges documented 
here. Best selection practices identified in Chapter 1 may assist analysts in narrowing down 
which MDEs are suitable for deployment and therefore health economic appraisal. It is 
impractical to conduct cost-effectiveness analyses of all MDEs that can be potentially 
procured(8,17); it may instead be advisable to use pragmatic decision-making frameworks. 
(17) 
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VALUE AND LIMITATIONS 
Findings documented contribute original insights towards research carried out in several 
domains.  
• Health technology assessment: Several international initiatives exist to improve 
resource allocation in LMICs. (e.g. see (25,36) and the International Decision 
Support Initiative initiated by NICE International) Notably this includes not only 
the development and promotion of GCEA and ICEA methods in resource 
constrained settings but also guidance on the implementation of HTA via national 
agencies and comments on the successful integration of such efforts into overall 
decision and policy-making. (30,37)Findings noted here emphasize that MDE 
specific HTA should consider both feasibility criteria (e.g. LMIC appropriate 
product design and technical specifications) and value for money. Contextually 
appropriate HTA exercises are needed for informing MDE procurement to capture 
all relevant stakeholders and influence underlying stakeholder 
interactions/dynamics. 
 
• Decision-making in LMIC health systems: Recent research into decision-making in 
LMICs emphasized the relevance of equity and feasibility criteria alongside 
normative (cost-effectiveness) criteria.(38–40) Conclusions of both the systematic 
review and qualitative study support such findings and offer further insight into the 
various factors of relevance in MDE procurement. In particular, the qualitative 
study in The Gambia and Romania suggests that MDEs are viewed not as simple 
‘instruments’ by which to achieve improved population health, but as forms of 
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symbolic capital. Additionally, findings of the systematic review and qualitative 
study highlight that LMIC stakeholders assign limited relevance to, or are only 
limitedly aware of, normative criteria for decision-making.  
 
• Biomedical engineering: Traditionally, biomedical engineering research activity 
has focused on product testing and design/technical specification or issues of 
regulation. Translation of such research/expertise into practice – in particular in the 
area of MDE procurement – has led to the development of Core Medical Device 
Lists(4), the Compendium for Innovative Technologies (41)and the creation of 
MDE procurement advisory agencies. The latter include for example CENETEC in 
Mexico, charities such as HUMATEM and private enterprises such as Fisthail 
Consulting (UK). Knowledge exchange mechanisms such as the WHO Global 
Forum on Medical Devices have also recently shot to the fore.(1) Research 
presented here highlights, however, the low availability and perceived relevance of 
biomedical engineers in MDE procurement across LMICs. The availability of 
engineers is likely to impact not only on procurement and resource allocation, but 
also on day-to-day functioning of health systems: in the absence of publicly 
employed engineers to assist in preventive and corrective MDE maintenance, 
health systems must rely on scarce commercially available maintenance services. 
Research presented here further suggests LMICs have limited knowledge of the 
various resources and tools available to them for procurement decision-making. To 
improve MDE procurement, biomedical engineers should engage more closely with 
clinicians and health technology assessment experts/health economic analysts. The 
success of MDE procurement in LMICs – that is the rational and pragmatic use of 
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scarce health resources – hinges on selecting the most appropriate, acceptable, 
affordable, available and cost-effective product available.  
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CONCLUDING REMARKS AND SUGGESTIONS FOR FURTHER RESEARCH 
This thesis acted as a hypothesis generating exercise meant to identify issues, 
stakeholders, dynamics and methods of relevance in MDE procurement. Nine key 
findings, spanning the four presented studies, are available and will be communicated to 
researchers and decision-makers with an interest in MDE procurement via peer-reviewed 
publications and conference participation.  
Research presented here also serves to identify areas where further inquiries are needed. 
Two areas are particularly noteworthy: 
1. Research into MDE management frameworks and the role of specialised human 
resources therein. Differences between private and public MDE management 
frameworks should be investigated, and where necessary used to revise current 
practices in either sector. For example, the study presented in Appendix 1 
highlights the efficiency of MDE maintenance in the private sector of India; 
decision-makers across Indian provinces are currently considering outsourcing 
MDE maintenance to private rather than publicly funded contractors. (42) 
Similarly, the role of health economists or biomedical engineers in MDE 
management could be investigated via global surveys. 
2. Research into the links between MDE management and population health 
outcomes. Links between the various MDE management frameworks and 
population health outcomes should also be probed: findings here suggest that 
countries where biomedical engineers and health economists are empowered to 
inform resource allocation, will have better population health outcomes. It is 
critical that research into MDE management is conducted to determine what 
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constitutes successful vs. wasteful management – the link of this to population 
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TABLES 





Summary of Number of biomedical  




High-income 0.66782712 1.0871152 40 
Low-income 0.00943365 0.02199022 17 
Lower-middle 
income 
0.12689962 0.26591026 34 
Upper-middle 
income 
0.18624437 0.3249349 33 
Total 0.30108152 0.69903259 124 
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We then conducted the first study to specifically explore issues affecting medical device 
maintenance in a MIC setting. The setting of our research was the Northwest province 
of India, chosen for its diversity in urbanized and semi-urbanized cities. We also as a 
secondary aim, compared maintenance between the public and private healthcare 





Maintenance of medical-devices is of importance in optimizing-utility, encouraging 
cost-efficiency and enhancing quality-of-care. Existing literature reported device 
maintenance to be neglected and understudied in low/middle-income countries (L/MIC). 
This warrants exploration as these countries have recently experienced a rise in demand 
for devices. India is a MIC with a device market set to undergo substantive growth 
within a range of private and public hospitals. We explored issues regarding 
maintenance of medical-devices in the North-West province of India, and the 




This qualitative study used semi-structured interviews with 31 health-care practitioners, 
administrators and directors from different institution sizes, in both private/public 
sectors. Purposive sampling using a snowball approach was used to select the 
participants. Interviews were audio-recorded and conducted using a validated topic-
guide. Thematic framework analysis employing an inductive and grounded approach 
was used for data analysis. 
 
Findings: 
We identified three themes that have a compounding-effect in causing delayed 
maintenance, (i) absence of Biomedical engineers (BE), (ii) Poor user-
responsibility/accountability for devices, procedural-delay in fault-reporting, (iii) 
Discrepancy in after-sales maintenance by companies. Quality of maintenance was 
found to be poorer in the public-sector, due to greater prevalence of these issues. We 
also found that, despite awareness of these problems being existent amongst decision-
makers, there was a lack-of-willingness to act, demonstrating neglect of device 
maintenance, particularly in the public-sector.  
 
Conclusions: 
Increased delegation of responsibility within the maintenance-process and regulation of 




Medical devices are equipment that facilitate diagnosis/prevention/treatment of disease 
and other conditions1. Historically, medical devices have been under-recognized and 
only recently been acknowledged by the World Health Organization, to be integral parts 
of health service provision, carrying substantial national-level budgetary expenditure 
implications 2-4. 
 
Maintenance of medical devices is of paramount importance in optimizing utility, 
encouraging cost-efficiency and enhancing quality of patient care5. Moreover, it has 
implications for patient/user safety and satisfaction5, 6.  
An effective maintenance programme comprises of inspection and preventive 
maintenance (IPM) to reduce failure-rates, and corrective maintenance (CM) to return 
broken-down devices to functioning states5, 6.  
 
In a higher-income country setting, maintenance of devices is carried out as part of set 
policies/guidelines, with due regulation5, 7. This ensures standardized and effective 
service provision for all patients alike. However, an extensive systematic literature 
review by our team (unpublished) has highlighted that, device maintenance is largely 
neglected and a gap in knowledge exists regarding device maintenance in low/middle-
income countries (L/MIC) 8. Previous studies have also reported, that on-average 50% 
of devices remain out-of-use in LICs, referencing poor maintenance as part of the 
reasoning9-13. However, no studies have yet been conducted on medical device 
maintenance in MICs. It is important to study this as many of these countries have 
recently experienced a significant rise in demand for medical devices, due to rising 
populations and increased awareness of benefits of healthcare delivery14, 15. 
 
Therefore, the primary aim of our study was to then to explore issues regarding 
maintenance of medical devices in the healthcare sector of a MIC, India. A secondary 
aim was to compare maintenance between the public and private healthcare sectors.  
 
India is a MIC, with the second largest population in the world16. It has a rapidly 
expanding health care sector comprised of a public and affluent private-sector17. Indian 
medical devices market was worth US$3.6 billion in 2010, and is set for substantial 
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growth to reach US$6.4 billion (compound annual growth rate 15.5%) by 2014, due to 
forthcoming planned investment14, 15. 
 
As of yet, no research has been conducted on the                                           
effectiveness/perceptions/efficacy of device maintenance in India and warrants 
exploration due to its implications on cost, maximizing-utility and quality of care. 




[Written in accordance with the criteria for reporting qualitative research (COREQ)] 18 
A qualitative study was undertaken in the Northwest province of India19, 21. This 




Due to limited previous literature, and in order to investigate the range of issues, a 
qualitative study-design was chosen. Semi-structured interviews were undertaken with 
health care practitioners/administrators/directors, across a range of hospitals that 
differed in size in both public/private-sectors. Interviews were used as the primary 
method of data collection as we explored experiences/perceptions of medical device 
maintenance. Focus groups, although initially planned, were not undertaken, due to 
identification of sensitive issues concerning budgeting and management of hospitals 
during preliminary discussions with potential interviewees. A ‘grounded-theory’ 
framework was used to orientate the study. 
 
Participant and Institution Selection 
Eligibility for the institute and participants is illustrated in table 1.  
 
Purposive sampling using a snowball approach was used, to study variety of opinion 
amongst specific participants and opportunistic sampling to achieve diversity. 
Recruitment and approach of participants followed a two-pronged strategy, firstly 
through collaborators and secondly through a field approach, see figure 1. Choice of 
institutions was based on maximizing representation of a range of levels of care, size 
and funding of institution. Table 2 illustrates characteristics and provides justification 
for chosen limits of institutions. 
Setting 
Interviews were predominantly conducted at hospitals and a few in the participant’s 




All interviews (average duration of 45 minutes) were audio-recorded, and were 
conducted using a topic guide to maximize consistency. This topic guide was previously 
validated in Gambian and Romanian studies (personal communication with Karin 
Diaconu) and pilot-tested upon arrival in India. Interviews were conducted until data 
saturation was reached. 
Analysis  
VG conducted all interviews and subsequent transcription. A thematic framework, using 
Nvivo software was used to analyze data, taking an inductive approach (illustrated by 
figure 2)21-23. Firstly, data-immersion was undertaken. Subsequently, a thematic-
framework was identified in which texts describing similar views of participants were 
highlighted (open coding) 24,25,26. Codes were then categorized to create meaningful 
clusters27. Subsequently, data were indexed, to find links amongst categories/sub-
categories of codes (axial coding). Deviant cases were identified and analyzed for 
correlations and contradictions. Subcategories were then linked to core-categories to 
identify themes (selective coding). Data were finally charted and mapped, during which 
themes were analyzed to generate theory28. One researcher completed coding. Coding 
was initially completed sector-wise i.e. public/private-sector and was triangulated with 
the research-team.  
 
Ethics 
The BMedSc Population Sciences and Humanities Internal Ethics Review Committee 
granted ethical-approval. For India, an independent ethical committee provided a 
declaration stating institutional consents to be sufficient. Consequentially, participants 
were only selected from consenting institutions (1 institution refused).  Free and 
informed consent was obtained from all study participants. Confidentiality was ensured 
through assignment of unique participant numbers. 
 
Results 
Altogether, 31 participants were interviewed. Participant demographics are detailed in 
table 3. One individual refused to participate, due to fear of confidentiality-breach. All 
participants were working in the public or private-sector or sometimes both.  
 
In India, we found maintenance to be contracted to the manufacturing company, 
negotiated at time of device purchase. This can be either a Comprehensive maintenance 
contract (CMC), which includes servicing and replacement of spares/consumable parts 
308 
or Annual Maintenance Contract (AMC) that only includes servicing. The path for 
device maintenance is illustrated, as found to be described, in figure 3. 
 
We identified that participants across both sectors repeatedly referenced delay in 
medical-device maintenance. They attached importance to this topic, as delayed 
maintenance provision would result in equipment down-time, thus impairing service 
provision. Upon further exploration, several themes relating to this topic emerged and 
are presented below. Figures 4-6 illustrate the broad categories involved in development 
of these themes.  
 
Lack of Specialists – Biomedical-Engineers 
Majority of participants mentioned a lack of biomedical engineers (BE) to be a 
fundamental cause for maintenance delay, particularly at the point of initial device 
breakdown. Participants identified that in BE absence, there was no system of in-house 
repair. Therefore, any fault with a device, minor or major, had to be reported to 
manufacturing companies, which are based in other states within the country. 
Consequentially, even for minor repairs, there was significant delay in sending company 
engineers and thus device maintenance.  
 
“… it's a big problem because sometimes there are very small problems with equipment 
and we have to wait for company person to come … which could be easily solved by a 
biomedical engineer”  
(Principal, Government Hospital) 
 
With regards to public-vs-private-sector comparison, deficiency of BE was reported to 
be equally prevalent in both sectors. There was however, some reporting of occasional 
technician employment in both sectors. These technicians though were stated to be 
under-qualified, lacking in training and were incorrectly identified to be similar to BE, 
by some participants. We, interpreted this to be evidence for a lack of awareness of the 
exact role of BE and their possible undervalued nature. Further validating this 
interpretation was the finding that, few participants referenced wider BE role in cost-
saving/device selection/user-training with majority only seemingly aware of their role in 
maintenance delay.  
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“You don’t have people with professional-degrees rather more of handymen” (Director, 
Corporate Hospital) 
 
“We call biomedical-engineers, local-repairers. Sometimes, they are available, but they 
are not experts.” (Clinician, Government Hospital) 
 
We identified that it was particularly decision-makers 
(superintendents/principals/directors) across both sectors that repeatedly referenced BE 
absence and its impact, demonstrating awareness at the highest administrative level. The 
fact that BE are still not employed, highlights a possible lack-of-availability of BE in 
India. 
 
Lack of responsibility/ Procedural-Delay 
Another identified source of delay was at the stage of fault-identification. Majority of 
participants mentioned a lack-of-circumscribed responsibility/accountability for devices 
to cause delay in reporting of faults and therefore delay in initiation of the maintenance-
process, thus prolonging device-downtime. Participants also stated that poor delegation 
of accountability resulted in improper use of devices and so contributed to increased 
failure rates. 
 
“ Users have to be made accountable for equipment in the Government-sector” 
(Director, Corporate Hospital) 
 
The procedure of fault-reporting was another frequently referenced root of delay. 
Participants reported this procedure to be unnecessarily lengthy due to inclusion of a 
needless amount of personnel in fault-report validation. Consequently, this led to delay 
in notifying companies of faults and thus prolonged device downtime.  We interpreted 
this to be a recurrence of the aforementioned sub-theme of ‘lack-of-responsibility’, 
where failure to delegate direct power/accountability for maintenance of a device, 
resulted in undue delay. 
 
With regards to public/private-sector comparison, majority of participants referenced 
these issues of lack-of-responsibility and procedural delay to be exclusive to the public-
sector. Participants explicated that due to direct fear of incurring losses, individuals in 
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the private-sector were made/felt directly responsible for devices, which cultivated into 
increased urgency for fault-identification and reporting as well as pressurising of 
companies to provide prompt service.  
 
“In government, fault-reporting is so lengthy, a small screw will take 1 / 2 months  to be 
fixed... Which is not the case in private-sector. Reason is whatever time device is not 
working; It is direct loss to him. ... …Nobody is in a hurry in government” (Clinician, 
Small Private) 
 
We identified referencing of ‘procedural delay’ to be predominantly by decision-makers 
(superintendents/directors/principals), leading us to deduce that awareness of this 
problem exists at the highest-level. We interpreted, that the fact that they continue to 
persist with this process demonstrates poor prioritization of maintenance. Further 
validating our argument is that clinicians working for both private and government 
sectors still persevere with delay issues in public institutions whilst being aware of 
better practice in their private practice.  
 
“In private, action is taken immediately”  
 
“In the Government, person taking care of the instrument, should have power to contact 
companies directly. Process should be shortcut”  
 
(Clinician, Working in both Government & Private Hospitals) 
 
Poor company response 
Majority of participants also referenced discrepancy in company response to be a source 
of delay. 
With regards to comparison between private and public-sector, majority of participants 
reported company response to be poor for the public-sector and excellent for the private. 
Reasons stated for this discrepancy were that of delayed payments in the public-sector 
and brand loyalty in the private. Participants reported, that as a consequence of 
procedural delay, payments to companies by the public-sector were often delayed and at 
times unpaid, whilst in the private, payments were always prompt.  
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Majority of participants also highlighted the importance of brand loyalty in the private-
sector. They explained how private hospitals preferred to house devices from the same 
brand in return for lucrative discounts from companies and prompt maintenance. Brand 
loyalty was stated to be impossible in the public-sector due to adherence to a set 
procedure of procurement, the tender-system.  
 
We then interpreted delayed payments and lack of brand loyalty to be negative 
motivators for companies, in providing prompt service to public hospitals. This, then 
cascades into delayed maintenance and increased device downtime in the public-sector.  
“An important thing in Government sector is that, most of times older dues are not paid 
to companies… so the company refuses repair” (Director, Corporate Hospital) 
“Even multinational-companies are not responding to our calls whilst to private-sector 
they are quicker as they think they could get more market from them.” (Superintendent, 
Government Hospital) 
 
Consequences of Delay 
Some participants highlighted key impacts of delayed maintenance specific to the 
public-sector. They revealed that due to delayed maintenance, a growing trend in public 
hospitals was to simply procure new devices and condemn (dispose) repairable ones, 
thus causing significant wastage of good resources.  
A minority of participants also talked about how delay in maintenance was creating a 
rich-poor divide as lower-socioeconomic groups, who are predominantly dependent on 
public hospitals and cannot afford private treatment, receive delayed healthcare due to 
increased device downtime in public hospitals. 
 
“sometimes in the Government, rather than going for maintenance, we go for purchase 
of a new machine …”   
(Clinician, Government Hospital) 
 
“lower socioeconomic groups, can only come to the government sector so if devices are 
not working, the patient suffers “ 




This was the first study undertaken to evaluate issues affecting medical device 
maintenance in MICs. Our study is novel in two aspects. Firstly, we identified sub-
optimal maintenance issues, specific to a MIC setting. This is important, as the majority 
of existing literature have focused on reasons for prolonged device breakdown in LICs. 
(e.g. Mullally, S., & Frize, M. (2008). Survey of clinical engineering effectiveness in 
developing world hospitals: equipment resources, procurement and donations. 
Conference Proceedings : ... Annual International Conference of the IEEE Engineering 
in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. 
Conference, 2008, 4499–502. http://doi.org/10.1109/IEMBS.2008.4650212;) Secondly, 
we identified reasons for a clear divide in quality of maintenance between sectors, with 
maintenance being substantially poorer in the public than private-sector.  
 
India’s Northwest province was chosen due to its diverse health care sector and 
participants from different institution sizes, in both private/public-sectors were 
interviewed. From the results, we identified three main themes that elucidate why 
medical device maintenance procedures in India are sub-optimal (figure 7). Absence of 
Biomedical engineers (BE) resulted in outsourcing of maintenance to companies 
situated in distant locations and limited avenues for in-house repair. Poor delegation of 
responsibility/accountability and procedural-delay were identified to hinder fault-
identification and fault-reporting. Prompt after-sales maintenance service by companies 
was found to be dependent on brand-loyalty and timely payments, which cannot be 
assured at all times. These themes were found to have a compounding effect in causing 
delay and thus prolonged device-downtime. Figure 8 and case studies 1,2 illustrate how 
these themes impact different stages of the maintenance-process. 
 
Regarding the secondary aim, themes of lack of responsibility/accountability and 
procedural delay were found to be exclusive to the public-sector; furthermore, this 
sector received poor company service due to aforementioned reasons. In contrast, the 
private sector enjoys prompt service in return for brand-loyalty with clinicians showing 
urgency for maintenance, due to delegated accountability and direct motivation by 
profits (figure 9).  
 
Unavailability of BE and its impact was a theme observed to be consistent with previous 
studies conducted in LICs 13,30. These studies also reported findings on limited 
employment of under-qualified technicians, which was also a finding in our study11, 30. 
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BE, in addition to fault-repair, have a wider role in hospital device-management 
encompassing user-training, preventative-maintenance and device-selection5, 31,32. 
However, we found awareness of these additional roles to be significantly lacking, with 
BE often being identified only for their role in fault-repair and sometimes being 
misclassified as local repairmen, demonstrating their undervalued nature. World Health 
Organization. (2010). Medical devices: Managing the Mismatch (An outcome of the 
Priority Medical Devices project). 
 
We found, that despite awareness of the impact of lack of responsibility/ accountability 
at the highest administrative level, there was a lack of willingness/ability to change the 
process. This demonstrates poor prioritization of device maintenance, a theme 
consistent with a forthcoming systematic review, which reported neglect of maintenance 
by decision-makers in LICs 8. Moreover, as procurement of devices in LMICs is 
centralized, funding is assured only for the actual purchase and not for follow-up service 
of devices, further evidencing neglect8.  
 
It was difficult to identify what avenues for preventive maintenance (PM) exist in the 
public-sector as company service is poor and BE are absent. This could then contribute 
to greater frequency of failure rates and create divide between sectors regarding 
functioning devices. This is consistent with previous LIC studies that reported poor 
adherence to PM schedules11, 13,30,33. This area warrants further research. 
 
Delayed maintenance procedures within public-sector have wide-ranging consequences. 
First, purchase of new equipment is preferred to the corrective maintenance of already 
available devices. This translates to lost resources.  
Second, service provision is impaired. This impacts principally upon low-
socioeconomic groups who make up 46.7% of the population34.   
 
Principally, we recommend employment of BE for both sectors. In addition to reducing 
delay in device repairs, their role in user-training, preventative-maintenance and device-
selection are fundamental aspects of device management. However, there are few BE 
available for employment in India due to lack of training institutions, as only few B-tech 
biomedical programs in private/semi-private exist, which calls for development of 
quality courses35. Moreover, 65% of devices, in India are imported36 and thus local BE 
face a substantial knowledge-gap, a barrier consistent with a previous LIC study37.  (I 
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know this detail is true .e the 65% of devices are imported and biomedical program are 
good but cannot find a good reference for this) 
  
Secondly, we recommend user-training (clinician/nurses/orderlies) as part of device 
deployment. For example, Medicines and Healthcare products Regulatory agency 
(MHRA) advises users to take an active role in fault-checking, cleaning and fault-
reporting of devices5, 6. Adoption of such processes would boost user 
responsibility/accountability for devices, particularly in the public-sector.  
 
Thirdly, we propose that India could develop its own regulatory boards/systems with 
regards to devices. These may operate similarly to the MHRA in the UK, and function 
to limit discrepancy of service provision and ensure observance of AMC/CMC by 
companies5, 6. This recommendation is however difficult to achieve as Department of 
Health is reported to have nominal jurisdiction over medical devices, due to their 
neglected nature35. Furthermore, the vast and diverse nature of India’s healthcare system 
presents a substantial challenge on influence of such an agency at a national level.  
(same here)  
 
The study had a large sample-size allowing saturation of findings and rich high-quality 
data to be collected. Purposive sampling with a snowball approach helped us to include 
a range of participants. Approach to analysis was inductive and through a thematic 
framework, allowing flexibility in consideration of themes.  
 
Limitations were that there was no researcher triangulation in data-collection, which 
could enhance researcher bias. This was limited by maintaining a reflexivity-journal and 
frequent debriefing after interviews. Regarding lack of method triangulation, although 
focus-groups were planned, they were not appropriate for sensitivity reasons and could 
have affected validity. Although collaborators were initially sourced through researcher 





From the results, we identified problems to be embedded at each stage of the 
maintenance process of devices, primarily in the public sector, causing major delay. We 
found that, despite awareness of these problems being existent amongst decision-
makers, there was a lack-of-willingness to act, demonstrating neglect of device 
maintenance, particularly in the public-sector. We then recommend, delegation of 
responsibility within the maintenance process and increased regulation of company 
service provision. However, imperatively we recommend that BE be employed in both 
sectors. Future research should focus on quantifying this delay in maintenance and 

































































































































































Inclusion criteria: Exclusion criteria: 
Participant should have a relevant profession in the health 
care setting related to device management, maintenance or 
purchase or prioritization of purchase. This includes health 
care practitioners, policy makers, administrators, managers 
or other occupations dealing with maintenance of medical 
devices (e.g. consultants) 
Individual does not 
provide informed 
consent or is unwilling 
to take part  
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TABLE 2: CHOICE OF INSTITUTIONS AND CHOSEN LIMITS (WITH JUSTIFICATIONS) 
Institution 
characteristic 
Limits Justification  











Size Maximum: 600 beds 











Funding Government Hospitals 
Private Corporate Hospitals 









TABLE 3: PARTICIPANT DEMOGRAPHICS 
Note: Some participants had dual roles: Example: some participants were clinicians as 
well as being directors of hospitals public/private sector 
 
Figures available upon request.
Participant characteristic  Number 
Number of interviews 31 
Gender Males: 28     Females: 3 
Type of Institution 
management 
Government: 6 
Corporate Private: 5 
Small-Private: 7 
Type of participants Government Clinicians: 13 
Government Superintendents: 3 
Government Principals: 2 
Corporate Clinicians: 8 
Small Private Clinicians: 7 
Corporate Directors:  7 
Small-private hospital owners: 6 
Chief Medical health officer: 1 
Biomedical engineer: 1 
Medical Device company owner: 1 
Private & government experience combined: 5 
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Case study 1: Maintenance in the government sector 
 
Scenario: Broken down Computed Tomography (CT) machine  








“No no biomedical engineers in our department definitely not in our institute” 
(Clinician, Government Hospital) 
 








“ Definitely in government sector there is nobody directly responsible for particular 
instrument … we  try take some personal responsibility …  but responsibility is not 
properly allocated” (Clinician, Government Hospital) 
 
“person isn’t given power to call (the company) to ask them to come and check 











… for everything for maintenance HOD has to write to superintendent then file will go 
to clerk. Clerk will find whether equipment is under CMC or not if it is they will pass it 
to accountant. Again, superintendent will OK it and give consent. Again it will come 
back to clerk, clerk will make the order it will then go to HOD and superintendent to 
sign and only then it will be issued. Such a long process  
(Prinicipal, Government Hospital) 
 
“In Government sector, once the breakdown occurs, then the head of the department 
writes to principal, then a complete report is made. Then that report is sent to the 
company, then company expects the advance of the payment to be made… Then the 
engineer comes, then he makes a report. Then that report goes to a committee. Then the 
committee decides that okay this has to be rectified and this much money has to be paid 
and again tenders are floated and the whole process takes many weeks to months” 
(Director, Corporate Hospital) 
 









“company people do not bother about government calls. They think that these are the 
hospitals where nobody is responsible … for private sector their response is quick” 
(Superintendent, Government Hospital) 
 









Case study 2: Maintenance in the private sector 
Scenario: Broken down X-ray machine 







“See, there is a shortage. If you ask me, there is definitely a shortage.” (Director, 
Corporate Hospital)  






 “…in the private sector, since it is my money or the boss’ money, bosses are keen that 
it gets repaired” (Clinician, Government Hospital) 
 






“I need to run my hospital… So I am ready to pay maintenance charges … 
 
“we feel that it’s better to keep all the monitors of the same brand, same ventilators of 
the same brand etc. so that we get good maintenance service and it helps in future 
negotiations” (Director, Corporate Hospital) 
“But, the private one they approach quickly to the company. … In the private it takes 
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Abstract 
Background: The need for innovative health technologies for low resource settings is 
well understood by policy makers and researchers. There are currently no guidelines to 
facilitate introduction of new technologies to low resource settings. A case study of the 
intramedullary nail and interlocking screw system (SIGN-nail), a device which allows 
internal fixation of fractures at a low cost without the need for image intensification, in 
Tanzania was used to explore barriers and facilitators for introduction of innovative 
technologies to low resource settings. 
Methods: Sixteen qualitative semi-structured interviews were conducted in three of 
four national referral hospitals with orthopedic facilities in Tanzania. Orthopedic 
surgeons, theatre nurses, administrators and technology manufacturers were 
interviewed. Two institutions used the SIGN-nail and one did not. Interview transcripts 
were analyzed using conventional content analysis.   
Findings: Collaboration between technology users and manufacturers are driving 
factors behind technology adoption. Existing demand for affordable and efficacious 
fracture care, the training program and reporting-feedback system used by SIGN 
manufacturers, ensured successful adoption and continued use of the device.  
Challenges in technology adoption resulted from lacking infrastructure and deficient 
skill mix among users, manufacturers not advertising products publicly, resistance to 
change by senior clinicians and issues in technology import due to customs delays. 
Interpretation: Our findings suggest continued collaboration, communication and 
knowledge exchange/training between technology developers, users and policy makers 
are primary facilitators to technology adoption and continued use.  
Funding: The University of Birmingham, Population Sciences and Humanities 
Bachelor of Medical Sciences program.  This study received no funding form SIGN and 





In May 2015, delegates of the 68th World Health Assembly supported a resolution on 
the strengthening of basic and emergency surgical and anaesthetic services, including 
the promotion of increased access to safe, quality and cost-effective surgical care. 
Critical to this effort is the availability and accessibility of affordable, appropriate, high-
quality medical technologies, including surgical devices and equipment.(1-3) However, 
many available technologies are geared towards use in high-income countries and prove 
expensive or unsuitable for low resource settings.(2-4) Uninterrupted electricity and 
clean water supply may be lacking, spare parts or consumables needed to keep devices 
operational may be unavailable or unaffordable, health care staff trained in the use of 
advanced technologies may be absent and the finances needed for device servicing 
unobtainable.(6-11) There is a need for innovative technologies that are affordable, 
address the above issues, and solve or compensate for problems with existing 
technologies.(5,8,9) 
 
Before manufactures can meaningfully engage with the production of such innovative 
technologies, however, it is necessary to explore the processes and reasons behind 
technology adoption. In a qualitative study on the adoption of CT scanners in Brazil, 
Silva and Viana suggest that technology adoption decisions are driven by clinician 
demand or industry influence. Guidelines on “whether, when and how” health facilities 
should invest in new technologies are lacking; adoption decisions are thus guided by 
considerations of institutional prestige and the choice of a technologically advanced 
product. A study on the adoption of MRI scanners in the USA has noted similar 
findings.(10,11) In the case of surgical technologies, Wilson identified several drivers 
for technology adoption: patient demand for innovative interventions, low costs to 
surgeons applying the technology, aggressive product promotion by manufacturers and 
perceived benefits such as better post-operative outcomes. Importantly, Wilson notes 
that the evidence base for efficacy of the technology may be a secondary factor in 
adoption decisions.(6)  
 
A systematic literature review of medical device and equipment procurement methods 
for LMICs by our team likewise indicates that technology acquisition decisions are 
often reached on an ad-hoc basis in the absence of agreed guidelines or health policies. 
(Unpublished - work in progress: Diaconu et al: "Methods for medical device and 
equipment procurement within low- and middle-income countries: Findings of a 
systematic literature review") Technical and economic criteria primarily influence 
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technology adoption choices. Decision makers prefer cost-saving technologies with 
specifications consistent with conditions encountered in deployment settings.  
 
While the papers cited provide insights into technology adoption choices, they pertain 
largely to middle- or high-income economies or to procurement methods of any and all 
medical devices rather than innovations. That is, studies focus on the introduction of 
technologies, which have been used and potentially evaluated in higher income settings 
rather than de novo products/designs. Questions of innovative technology adoption - 
particularly of surgical innovations - in LICs thus remain unanswered.  
 
To begin to address this gap in the literature, we have conducted a case study of the 
intramedullary nail and interlocking screw system (SIGN-nail),(12) and its introduction 
to public sector hospitals in Tanzania. The aim of this case study is explore the adoption 
of surgical innovations in LICs and formulate recommendations for the effective 
introduction of technologies to resource-poor settings. Our case study illustrates the 
institutional and governmental processes behind technology adoption choices; we also 
identify barriers/facilitators to the adoption and sustained use of the SIGN-nail in 





Ethical approvals were granted by the University of Birmingham and Tanzanian 
National Institute of Medical Research. (Appendices 1-2) 
 
This is a qualitative case study employing semi-structured interviews for data collection 
and a grounded theory approach for analysis.(13) 
 
AG conducted the interviews under the supervision and guidance of all co-authors. KD, 
CC and SMH conducted routine remote supervision meetings via Skype to discuss 
project progress, potential issues in participant recruitment and data collection, 
including transcription, emerging themes and data saturation. IN and BH facilitated 
AG's contact with surgical staff in individual health care facilities and clarified any 
queries relating to data collection or the Tanzanian health care system. 
 
Setting: Tanzania was selected due to widespread use of the SIGN–nail (Box 1) in the 
public health sector. Government run national referral hospitals were targeted and 
selected as they provide the majority of orthopaedic care in Tanzania. Referral hospitals 
are additionally responsible for treating the bulk of orthopaedic patients, thus proving 
generally comparable to the majority of public health care providers in LICs.(14) Of the 
four national referral hospitals in Tanzania, three make use of the SIGN-nail and one 
does not. Interviews were conducted in two hospitals that use the SIGN-nail and one 
hospital that does not; the latter served as a comparator for identifying factors that 
prevent the uptake of the technology. The SIGN manufacturers provided details of 
contacts in the hospitals that were able to facilitate data collection; all approached 
institutions were assured that the study is independent from the manufacturers. 
 
Participants: AG interviewed sixteen health care professionals in three Tanzanian 
referral hospitals; no approached person declined participation. Participants were 
selected through purposive sampling for their involvement in the treatment/management 
of long bone fractures or the selection and introduction of new technologies in their 
institution. Orthopedic surgeons, general surgeons, theatre nurses and members of 
hospital management were targeted and identified through chain referral.  
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Data collection: All interviews in Tanzania were conducted in private, face-to-face, 
one-on-one, in the participant’s workplace in English, using topic guides piloted in the 
UK and Tanzania. Participants had no prior knowledge or relationship with the 
interviewer. The interviewer clarified he had no relationship with the technology 
manufacturer. Two SIGN developers and manufacturers provided answers to interview 
questions via email. 
The research team discussed data saturation during data collection and interviews 
continued until this was achieved. No repeat interviews were conducted. Interviews 
ranged between 15-45 minutes and were audio-recorded. AG, a third year medical 
student at the University of Birmingham, conducted, transcribed and analyzed all 
interviews. Participants were not shown transcripts for correction.  
 
Prior to study commencement AG undertook a course in qualitative research methods; 
he received further training in qualitative research methods from SMH and KD, both 
supervisors having conducted previous qualitative studies in low- and middle-income 
countries.  
 
Informed consent was obtained from all participants prior to interview. Participants 
were encouraged to share their views and experiences freely. Participants were asked 
open questions regarding the treatment of long bone fractures and the process for 
introducing new technologies in their institution, along with their attitude towards the 
intramedullary nail and interlocking screw system, the associated training program and 
reporting database for patient outcomes.  
 
Data Analysis: Data were analyzed using conventional content analysis.(13) 
Transcripts were coded inductively using NVIVO 10 beta software and charted by 
code.(15) The coding rationale was discussed within the research team and with 
external researchers. Content analysis was used to index the text and identify emergent 
themes.(16) Conclusions drawn from the data were then discussed within the research 





Table 1 describes Tanzanian participant characteristics. We also received written 
responses to interview questions from the technology manufacturers and present 
comments and findings of this in Box 2. 
 




Emergent themes and subthemes along with supporting quotes are presented in Table 
2.1.  
 
Barriers and facilitators encountered in technology adoption  
While all health technologies must be approved by the Tanzania Food and Drug 
Authority (TFDA) prior to use,(17) participants reported that no formal system or 
process for technology adoption existed within individual health facilities. Hospital 
management and individual clinical departments were described as responsible for 
adoption decisions. 
 
Participants within the hospitals using the SIGN technology noted that the primary 
facilitating factor for adoption was the recommendation of a 'trusted contact'. Surgeons 
with prior experience of the technology would visit Tanzanian health facilities and 
recommend the use of the SIGN-nail given infrastructural conditions encountered. 
Visiting surgeons from the US would also operate using the SIGN technology, thus 
demonstrating and promoting its use.  
 
In hospitals not making use of the nail, the absence of such a recommendation was 
noted as the main barrier to adoption. Due to its particular business model, the SIGN 
nail is currently available only through direct contact with the manufacturers - lack of a 
trusted contact impedes this. Participants at this institution mentioned that their hospital 
would be willing to pay for the device if it were available on the market.  
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Participants in the hospitals using the SIGN-nail revealed a further barrier to technology 
adoption. Junior surgeons reflected that senior practitioners opposed the initial use of 
the technology; this resistance to new clinical practice was gradually overcome as the 
benefits of using the technology became apparent. 
 
All participants mentioned the absence of suitable theatres for orthopedic surgery and 
lack of surgical equipment and trained clinical staff as a further barrier to adoption. 
However, participants in the institution that does not use the SIGN nail reported that 
suitable theatres, trained staff and necessary equipment are available; therefore, these do 
not pose a barrier here. The developers too noted lack of capacity in recipient hospitals 
as a barrier to rollout of the SIGN nail.  
 
Motivating factors for technology adoption 
Within the hospitals using the SIGN technology, participants mentioned three reasons 
for adoption. First, surgeons and managers reflected that using the SIGN-nail ensured 
cost-savings for the health facility. Participants mentioned that the shorter hospital stay, 
the reduced postoperative complications and availability of the device as a charitable 
donation greatly decreased the cost of fracture care to the hospital. This was noted as the 
main motivation for the adoption of the device in institutions.  
 
Second, alongside technology adoption, facilities would benefit from a free but 
mandatory training program: this improved human resource skills and reduced hospital 
costs by increasing staff efficiency, reducing complication rates and hospital length of 
stay. Surgeons reflected that the practical training program, using live patients in 
particular, improved technique and enabled them to use the device independently (Table 
2.1). Some surgeons accessed additional training at yearly conferences run by the 
technology developers in the USA. Attending surgeons later share learned techniques at 
home institutions. The technology manufacturers also regularly visit the institutions to 
monitor outcomes and provide further training when changes have been made to the 
device. However, theatre nurses recommended that the developers provide formal 
training for nurses to ensure proper technique in the preparation of the device. (Table 
2.1).  
 
Third, the SIGN reporting system enables surgeons to receive feedback on any 
conducted operations. Surgeons are required to upload individual case notes with patient 
X-rays, before and after each operation, onto an online database. The developers can 
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then offer feedback with a view to improve future patient outcomes. Once a threshold of 
20 operations has been reported the developers automatically replenish the institutions 
stock of intramedullary nails.  
 
Factors influencing continued technology use and/or supply 
Participants mentioned three reasons for continuing to use the SIGN-nail after adoption. 
First, surgeons reported improved patient outcomes when using the SIGN-nail as 
compared to other treatments. Patients treated with the SIGN-nail stayed in hospital for 
shorter periods of time, recovered quicker and encountered a lower incidence of 
complications such as postoperative infection.  
 
Second, surgeons and managers felt the communication with the manufacturer was 
productive and reciprocal as the developers repeatedly made changes to the device 
based on user feedback. Participants mentioned that this allowed them to take 
ownership of the product as well as making the device easier to use and better suited to 
the target setting and population. Third, users appreciated the manufacturer being a 
reliable supplier of the device; the predictable supply ensures that institutions are able to 
sustainably integrate the technology into the hospital model.  However, hospital based 
participants and developers both reported shipment delays due Tanzanian customs 
procedures. 
Participants also reflected on barriers to the continued use of the SIGN-nail. Surgeons 
cited two particular concerns related to surgery reporting mechanisms. Some surgeons 
were unable to report surgeries due to breakage of X-ray machines, rendering it 
impossible to upload pre and post-operative X-rays to the database. Other surgeons 
experienced difficulty in meeting the developer’s minimum follow-up requirement of 
20%. Many patients were lost to follow-up, as patients could not afford to return to the 
hospital for a follow-up appointment. Both of these posed a problem in replenishing 
stock of SIGN-nails: manufacturers send out new nail shipments only when follow-up 
requirements are met.  
 
Senior surgeons and managers echoed these views and noted that at times it was 
difficult for their colleagues to report operations due to time and resource constraints.  
Each of the two hospitals using the SIGN-nail had a senior orthopedic surgeon who was 
responsible for uploading operation reports to the online database. These surgeons 
ensured that all SIGN-nail insertions were recorded. Developers similarly noted that 





This is one of the first studies to explore the adoption of an innovative surgical medical-
device in a low-income country.  
The SIGN intramedullary-nail is a technology targeted towards use in low-income 
countries, disseminated through an atypical business-model, which entails minimal 
health facility/patient costs, offers surgeons access to specialized training and imposes a 
patient monitoring/user-feedback mechanism. Participants in Tanzanian health-facilities 
consider the device a cheaper and more effective treatment alternative for long-bone 
fractures and initially adopted the technology based on favorable recommendations 
from trusted colleagues. Device dissemination thus hinges on "word of mouth" and the 
recommendation of current to potential users, and facilitation of contact between the 
latter and manufacturers. We identify the lack of trusted contacts to mediate between 
developers/potential users as the principal barrier in adoption.  
 
Further barriers noted are lacking health facility infrastructure and/or inability of health 
facility staff to report patient outcomes to manufacturer standards. Similar to issues 
encountered in device donations, institutions should only select technologies for use if 
these can be supported by the necessary infrastructure and human resource skill mix 
available.(2,6,9,18) Albeit a complex device, the SIGN nail was successfully adopted in 
hospitals with available surgical theatres and trained staff. The ancillary training 
program offered by the manufacturers helped adoption and ensured an upgrade in 
human resource skill mix. The additional reporting mechanism guaranteed continuous 
communication between users and technology developers, thus closing any potential 
feedback loop relating to product design, efficacy or user concerns.  This is in line with 
international recommendations for developers to conduct post marketing surveillance to 
ensure that the device is safe and efficacious for the length of its life cycle.(19) 
 
The SIGN case and business-model illustrates how initial technology adoption choices 
are driven by peer-networks and demands for cheaper and more effective health 
interventions. This finding supports wider trends within the literature, which suggest 
users in low-resource settings prefer technologies and innovations that respond to clear 
demands for cheaper and more effective healthcare. (Unpublished - work in progress: 
Diaconu et al: "Methods for medical device and equipment procurement within low- 
and middle-income countries: Findings of a systematic literature review")  
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Continued technology use is driven by constant collaboration and communication 
between technology recipients/users and donors/manufacturers/developers. In order to 
increase access to such technologies and innovations in particular, 
developers/manufacturers should be accessible to potential clients and advertise their 
products widely. The WHO Compendium of Innovative Technologies is one potential 
avenue to achieve this.(2,6,19) Developers should also ensure that their business model 
is suited to the capabilities and needs of the recipient. In this case, the fact that the 
device was donated made it accessible to institutions and patients that would not be able 
to afford it otherwise. However, should such a device become more widely available, it 
may not be possible to offer all support structures included in the current business 
model against no cost. Support systems may then need to be costed out to continue their 
application, thus imposing a restraint on the device's on-going efficient use. 
 
Our findings are limited in that the study was conducted in publicly funded health care 
facilities and using a medical device supplied through an atypical business-model; 
conclusions may therefore not reflect the views and experiences of charitable and 
private sector hospitals. The latter also provide a significant proportion of Tanzania’s 
healthcare(14) and of that of LICs worldwide.  Additionally, a great number of 
participants enjoy a close relationship with the manufacturers: it is possible participants 
may therefore feel less inclined to voice negative attitudes. The particular business 
model supporting SIGN nail provision may additionally unduly influence participants’ 
views: devices are provided free of charge and participants may therefore hesitate to 
provide any negative views of the product. Additionally, the interviewer’s views may 
also be colored by participants’ reports of the product’s benefits. The use of only one 
interviewer minimized the effects of interviewer bias. Many participants were not native 
English speakers, however, all participants were proficient in English and language did 
not become a barrier in conducting the interviews. Where issues in comprehension 
occurred, the interviewer asked the participant to clarify their response. It was ensured 
that the question was well understood before proceeding. 
 
Conclusion 
Collaboration between developers, recipient institutions and policy makers is essential 
in the successful introduction of innovative surgical technologies. Provision of training 
and continued technical support by developers is likely to promote the sustained and 
correct use of the new technology. Such provisions may however restrict or slow down 
dissemination due to incurred program costs. Further case studies on different devices 
and settings - particularly the private health care sector - are needed to inform potential 
recommendations in this area. 
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international.	 It	 is	 widely	 used	 in	 resource-limited	 settings	 and	 disaster	 zones	 in	 53	




occasion	pay	 for	 customs	charges	 incurred	 through	 technology	 import.	The	developer	
may	 cover	 these	 on	 a	 per-need	 basis.	 The	 device	 is	 associated	 with	 both	 an	 online	
database	onto	which	users	upload	case	 reports	and	a	user	 training	program	provided	
free	 of	 charge	 by	 SIGN	 surgeons.	 The	 prolonged	 relationship	 between	 donor	 and	




























Characteristic  Number of participants (n=16) 
Gender Male: 13 
Position 
 
Nurse: 4  
Orthopedic surgeon: 5 
Hospital director: 3 
General surgeon: 2 
Resident, trauma and orthopedics: 1 
Hospital administrator (non-clinical): 1 
Hospital use of SIGN nail Yes: 12 
No: 4 
341 
Table 2: Themes identified across interviews 









system =  
Lack of a formal 
system for the 
adoption of new 
technologies in 
institutions 
“There is no formal system, just an in built culture” 
Orthopaedic surgeon 
“I think the decision makers in the hospital should 
depend on evidence on whatever technique they 
want to introduce.” Hospital director  
Trusting and acting 
on peers opinions 
on technology = 
Presence of trusted 
contacts to broker 
interaction with the 
developers 
“The	 SIGN	 system	 was	 brought	 in	 by	 visitors	
from	the	USA,	these	were	orthopaedic	surgeons.	
They	 would	 come	 in	 with	 supplies.	 One	 of	 the	
supplies	they	brought	us	was	the	SIGN	system.”	
Orthopaedic	surgeon			
“Surgeons	 at	 local	 hospital	 s	 seek	 us	 out	 after	
hearing	about	our	programme	at	one	of	the	local	
orthopaedic	meetings	or	surgeons	already	using	
it	want	 to	 spread	 SIGN	 further	 in	 their	 county”	
Developer		
Absence of trusted 
contacts 
“The	 problem	 is	 to	 access	 the	 developers.	
Because	we	are	ready	to	get	some	funds…	there	
is	 not	 even	 the	 option	 to	 contribute	 a	 small	
amount	of	money	and	get	the	nail.	Because	if	we	
had	 that	 option	we	would	 have	 said	 ok	we	 can	
go	 and	 beg	 from	 here	 and	 there	 to	 get	 that	
money	 but	 we	 never	 got	 that	 offer.”	 Chief	 of	
surgery		 
Resisting change in 
current practice  
“There	 is	no	real	physical	barrier;	 the	barrier	 is	
the	 people	 themselves.	 There	 are	 people	 who	
would	 like	 to	 change	and	 there	are	people	who	
resist.	 There	 are	 people	 with	 their	 own	




was	 that	 the	 first	 case	 took	 us	 a	 long	 time	 and	
we	 thought,	 this	 is	 very	 difficult	 to	 do	 and	 we	
have	 some	 senior	 surgeons	 who	 said	 that	 it’s	
difficult	to	teach	an	old	dog	new	tricks."		 -	
Orthopaedic	surgeon	 
Lacking capacity in 
recipient hospitals  
“We	 have	 only	 2	 universities	 that	 train	





“Many	 hospitals	 in	 Tanzania	 still	 don’t	 have	
theatres	 where	 you	 can	 perform	 orthopaedic	
surgery	safely.”	Orthopaedic	surgeon	








through use of the 
SIGN nail = 
Reduced running 
costs to institutions 
and patients as a 
result of adopting 
the SIGN nail - e.g. 





the	 wards	 were	 getting	 cleared	 so	 patients	
needing	other	procedures	could	be	taken	care	of.	
So	 we	 can	 treat	 many	 more	 patients	 without	




Provision of a 
training 
programme 









“Further	 training	 is	 provided	 via	 the	 surgical	
database	 which	 is	 reviewed	 by	 orthopaedic	
surgeons	on	our	board”Developer	
“This	 process	 has	 evolved	 more	 as	 SIGN	













report,	 they	 review	 it	 and	 they	 comment…it’s	 a	
form	of	learning.”	
-	Resident	in	orthopaedics	
“It	 is	 like	 we	 are	 closer	 and	 they	 can	 work	 on	
things	 quicker.	 [The	 database]	 is	 for	 raising	
concerns	 and	 requests	 like	 this	 instrument	 has	






“The	 SIGN	 nail	 needs	 less	 hospital	 stay,	 if	 a	
patient	comes	in	today	and	you	do	the	SIGN	nail,	
after	2	days	you	can	discharge	the	patient.	And	if	
the	 wound	 is	 healing	 well,	 no	 sepsis,	 no	
infection,	 in	 12-18	months	 you	 can	 remove	 the	






Changes made to 
device based on 
user feedback 
“The	 improvements	 are	 mostly	 made	 after	
suggestions	 from	 surgeons	 depending	 on	 their	
experiences	 with	 it	 and	 that	 is	 good	 practice	
because	 it	 lets	 the	 orthopaedic	 surgeon	 have	
ownership	 of	 the	 implant.”	 -	 Orthopaedic	
surgeon 
Reliable supply of 
the device 
“For	every	nail	you	insert,	you	have	to	record,	do	
pre	 op	 X-rays	 and	 post	 op	 X-rays	 and	 send	 the	
information	to	the	SIGN	headquarters.	That	nail	
will	 be	 replaced	 immediately.”	 -	 Orthopaedic	
surgeon		
Delays in shipment  “When	we	run	out	of	SIGN	nails	we	 just	 report,	
we	 tell	 the	 team	 responsible	 for	 reporting	 and	
ordering,	 then	 they	 order	 through	 SIGN.	
Sometimes	we	have	a	problem	with	the	clearing	
and	forwarding	processes”		 -Theatre	manager	
“Sometimes	 we	 have	 problems	 with	 the	
transportation	of	the	nail,	when	they	come	from	

















APPENDIX 3: FINDINGS OF THE QUALITATIVE META-











Code Definition Effect 
size % 
Example quotes or 
fragments 
1. Identification and 
understanding of health 
needs is a first step in 
identifying where greatest 
population impact can be 
achieved: relevant health 
care areas, including 
technology purchases, are 
prioritized. 
 
2. Verification of health 
needs may play a role in 
restricting the 
procurement of medical 
devices: i.e. should 
devices and equipment 
not correspond to a 
priority health condition 




Identifying the priority 
health problems of a 
defined population in 
order to achieve health 




References to disease 
areas, issues or clinical 
guidelines without 
reference to these being 
a priority 
27.72 “disease problem” (SR20) 
“burden of disease” 
(SR26) 





Analyses of the health 




32.67 “certificate of need” 
(SR23) 
“needs assessment (SR26) 
“situational analysis” 
(SR57) 
 “local needs identified 
through prevalence and 
checked with providers” 
(SR140) 
Achieving 
population benefits  
References to how 
tackling a health 
problem (whether 
specified or not) yields 
benefits to populations 
14.85 “benefit to the population, 
social impact, community 
and professional demand, 
importance for improving 
patient condition, 









Code Definition Effect 
size % 
Example quotes or 
fragments 
 
health outcomes” (SR 85) 
“treating and diagnosing 
TB is beneficial both for 
HIV and non-HIV 
patients” 
“maximize use on 
different patient types” 
(SR 55) 
“targeting health needs 
and adverse outcomes 
(risks)” (SR 130) 
Health priorities Discussion of health 
priorities or identified 
clinical areas/fields of 
priority 
9.9 “clinical area to focus on: 
trauma care” (SR 218) 
“prevalent emergency 
condition in reproductive 
health (SR 208) 
“forensic science” (SR 
232) 
Achieving impact Addressing health 
issues with the aim of 
achieving impact 











Code Definition Effect 
size % 
Example quotes or 
fragments 
 
3. Cost-effective medical 





constraints impact upon 
the choice of technologies 
for procurement: 
i.e. if funding streams for 
particular conditions are 
available, devices for 
those conditions are 
prioritized within the 
funding round.  
 
5. Devices and equipment 
imposing minimal costs 
upon the health system 











References to economic 
methods of evaluation 
to inform decision 
making 
27.72 “establish cost-effective 
way of dealing with 
disease problem” (SR 18) 
“cost-efficiency and 







of needs, political 
support and other value 
considerations  
7.92 “health technology 
assessment” (24) 
“based on technology 
assessment and a six 




measurement of actual 
performance” (SR 95) 
Defining financial 







Budget constraints or 
thresholds set for 
equipment 
15.84 “depending upon a cost-
threshold a certificate of 
need process is adhered 
to” (SR 23) 
Cost-reduction Mentions of approach 
to minimize costs 









Code Definition Effect 
size % 
Example quotes or 
fragments 
associated with 
technology purchases “average and reasonable 
cost” (SR 43) 
“ongoing costs” (SR 55) 
“bulk purchases lead to 
cost reductions” (SR 153) 
Exploring feasibility of 
purchases by defining 
financing arrangements 









9.9 “impact, effectiveness, 
scalability” (SR 29) 
“usefulness” (SR 56) 
Financing 
arrangements 
Financing sources for 
device procurement / 
management 
6.93 “procurement linked to 
aid contracts and 
programs chosen by 
donors… diversion of 
money into different 
programs is 
unfavourable” (SR 53) 
“financing ability” (SR 
80) 
5. Consensus decision 
making methods and 
evaluations of past 
procurement processes 
Methods for evidence 






processes related to 
procurement, including 
planning and further 
3.96 “Evaluation of 
technologies may not be 
sufficient, review the 









Code Definition Effect 
size % 
Example quotes or 
fragments 
and outcomes are 
preferred for reaching 





management we want to achieve and 








4.95 “consensus method 
(involving experts) but 
focused on the review of 







predetermined criteria  
 
0.99  
6. Health care services 
and packages to be 
provided at each health 
care level directly 
influence which devices 
and equipment are 
prioritized and procured. 
 
8. For newly introduced 
Defining the health 
service structure 
(ES: 33.66%) 
Care packages and 






services to be provided 
at primary, secondary 
or tertiary care levels 
43.56 “defining basic packages 
of care at each service 
delivery level” (SR 29) 
“Collaborate with 
provincial and national 
authorities to find the 
suitable package for the 
setting” (SR 54) 









Code Definition Effect 
size % 
Example quotes or 
fragments 
health services, policies 
for medical device 
management should be 
put in place. 
sites and structuring of 
services” (SR 87) 
Defining services 
and procurement 
plans by defining 
targets and 
ensuring 
forecasting is done 
Setting procurement 




23.76 “ensuring adjustment to 
patient volume” (SR 40) 
“create purchasing plans 
with projections of use” 
(SR 61) 
“ability to deliver pre-
specifies treatment 
targets”  (SR 73) 











Mention of policies or 
management 
frameworks relating to 
medical devices and 
their procurement 
9.9 “plan for a national policy 
on injection equipment 
and safety boxes” (SR 
153) 
“waste management 
policies should include 
details on where disposal 
happens in facilities, and 
whether disposal is 
regional or national” (SR 
154) 









Code Definition Effect 
size % 
Example quotes or 
fragments 
as part of a health 
management policy but 
not with specific detail as 
to how to undertake this” 
(SR 226) 
9. Prioritize equipment 
which can be safely used 
and managed in 
deployment settings. 
 
i) Prioritize equipment 
with LMIC friendly 
specifications. 
 
ii) Prioritize equipment 
that can be easily used 
and maintained within 
health facilities. 
 
Desired features of 
medical devices for 
LMICs 
(ES: 28.71%) 
Risk and safety Associated risk of 
device use or misuse 
and issues of safety 
19.8 “high risk devices” (SR 
35)  
“safety” (SR 29) and 
“safety profiles” (SR 80) 




Desired or undesired 
characteristics of 
devices to be procured 
47.52 “long-life” (SR 40) 
“resistant to ambient 
conditions” (SR 54) 
“electricity, device design 
(e.g. whether hand-held or 
desktop operated – theft 
may be an issue), weight, 
operating temperature and 
humidity, hard and robust 
casings, battery life, 









Code Definition Effect 
size % 
Example quotes or 
fragments 
“high sensitivity and 
specificity” (SR 43) 
“function and simplicity” 
(SR 107) 
“devices are to 
compensate for lacking 
human resource skills and 
have reduced operational 





products, and quality 
assurance and control 
procedures 
18.81 “quality equipment” (SR 
54) and “quality assured 
products” (SR 181) 
“pre-qualification for the 
IUD showed one product 
suitable for most patients 
and manufacturing 
capacity was suitable to 
low-income settings as 
well” (SR 207) 
Managing equipment in 
the field in LMICs: 
what is needed 
Matching facilities 
and their staff to 
medical device 
Convergence of facility 
design and conditions, 
staff abilities/training 
49.5 “facility type and 
conditions as well as 









Code Definition Effect 
size % 
Example quotes or 
fragments 
(ES: 32.34%) 
specifications needs and medical 
device specifications in 
deployment setting 
should dictate 
prioritization” (SR 60) 
“skills and knowledge of 
staff” (SR 80) 
“available local technical 
skills” (SR 87) 
Maintenance and 
spare parts 
Discussion of how 
maintenance should be 
conducted, why it is 
needed, how spare parts 
fit into the problem 
27.72 “maintenance and service 
need priority and should 
be adapted to local needs” 
(SR 61) 
“minimal parts and 
consumables, simple, 
minimal maintenance and 




Who provides services 
and spare parts? 
19.8 “local supplier availability 
for instrument 
maintenance and reagent 





Regulation Specification of devices 
and how they accord 
with international or 
national regulatory 
5.94 “ICF and ISO are used to 
delineate core sets of 










Code Definition Effect 
size % 




technology assessments at 
stages of pre-market 
clearance or post-market 
surveillance” (SR 126) 
















Descriptions of how 
procurement processes 
work/do not work in 
LMICs 
10.89 “Centralized procurement 
discouraged although may 
be advantageous, different 
timings of arrival 
observed” (SR 56) 
“developing a rational and 
efficient tendering 
procedure involves not 
only price but also 
maintenance and service 
considerations, all should 
be adapted to local needs” 
(SR 61) 




Political aspects of 
procurement 
Mention of how politics 
shapes procurement 
7.92 “Prioritization occurs 
around six factors: … 











Code Definition Effect 
size % 
Example quotes or 
fragments 
“Prioritization entails … 
the need for 
organizational 
sponsorship and 








13.86 “Prioritization occurs 
around six factors: … 
(technology) to be 
culturally acceptable” (86) 
“7 questions guide the 
definition of what is 
essential or not, including 
consideration of access 












APPENDIX 4: INTERVIEW TOPIC GUIDE (CHAPTER 2)
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Semi-structured interview and focus group topic guide: 
Prioritization of medical devices in The Gambia 
This guide comprises a list of topics and instructions that the researcher can use to 
generate discussion in interviews and focus groups and to keep the discussion on track. 
The researcher will not necessarily use all of them in each interview/focus group – this 
will depend on the extent to which  the research questions are answered without being 
prompted. 
Guidance for interviewer: 
Begin by introducing yourself and try to ensure that the participant/participants are 
relaxed. First go over the consent forms and explain all data handling procedures: 
audio recordings, transcribing, where data is stored, for how long, and that the data 
will be anonymised. Emphasize that participants do not need to answer questions 
should they not wish to do so and that they can withdraw up to two months after the 
time of interview/focus group. 
 Explain that the interview or focus group will go on for about an hour – an hour and a 
half maximum. Loosely describe that the interview or focus group consists of discussion 
around 3 segments, emphasizing that you want to understand a) the processes behind 
medical device selection and prioritization in the Gambia as well as the barriers and 
facilitators affecting this and b) the way donated medical equipment is used and 




Ask participants to introduce themselves briefly and include relevant information on 
participant names, age, gender as well as professional experience. Probe about how long 
participants have been in their role, what organizations they have previously been 
employed in in order to ascertain their range of professional experience and where/when 
their educational training took place. 
Sample question: Q1. Could you please introduce yourself and tell me about your past 
educational and professional experience? 
2. Research	topic:	questions	around	primary	objectives		
This section will focus on medical device experience and selection/prioritization 
practices as well as the management and utilization of donated medical equipment. It is 
important to understand the organizational/ institutional/ regional/national landscape as 
well as the range of issues affecting medical device selection/prioritization. 
Sample questions/instructions: 
Q2. Tell me about your experience with medical devices.  
Q3. What kind of medical devices do you regularly use or manage? 
Q4. Were these devices acquired in The Gambia or donated? (Probe can revolve 
around: medical equipment donation, functioning of said equipment, meeting needs, 
maintenance) 
Q5. Tell me about medical device selection: how do people in your facility choose 
which devices to buy? (Probe can revolve around: staff involved in procurement 
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decisions, methods for reaching decisions, factors affecting decisions, dynamics around 
procurement (e.g. national-regional instructions/restrictions?)  
Q6. Who makes device selection choices? Why do you think that is? 
Q7. What factors affect which medical devices are bought or selected for buying? 
Q8. What needs do you associate with medical devices? (Probe about whether these 
needs are addressed?) 
Q9. What is a priority medical device? How do you know that?  
Q10. What guidance or tools – if any – do you need in order to undertake device 
procurement/ selection? 
Q11. What is the most pressing issue for medical device procurement? 
Q12. What are your suggestions for medical device selection and prioritization? 
Q13. What are your suggestions for medical device/equipment donations? 
3. Research	topic:	questions	around	secondary	objectives		
This section focuses on the current use of medical device procurement 
guidelines/systems/recommendations and aims to identify what types of guidelines are 
used and how effective/used they are. 
Sample question: Q14. Do you or your facility currently use any guidance or guidelines 
on what medical devices to buy?  




Guidance for interviewer: 
Close the interview/focus group by thanking the participants for taking part and explain 
how the findings of the current research will be used.  
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Interview consent form: 
Prioritization of medical devices in The Gambia 
 
This is a study investigating how health care professionals, managers, consultants and policy-
makers within The Gambia undertake prioritization, selection or procurement of medical 
devices and medical equipment. The study will also investigate how donated medical equipment 
is managed and utilised within The Gambia. 
 
You are asked to participate in an interview undertaken by one of the researchers in the study – 
the interview will last approximately 1-1.5 hours and will be arranged at a time convenient for 
you. During the interview, you will be asked questions around how choices are made regarding 
which devices are procured in your institution or within The Gambia and regarding how medical 
equipment/device donations are managed. You can choose not to answer a question if you do 
not want to. 
 
All of the information you provide will be anonymised and kept confidential. For ease, we 
would like to audio record the interview with you – this data will be kept safe and confidential 
at the University of Birmingham in the UK. We would also like to use relevant quotations in 
future research reports, publications and presentations – these will not identify you in any way 
and no identifying information will be attached to these quotes. Quotations may use a fake name 
for labelling, and general information on the facility type/country you are from may be 
included: e.g. ‘hospital, low-income country’. 
 
The benefit of this study is that it will inform the development of a wider international medical 
device procurement method which could aid staff such as yourself in future medical device 
selection and prioritization decisions if implemented. You could thus be able to save money for 
your institution and increase efficiency.  The findings of this research will be made freely 
available to The Gambia Ministry of Health and all participants and institutions that took part.  
 
Please initial the below statements in the right hand column if you agree to take part in the 
study.  
 
I have been given enough information about this research study  
I understand how the information I provide will be used  
I agree to speak to the researchers about my experience relating to 
medical devices 
 
I understand that I can leave the study up to two months after my focus 
group and do not have to answer questions if I do not want to 
 
I am happy for the researchers to audio record what I say and use and 
store the recorded data 
 
I give permission for my words to be used in publications and 
presentation but understand that my name will never be mentioned and 
that I will not be identified through this 
 
 
Participant name/Unique ID: ……………………………………………………………   
Signature: …………………………………….. 
Researcher witnessing consent: …………………………………………………………….. 
Date: ……………………………………………………………………………… 
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